id	sid	tid	token	lemma	pos
dpc-4838	1	1	dermatology	dermatology	NOUN
dpc-4838	1	2	:	:	PUNCT
dpc-4838	1	3	practical	practical	ADJ
dpc-4838	1	4	and	and	CCONJ
dpc-4838	1	5	conceptual	conceptual	ADJ
dpc-4838	1	6	original	original	ADJ
dpc-4838	1	7	article	article	NOUN
dpc-4838	1	8	|	|	ADV
dpc-4838	1	9	dermatol	dermatol	ADJ
dpc-4838	1	10	pract	pract	NOUN
dpc-4838	1	11	concept	concept	NOUN
dpc-4838	1	12	.	.	PUNCT
dpc-4838	2	1	2025;15(1):4838	2025;15(1):4838	NUM
dpc-4838	2	2	1	1	NUM
dpc-4838	2	3	risankizumab	risankizumab	NOUN
dpc-4838	2	4	versus	versus	ADP
dpc-4838	2	5	secukinumab	secukinumab	NOUN
dpc-4838	2	6	:	:	PUNCT
dpc-4838	2	7	a	a	DET
dpc-4838	2	8	real	real	ADJ
dpc-4838	2	9	-	-	PUNCT
dpc-4838	2	10	world	world	NOUN
dpc-4838	2	11	efficacy	efficacy	NOUN
dpc-4838	2	12	and	and	CCONJ
dpc-4838	2	13	cost	cost	NOUN
dpc-4838	2	14	per	per	ADP
dpc-4838	2	15	responder	responder	NOUN
dpc-4838	2	16	comparison	comparison	NOUN
dpc-4838	2	17	in	in	ADP
dpc-4838	2	18	 	 	SPACE
dpc-4838	2	19	patients	patient	NOUN
dpc-4838	2	20	with	with	ADP
dpc-4838	2	21	psoriasis	psoriasis	NOUN
dpc-4838	2	22	in	in	ADP
dpc-4838	2	23	italy	italy	PROPN
dpc-4838	2	24	federico	federico	PROPN
dpc-4838	2	25	pirro1,2	pirro1,2	PROPN
dpc-4838	2	26	,	,	PUNCT
dpc-4838	2	27	giacomo	giacomo	NOUN
dpc-4838	2	28	caldarola1,2	caldarola1,2	PROPN
dpc-4838	2	29	,	,	PUNCT
dpc-4838	2	30	nicoletta	nicoletta	PROPN
dpc-4838	2	31	bernardini3	bernardini3	PROPN
dpc-4838	2	32	,	,	PUNCT
dpc-4838	2	33	maria	maria	PROPN
dpc-4838	2	34	grazia	grazia	PROPN
dpc-4838	2	35	celeste4	celeste4	PROPN
dpc-4838	2	36	,	,	PUNCT
dpc-4838	2	37	annunziata	annunziata	ADJ
dpc-4838	2	38	dattola5	dattola5	PROPN
dpc-4838	2	39	,	,	PUNCT
dpc-4838	2	40	eleonora	eleonora	PROPN
dpc-4838	2	41	de	de	PROPN
dpc-4838	2	42	luca1,2	luca1,2	PROPN
dpc-4838	2	43	,	,	PUNCT
dpc-4838	2	44	marco	marco	PROPN
dpc-4838	2	45	galluzzo6	galluzzo6	PROPN
dpc-4838	2	46	,	,	PUNCT
dpc-4838	2	47	domenico	domenico	PROPN
dpc-4838	2	48	giordano7	giordano7	PROPN
dpc-4838	2	49	,	,	PUNCT
dpc-4838	2	50	chiara	chiara	PROPN
dpc-4838	2	51	 	 	SPACE
dpc-4838	2	52	izzi4	izzi4	PROPN
dpc-4838	2	53	,	,	PUNCT
dpc-4838	2	54	giulia	giulia	PROPN
dpc-4838	2	55	maretti8	maretti8	PROPN
dpc-4838	2	56	,	,	PUNCT
dpc-4838	2	57	lorenzo	lorenzo	PROPN
dpc-4838	2	58	marcelli6	marcelli6	NOUN
dpc-4838	2	59	,	,	PUNCT
dpc-4838	2	60	roberto	roberto	PROPN
dpc-4838	2	61	ravasio9	ravasio9	PROPN
dpc-4838	2	62	,	,	PUNCT
dpc-4838	2	63	antonio	antonio	PROPN
dpc-4838	2	64	giovanni	giovanni	PROPN
dpc-4838	2	65	richetta5	richetta5	PROPN
dpc-4838	2	66	,	,	PUNCT
dpc-4838	2	67	nevena	nevena	PROPN
dpc-4838	2	68	skroza3	skroza3	PROPN
dpc-4838	2	69	,	,	PUNCT
dpc-4838	2	70	marina	marina	NOUN
dpc-4838	2	71	talamonti6	talamonti6	PROPN
dpc-4838	2	72	,	,	PUNCT
dpc-4838	2	73	arianna	arianna	PROPN
dpc-4838	2	74	zangrilli6	zangrilli6	PROPN
dpc-4838	2	75	,	,	PUNCT
dpc-4838	2	76	luca	luca	PROPN
dpc-4838	2	77	bianchi6	bianchi6	PROPN
dpc-4838	2	78	,	,	PUNCT
dpc-4838	2	79	giovanni	giovanni	PROPN
dpc-4838	2	80	pellacani5	pellacani5	PROPN
dpc-4838	2	81	,	,	PUNCT
dpc-4838	2	82	severino	severino	PROPN
dpc-4838	2	83	persechino7	persechino7	PROPN
dpc-4838	2	84	,	,	PUNCT
dpc-4838	2	85	concetta	concetta	PROPN
dpc-4838	2	86	potenza3	potenza3	PROPN
dpc-4838	2	87	,	,	PUNCT
dpc-4838	2	88	ketty	ketty	PROPN
dpc-4838	2	89	peris1,2	peris1,2	PROPN
dpc-4838	2	90	,	,	PUNCT
dpc-4838	2	91	clara	clara	PROPN
dpc-4838	2	92	de	de	PROPN
dpc-4838	2	93	simone1,2	simone1,2	PROPN
dpc-4838	2	94	1	1	NUM
dpc-4838	2	95	uoc	uoc	NOUN
dpc-4838	2	96	di	di	NOUN
dpc-4838	2	97	dermatologia	dermatologia	PROPN
dpc-4838	2	98	,	,	PUNCT
dpc-4838	2	99	dipartimento	dipartimento	ADP
dpc-4838	2	100	di	di	PROPN
dpc-4838	2	101	scienze	scienze	PROPN
dpc-4838	2	102	mediche	mediche	PROPN
dpc-4838	2	103	e	e	PROPN
dpc-4838	2	104	chirurgiche	chirurgiche	PROPN
dpc-4838	2	105	,	,	PUNCT
dpc-4838	2	106	fondazione	fondazione	PROPN
dpc-4838	2	107	policlinico	policlinico	PROPN
dpc-4838	2	108	universitario	universitario	PROPN
dpc-4838	2	109	a.	a.	PROPN
dpc-4838	2	110	gemelli	gemelli	PROPN
dpc-4838	2	111	irccs	irccs	PROPN
dpc-4838	2	112	,	,	PUNCT
dpc-4838	2	113	rome	rome	PROPN
dpc-4838	2	114	,	,	PUNCT
dpc-4838	2	115	italy	italy	PROPN
dpc-4838	2	116	2	2	NUM
dpc-4838	2	117	dermatologia	dermatologia	NOUN
dpc-4838	2	118	,	,	PUNCT
dpc-4838	2	119	dipartimento	dipartimento	ADP
dpc-4838	2	120	di	di	NOUN
dpc-4838	2	121	medicina	medicina	PROPN
dpc-4838	2	122	e	e	PROPN
dpc-4838	2	123	chirurgia	chirurgia	PROPN
dpc-4838	2	124	traslazionale	traslazionale	PROPN
dpc-4838	2	125	,	,	PUNCT
dpc-4838	2	126	università	università	PROPN
dpc-4838	2	127	cattolica	cattolica	PROPN
dpc-4838	2	128	del	del	PROPN
dpc-4838	2	129	sacro	sacro	PROPN
dpc-4838	2	130	cuore	cuore	PROPN
dpc-4838	2	131	,	,	PUNCT
dpc-4838	2	132	rome	rome	PROPN
dpc-4838	2	133	,	,	PUNCT
dpc-4838	2	134	italy	italy	PROPN
dpc-4838	2	135	3	3	NUM
dpc-4838	2	136	dermatology	dermatology	NOUN
dpc-4838	2	137	unit	unit	NOUN
dpc-4838	2	138	“	"	PUNCT
dpc-4838	2	139	d.	d.	PROPN
dpc-4838	2	140	innocenzi	innocenzi	PROPN
dpc-4838	2	141	”	"	PUNCT
dpc-4838	2	142	,	,	PUNCT
dpc-4838	2	143	department	department	NOUN
dpc-4838	2	144	of	of	ADP
dpc-4838	2	145	medical	medical	ADJ
dpc-4838	2	146	and	and	CCONJ
dpc-4838	2	147	surgical	surgical	ADJ
dpc-4838	2	148	sciences	science	NOUN
dpc-4838	2	149	and	and	CCONJ
dpc-4838	2	150	biotechnologies	biotechnology	NOUN
dpc-4838	2	151	,	,	PUNCT
dpc-4838	2	152	sapienza	sapienza	PROPN
dpc-4838	2	153	university	university	PROPN
dpc-4838	2	154	of	of	ADP
dpc-4838	2	155	rome	rome	PROPN
dpc-4838	2	156	-	-	PUNCT
dpc-4838	2	157	polo	polo	NOUN
dpc-4838	2	158	pontino	pontino	NOUN
dpc-4838	2	159	,	,	PUNCT
dpc-4838	2	160	latina	latina	PROPN
dpc-4838	2	161	,	,	PUNCT
dpc-4838	2	162	italy	italy	PROPN
dpc-4838	2	163	4	4	NUM
dpc-4838	2	164	hospital	hospital	NOUN
dpc-4838	2	165	pharmacy	pharmacy	NOUN
dpc-4838	2	166	,	,	PUNCT
dpc-4838	2	167	policlinico	policlinico	NOUN
dpc-4838	2	168	tor	tor	NOUN
dpc-4838	2	169	vergata	vergata	PROPN
dpc-4838	2	170	,	,	PUNCT
dpc-4838	2	171	rome	rome	PROPN
dpc-4838	2	172	,	,	PUNCT
dpc-4838	2	173	italy	italy	PROPN
dpc-4838	2	174	5	5	NUM
dpc-4838	2	175	unit	unit	NOUN
dpc-4838	2	176	of	of	ADP
dpc-4838	2	177	dermatology	dermatology	NOUN
dpc-4838	2	178	,	,	PUNCT
dpc-4838	2	179	department	department	NOUN
dpc-4838	2	180	of	of	ADP
dpc-4838	2	181	internal	internal	ADJ
dpc-4838	2	182	medicine	medicine	NOUN
dpc-4838	2	183	and	and	CCONJ
dpc-4838	2	184	medical	medical	ADJ
dpc-4838	2	185	specialties	specialty	NOUN
dpc-4838	2	186	,	,	PUNCT
dpc-4838	2	187	sapienza	sapienza	PROPN
dpc-4838	2	188	university	university	PROPN
dpc-4838	2	189	,	,	PUNCT
dpc-4838	2	190	rome	rome	PROPN
dpc-4838	2	191	,	,	PUNCT
dpc-4838	2	192	italy	italy	PROPN
dpc-4838	2	193	6	6	NUM
dpc-4838	2	194	dermatology	dermatology	NOUN
dpc-4838	2	195	unit	unit	NOUN
dpc-4838	2	196	,	,	PUNCT
dpc-4838	2	197	department	department	NOUN
dpc-4838	2	198	of	of	ADP
dpc-4838	2	199	systems	system	NOUN
dpc-4838	2	200	medicine	medicine	NOUN
dpc-4838	2	201	,	,	PUNCT
dpc-4838	2	202	university	university	NOUN
dpc-4838	2	203	of	of	ADP
dpc-4838	2	204	rome	rome	PROPN
dpc-4838	2	205	tor	tor	PROPN
dpc-4838	2	206	vergata	vergata	PROPN
dpc-4838	2	207	,	,	PUNCT
dpc-4838	2	208	rome	rome	PROPN
dpc-4838	2	209	,	,	PUNCT
dpc-4838	2	210	italy	italy	PROPN
dpc-4838	2	211	7	7	NUM
dpc-4838	2	212	department	department	PROPN
dpc-4838	2	213	of	of	ADP
dpc-4838	2	214	neurosciences	neuroscience	NOUN
dpc-4838	2	215	,	,	PUNCT
dpc-4838	2	216	mental	mental	ADJ
dpc-4838	2	217	health	health	NOUN
dpc-4838	2	218	and	and	CCONJ
dpc-4838	2	219	sensory	sensory	ADJ
dpc-4838	2	220	organs	organ	NOUN
dpc-4838	2	221	,	,	PUNCT
dpc-4838	2	222	sapienza	sapienza	PROPN
dpc-4838	2	223	university	university	PROPN
dpc-4838	2	224	of	of	ADP
dpc-4838	2	225	roma	roma	PROPN
dpc-4838	2	226	,	,	PUNCT
dpc-4838	2	227	rome	rome	PROPN
dpc-4838	2	228	,	,	PUNCT
dpc-4838	2	229	italy	italy	PROPN
dpc-4838	2	230	8	8	NUM
dpc-4838	2	231	dermatology	dermatology	NOUN
dpc-4838	2	232	unit	unit	NOUN
dpc-4838	2	233	,	,	PUNCT
dpc-4838	2	234	department	department	NOUN
dpc-4838	2	235	of	of	ADP
dpc-4838	2	236	clinical	clinical	ADJ
dpc-4838	2	237	internal	internal	ADJ
dpc-4838	2	238	,	,	PUNCT
dpc-4838	2	239	anesthesiological	anesthesiological	ADJ
dpc-4838	2	240	and	and	CCONJ
dpc-4838	2	241	cardiovascular	cardiovascular	ADJ
dpc-4838	2	242	science	science	NOUN
dpc-4838	2	243	,	,	PUNCT
dpc-4838	2	244	university	university	NOUN
dpc-4838	2	245	of	of	ADP
dpc-4838	2	246	la	la	PROPN
dpc-4838	2	247	sapienza	sapienza	PROPN
dpc-4838	2	248	,	,	PUNCT
dpc-4838	2	249	rome	rome	PROPN
dpc-4838	2	250	,	,	PUNCT
dpc-4838	2	251	italy	italy	PROPN
dpc-4838	2	252	9	9	NUM
dpc-4838	2	253	heor	heor	PROPN
dpc-4838	2	254	&	&	CCONJ
dpc-4838	2	255	rwe	rwe	PROPN
dpc-4838	2	256	lead	lead	PROPN
dpc-4838	2	257	,	,	PUNCT
dpc-4838	2	258	market	market	NOUN
dpc-4838	2	259	access	access	NOUN
dpc-4838	2	260	provider	provider	NOUN
dpc-4838	2	261	,	,	PUNCT
dpc-4838	2	262	milano	milano	PROPN
dpc-4838	2	263	,	,	PUNCT
dpc-4838	2	264	italy	italy	PROPN
dpc-4838	2	265	key	key	PROPN
dpc-4838	2	266	message	message	NOUN
dpc-4838	2	267	:	:	PUNCT
dpc-4838	2	268	risankizumab	risankizumab	PROPN
dpc-4838	2	269	proved	prove	VERB
dpc-4838	2	270	superior	superior	ADJ
dpc-4838	2	271	efficacy	efficacy	NOUN
dpc-4838	2	272	and	and	CCONJ
dpc-4838	2	273	cost	cost	NOUN
dpc-4838	2	274	-	-	PUNCT
dpc-4838	2	275	effectiveness	effectiveness	NOUN
dpc-4838	2	276	versus	versus	ADP
dpc-4838	2	277	secukinumab	secukinumab	NOUN
dpc-4838	2	278	in	in	ADP
dpc-4838	2	279	patients	patient	NOUN
dpc-4838	2	280	with	with	ADP
dpc-4838	2	281	psoriasis	psoriasis	NOUN
dpc-4838	2	282	in	in	ADP
dpc-4838	2	283	a	a	DET
dpc-4838	2	284	real	real	ADJ
dpc-4838	2	285	-	-	PUNCT
dpc-4838	2	286	life	life	NOUN
dpc-4838	2	287	,	,	PUNCT
dpc-4838	2	288	multicenter	multicenter	NOUN
dpc-4838	2	289	study	study	NOUN
dpc-4838	2	290	key	key	ADJ
dpc-4838	2	291	words	word	NOUN
dpc-4838	2	292	:	:	PUNCT
dpc-4838	2	293	efficacy	efficacy	NOUN
dpc-4838	2	294	,	,	PUNCT
dpc-4838	2	295	cost	cost	NOUN
dpc-4838	2	296	per	per	ADP
dpc-4838	2	297	responder	responder	NOUN
dpc-4838	2	298	,	,	PUNCT
dpc-4838	2	299	risankizumab	risankizumab	NOUN
dpc-4838	2	300	,	,	PUNCT
dpc-4838	2	301	secukinumab	secukinumab	NOUN
dpc-4838	2	302	,	,	PUNCT
dpc-4838	2	303	psoriasis	psoriasis	NOUN
dpc-4838	2	304	citation	citation	NOUN
dpc-4838	2	305	:	:	PUNCT
dpc-4838	2	306	pirro	pirro	PROPN
dpc-4838	2	307	f	f	PROPN
dpc-4838	2	308	,	,	PUNCT
dpc-4838	2	309	caldarola	caldarola	PROPN
dpc-4838	2	310	g	g	PROPN
dpc-4838	2	311	,	,	PUNCT
dpc-4838	2	312	bernardini	bernardini	PROPN
dpc-4838	2	313	n	n	CCONJ
dpc-4838	2	314	,	,	PUNCT
dpc-4838	3	1	et	et	PROPN
dpc-4838	3	2	al	al	PROPN
dpc-4838	3	3	.	.	PROPN
dpc-4838	3	4	risankizumab	risankizumab	PROPN
dpc-4838	3	5	vs	vs	ADP
dpc-4838	3	6	secukinumab	secukinumab	NOUN
dpc-4838	3	7	:	:	PUNCT
dpc-4838	3	8	a	a	DET
dpc-4838	3	9	real	real	ADJ
dpc-4838	3	10	-	-	PUNCT
dpc-4838	3	11	world	world	NOUN
dpc-4838	3	12	efficacy	efficacy	NOUN
dpc-4838	3	13	and	and	CCONJ
dpc-4838	3	14	cost	cost	NOUN
dpc-4838	3	15	per	per	ADP
dpc-4838	3	16	responder	responder	NOUN
dpc-4838	3	17	comparison	comparison	NOUN
dpc-4838	3	18	in	in	ADP
dpc-4838	3	19	patients	patient	NOUN
dpc-4838	3	20	with	with	ADP
dpc-4838	3	21	psoriasis	psoriasis	NOUN
dpc-4838	3	22	in	in	ADP
dpc-4838	3	23	italy	italy	PROPN
dpc-4838	3	24	.	.	PUNCT
dpc-4838	4	1	dermatol	dermatol	NOUN
dpc-4838	4	2	pract	pract	PROPN
dpc-4838	4	3	concept	concept	NOUN
dpc-4838	4	4	.	.	PUNCT
dpc-4838	5	1	2025;15(1):4838	2025;15(1):4838	X
dpc-4838	5	2	.	.	PUNCT
dpc-4838	5	3	doi	doi	NOUN
dpc-4838	5	4	:	:	PUNCT
dpc-4838	5	5	https://doi.org/10.5826/dpc.1501a4838	https://doi.org/10.5826/dpc.1501a4838	X
dpc-4838	5	6	accepted	accept	VERB
dpc-4838	5	7	:	:	PUNCT
dpc-4838	5	8	august	august	PROPN
dpc-4838	5	9	28	28	NUM
dpc-4838	5	10	,	,	PUNCT
dpc-4838	5	11	2024	2024	NUM
dpc-4838	5	12	;	;	PUNCT
dpc-4838	5	13	published	publish	VERB
dpc-4838	5	14	:	:	PUNCT
dpc-4838	6	1	january	january	PROPN
dpc-4838	6	2	2025	2025	NUM
dpc-4838	6	3	copyright	copyright	NOUN
dpc-4838	6	4	:	:	PUNCT
dpc-4838	6	5	©	©	PROPN
dpc-4838	6	6	2024	2024	NUM
dpc-4838	6	7	pirro	pirro	PROPN
dpc-4838	6	8	et	et	PROPN
dpc-4838	6	9	al	al	PROPN
dpc-4838	6	10	.	.	PUNCT
dpc-4838	7	1	this	this	PRON
dpc-4838	7	2	is	be	AUX
dpc-4838	7	3	an	an	DET
dpc-4838	7	4	open	open	ADJ
dpc-4838	7	5	-	-	PUNCT
dpc-4838	7	6	access	access	NOUN
dpc-4838	7	7	article	article	NOUN
dpc-4838	7	8	distributed	distribute	VERB
dpc-4838	7	9	under	under	ADP
dpc-4838	7	10	the	the	DET
dpc-4838	7	11	terms	term	NOUN
dpc-4838	7	12	of	of	ADP
dpc-4838	7	13	the	the	DET
dpc-4838	7	14	creative	creative	ADJ
dpc-4838	7	15	commons	common	NOUN
dpc-4838	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4838	7	17	license	license	NOUN
dpc-4838	7	18	(	(	PUNCT
dpc-4838	7	19	by	by	ADP
dpc-4838	7	20	-	-	PUNCT
dpc-4838	7	21	nc-4.0	nc-4.0	NOUN
dpc-4838	7	22	)	)	PUNCT
dpc-4838	7	23	,	,	PUNCT
dpc-4838	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4838	7	25	,	,	PUNCT
dpc-4838	7	26	which	which	PRON
dpc-4838	7	27	permits	permit	VERB
dpc-4838	7	28	unrestricted	unrestricted	ADJ
dpc-4838	7	29	noncommercial	noncommercial	ADJ
dpc-4838	7	30	use	use	NOUN
dpc-4838	7	31	,	,	PUNCT
dpc-4838	7	32	distribution	distribution	NOUN
dpc-4838	7	33	,	,	PUNCT
dpc-4838	7	34	and	and	CCONJ
dpc-4838	7	35	reproduction	reproduction	NOUN
dpc-4838	7	36	in	in	ADP
dpc-4838	7	37	any	any	DET
dpc-4838	7	38	medium	medium	NOUN
dpc-4838	7	39	,	,	PUNCT
dpc-4838	7	40	provided	provide	VERB
dpc-4838	7	41	the	the	DET
dpc-4838	7	42	original	original	ADJ
dpc-4838	7	43	authors	author	NOUN
dpc-4838	7	44	and	and	CCONJ
dpc-4838	7	45	source	source	NOUN
dpc-4838	7	46	are	be	AUX
dpc-4838	7	47	credited	credit	VERB
dpc-4838	7	48	.	.	PUNCT
dpc-4838	8	1	funding	funding	NOUN
dpc-4838	8	2	:	:	PUNCT
dpc-4838	8	3	none	none	NOUN
dpc-4838	8	4	.	.	PUNCT
dpc-4838	9	1	competing	compete	VERB
dpc-4838	9	2	interests	interest	NOUN
dpc-4838	9	3	:	:	PUNCT
dpc-4838	9	4	none	none	NOUN
dpc-4838	9	5	.	.	PUNCT
dpc-4838	10	1	authorship	authorship	NOUN
dpc-4838	10	2	:	:	PUNCT
dpc-4838	10	3	all	all	DET
dpc-4838	10	4	authors	author	NOUN
dpc-4838	10	5	have	have	AUX
dpc-4838	10	6	contributed	contribute	VERB
dpc-4838	10	7	significantly	significantly	ADV
dpc-4838	10	8	to	to	ADP
dpc-4838	10	9	this	this	DET
dpc-4838	10	10	publication	publication	NOUN
dpc-4838	10	11	.	.	PUNCT
dpc-4838	11	1	corresponding	correspond	VERB
dpc-4838	11	2	author	author	NOUN
dpc-4838	11	3	:	:	PUNCT
dpc-4838	11	4	pirro	pirro	PROPN
dpc-4838	11	5	federico	federico	PROPN
dpc-4838	11	6	,	,	PUNCT
dpc-4838	11	7	uoc	uoc	PROPN
dpc-4838	11	8	dermatologia	dermatologia	NOUN
dpc-4838	11	9	,	,	PUNCT
dpc-4838	11	10	fondazione	fondazione	PROPN
dpc-4838	11	11	policlinico	policlinico	PROPN
dpc-4838	11	12	universitario	universitario	PROPN
dpc-4838	11	13	a.	a.	PROPN
dpc-4838	11	14	gemelli	gemelli	PROPN
dpc-4838	11	15	irccs	irccs	PROPN
dpc-4838	11	16	,	,	PUNCT
dpc-4838	11	17	largo	largo	PROPN
dpc-4838	11	18	agostino	agostino	PROPN
dpc-4838	11	19	gemelli	gemelli	PROPN
dpc-4838	11	20	8	8	NUM
dpc-4838	11	21	rome	rome	PROPN
dpc-4838	11	22	,	,	PUNCT
dpc-4838	11	23	italy	italy	PROPN
dpc-4838	11	24	.	.	PUNCT
dpc-4838	12	1	e	e	X
dpc-4838	12	2	-	-	NOUN
dpc-4838	12	3	mail	mail	NOUN
dpc-4838	12	4	:	:	PUNCT
dpc-4838	12	5	federico.pirro90@gmail.com	federico.pirro90@gmail.com	X
dpc-4838	12	6	2	2	NUM
dpc-4838	12	7	original	original	ADJ
dpc-4838	12	8	article	article	NOUN
dpc-4838	12	9	|	|	ADV
dpc-4838	12	10	dermatol	dermatol	ADJ
dpc-4838	12	11	pract	pract	NOUN
dpc-4838	12	12	concept	concept	NOUN
dpc-4838	12	13	.	.	PUNCT
dpc-4838	13	1	2025;15(1):4838	2025;15(1):4838	NUM
dpc-4838	13	2	introduction	introduction	NOUN
dpc-4838	13	3	psoriasis	psoriasis	NOUN
dpc-4838	13	4	is	be	AUX
dpc-4838	13	5	a	a	DET
dpc-4838	13	6	chronic	chronic	NOUN
dpc-4838	13	7	,	,	PUNCT
dpc-4838	13	8	inflammatory	inflammatory	ADJ
dpc-4838	13	9	,	,	PUNCT
dpc-4838	13	10	immune	immune	NOUN
dpc-4838	13	11	-	-	PUNCT
dpc-4838	13	12	mediated	mediate	VERB
dpc-4838	13	13	disease	disease	NOUN
dpc-4838	13	14	with	with	ADP
dpc-4838	13	15	high	high	ADJ
dpc-4838	13	16	prevalence	prevalence	NOUN
dpc-4838	13	17	in	in	ADP
dpc-4838	13	18	the	the	DET
dpc-4838	13	19	italian	italian	ADJ
dpc-4838	13	20	population	population	NOUN
dpc-4838	13	21	,	,	PUNCT
dpc-4838	13	22	ranging	range	VERB
dpc-4838	13	23	from	from	ADP
dpc-4838	13	24	1.8	1.8	NUM
dpc-4838	13	25	%	%	NOUN
dpc-4838	13	26	to	to	PART
dpc-4838	13	27	4.8	4.8	NUM
dpc-4838	13	28	%	%	NOUN
dpc-4838	13	29	[	[	X
dpc-4838	13	30	1,2	1,2	NUM
dpc-4838	13	31	]	]	PUNCT
dpc-4838	13	32	and	and	CCONJ
dpc-4838	13	33	affecting	affect	VERB
dpc-4838	13	34	over	over	ADP
dpc-4838	13	35	100	100	NUM
dpc-4838	13	36	million	million	NUM
dpc-4838	13	37	people	people	NOUN
dpc-4838	13	38	worldwide	worldwide	ADV
dpc-4838	13	39	,	,	PUNCT
dpc-4838	13	40	with	with	ADP
dpc-4838	13	41	plaque	plaque	NOUN
dpc-4838	13	42	psoriasis	psoriasis	NOUN
dpc-4838	13	43	being	be	AUX
dpc-4838	13	44	the	the	DET
dpc-4838	13	45	most	most	ADV
dpc-4838	13	46	common	common	ADJ
dpc-4838	13	47	variant	variant	NOUN
dpc-4838	13	48	[	[	X
dpc-4838	13	49	3	3	NUM
dpc-4838	13	50	]	]	PUNCT
dpc-4838	13	51	.	.	PUNCT
dpc-4838	14	1	the	the	DET
dpc-4838	14	2	concept	concept	NOUN
dpc-4838	14	3	of	of	ADP
dpc-4838	14	4	psoriasis	psoriasis	NOUN
dpc-4838	14	5	as	as	ADP
dpc-4838	14	6	a	a	DET
dpc-4838	14	7	systemic	systemic	ADJ
dpc-4838	14	8	inflammatory	inflammatory	ADJ
dpc-4838	14	9	disease	disease	NOUN
dpc-4838	14	10	is	be	AUX
dpc-4838	14	11	now	now	ADV
dpc-4838	14	12	well	well	ADV
dpc-4838	14	13	established	establish	VERB
dpc-4838	14	14	[	[	PUNCT
dpc-4838	14	15	4,5	4,5	NUM
dpc-4838	14	16	]	]	PUNCT
dpc-4838	14	17	,	,	PUNCT
dpc-4838	14	18	with	with	ADP
dpc-4838	14	19	a	a	DET
dpc-4838	14	20	complex	complex	ADJ
dpc-4838	14	21	network	network	NOUN
dpc-4838	14	22	of	of	ADP
dpc-4838	14	23	dendritic	dendritic	ADJ
dpc-4838	14	24	cells	cell	NOUN
dpc-4838	14	25	,	,	PUNCT
dpc-4838	14	26	t	t	NOUN
dpc-4838	14	27	-	-	PUNCT
dpc-4838	14	28	cells	cell	NOUN
dpc-4838	14	29	and	and	CCONJ
dpc-4838	14	30	cytokines	cytokine	NOUN
dpc-4838	14	31	eventually	eventually	ADV
dpc-4838	14	32	leading	lead	VERB
dpc-4838	14	33	to	to	ADP
dpc-4838	14	34	inflammation	inflammation	NOUN
dpc-4838	14	35	,	,	PUNCT
dpc-4838	14	36	neutrophilic	neutrophilic	ADJ
dpc-4838	14	37	chemotaxis	chemotaxis	ADJ
dpc-4838	14	38	and	and	CCONJ
dpc-4838	14	39	keratinocytes	keratinocyte	VERB
dpc-4838	14	40	proliferation	proliferation	NOUN
dpc-4838	14	41	[	[	X
dpc-4838	14	42	6	6	NUM
dpc-4838	14	43	]	]	PUNCT
dpc-4838	14	44	.	.	PUNCT
dpc-4838	15	1	while	while	SCONJ
dpc-4838	15	2	previously	previously	ADV
dpc-4838	15	3	considered	consider	VERB
dpc-4838	15	4	a	a	DET
dpc-4838	15	5	th1	th1	NOUN
dpc-4838	15	6	-	-	PUNCT
dpc-4838	15	7	mediated	mediate	VERB
dpc-4838	15	8	disease	disease	NOUN
dpc-4838	15	9	,	,	PUNCT
dpc-4838	15	10	the	the	DET
dpc-4838	15	11	most	most	ADV
dpc-4838	15	12	recent	recent	ADJ
dpc-4838	15	13	findings	finding	NOUN
dpc-4838	15	14	regarding	regard	VERB
dpc-4838	15	15	psoriasis	psoriasis	NOUN
dpc-4838	15	16	pathogenesis	pathogenesis	NOUN
dpc-4838	15	17	highlight	highlight	VERB
dpc-4838	15	18	the	the	DET
dpc-4838	15	19	central	central	ADJ
dpc-4838	15	20	role	role	NOUN
dpc-4838	15	21	of	of	ADP
dpc-4838	15	22	the	the	DET
dpc-4838	15	23	il23	il23	PROPN
dpc-4838	15	24	/	/	SYM
dpc-4838	15	25	th17	th17	PROPN
dpc-4838	15	26	axis	axis	NOUN
dpc-4838	15	27	,	,	PUNCT
dpc-4838	15	28	with	with	ADP
dpc-4838	15	29	il17	il17	PROPN
dpc-4838	15	30	and	and	CCONJ
dpc-4838	15	31	il23	il23	PROPN
dpc-4838	15	32	being	be	AUX
dpc-4838	15	33	key	key	ADJ
dpc-4838	15	34	mediators	mediator	NOUN
dpc-4838	15	35	in	in	ADP
dpc-4838	15	36	establishing	establish	VERB
dpc-4838	15	37	psoriasis	psoriasis	NOUN
dpc-4838	15	38	inflammatory	inflammatory	ADJ
dpc-4838	15	39	cascade	cascade	NOUN
dpc-4838	15	40	[	[	X
dpc-4838	15	41	7,8	7,8	NUM
dpc-4838	15	42	]	]	PUNCT
dpc-4838	15	43	.	.	PUNCT
dpc-4838	16	1	as	as	ADP
dpc-4838	16	2	a	a	DET
dpc-4838	16	3	result	result	NOUN
dpc-4838	16	4	of	of	ADP
dpc-4838	16	5	the	the	DET
dpc-4838	16	6	growing	grow	VERB
dpc-4838	16	7	understanding	understanding	NOUN
dpc-4838	16	8	of	of	ADP
dpc-4838	16	9	the	the	DET
dpc-4838	16	10	pathogenesis	pathogenesis	NOUN
dpc-4838	16	11	of	of	ADP
dpc-4838	16	12	psoriasis	psoriasis	NOUN
dpc-4838	16	13	,	,	PUNCT
dpc-4838	16	14	there	there	PRON
dpc-4838	16	15	has	have	AUX
dpc-4838	16	16	been	be	AUX
dpc-4838	16	17	a	a	DET
dpc-4838	16	18	steady	steady	ADJ
dpc-4838	16	19	development	development	NOUN
dpc-4838	16	20	of	of	ADP
dpc-4838	16	21	more	more	ADV
dpc-4838	16	22	targeted	targeted	ADJ
dpc-4838	16	23	and	and	CCONJ
dpc-4838	16	24	effective	effective	ADJ
dpc-4838	16	25	therapies	therapy	NOUN
dpc-4838	16	26	.	.	PUNCT
dpc-4838	17	1	the	the	DET
dpc-4838	17	2	introduction	introduction	NOUN
dpc-4838	17	3	of	of	ADP
dpc-4838	17	4	antiinterleukin	antiinterleukin	PROPN
dpc-4838	17	5	(	(	PUNCT
dpc-4838	17	6	il	il	PROPN
dpc-4838	17	7	)	)	PUNCT
dpc-4838	17	8	drugs	drug	NOUN
dpc-4838	17	9	,	,	PUNCT
dpc-4838	17	10	inhibiting	inhibit	VERB
dpc-4838	17	11	the	the	DET
dpc-4838	17	12	action	action	NOUN
dpc-4838	17	13	of	of	ADP
dpc-4838	17	14	il17	il17	PROPN
dpc-4838	17	15	or	or	CCONJ
dpc-4838	17	16	il23	il23	PROPN
dpc-4838	17	17	at	at	ADP
dpc-4838	17	18	different	different	ADJ
dpc-4838	17	19	levels	level	NOUN
dpc-4838	17	20	of	of	ADP
dpc-4838	17	21	psoriasis	psoriasis	NOUN
dpc-4838	17	22	inflammatory	inflammatory	ADJ
dpc-4838	17	23	network	network	NOUN
dpc-4838	17	24	[	[	X
dpc-4838	17	25	9	9	NUM
dpc-4838	17	26	]	]	PUNCT
dpc-4838	17	27	,	,	PUNCT
dpc-4838	17	28	has	have	AUX
dpc-4838	17	29	set	set	VERB
dpc-4838	17	30	a	a	DET
dpc-4838	17	31	new	new	ADJ
dpc-4838	17	32	standard	standard	NOUN
dpc-4838	17	33	in	in	ADP
dpc-4838	17	34	the	the	DET
dpc-4838	17	35	treatment	treatment	NOUN
dpc-4838	17	36	of	of	ADP
dpc-4838	17	37	moderate	moderate	ADJ
dpc-4838	17	38	-	-	PUNCT
dpc-4838	17	39	to	to	ADP
dpc-4838	17	40	severe	severe	ADJ
dpc-4838	17	41	forms	form	NOUN
dpc-4838	17	42	of	of	ADP
dpc-4838	17	43	psoriasis	psoriasis	NOUN
dpc-4838	17	44	,	,	PUNCT
dpc-4838	17	45	offering	offer	VERB
dpc-4838	17	46	superior	superior	ADJ
dpc-4838	17	47	efficacy	efficacy	NOUN
dpc-4838	17	48	and	and	CCONJ
dpc-4838	17	49	safety	safety	NOUN
dpc-4838	17	50	profiles	profile	NOUN
dpc-4838	17	51	when	when	SCONJ
dpc-4838	17	52	compared	compare	VERB
dpc-4838	17	53	to	to	ADP
dpc-4838	17	54	conventional	conventional	ADJ
dpc-4838	17	55	systemic	systemic	ADJ
dpc-4838	17	56	therapies	therapy	NOUN
dpc-4838	17	57	(	(	PUNCT
dpc-4838	17	58	i.e.	i.e.	X
dpc-4838	17	59	,	,	PUNCT
dpc-4838	17	60	methotrexate	methotrexate	NOUN
dpc-4838	17	61	and	and	CCONJ
dpc-4838	17	62	cyclosporine	cyclosporine	ADJ
dpc-4838	17	63	)	)	PUNCT
dpc-4838	17	64	and	and	CCONJ
dpc-4838	17	65	anti	anti	ADJ
dpc-4838	17	66	-	-	ADJ
dpc-4838	17	67	tnf	tnf	ADJ
dpc-4838	17	68	drugs	drug	NOUN
dpc-4838	17	69	(	(	PUNCT
dpc-4838	17	70	etanercept	etanercept	NOUN
dpc-4838	17	71	,	,	PUNCT
dpc-4838	17	72	infliximab	infliximab	NOUN
dpc-4838	17	73	,	,	PUNCT
dpc-4838	17	74	adalimumab	adalimumab	NOUN
dpc-4838	17	75	,	,	PUNCT
dpc-4838	17	76	certolizumab	certolizumab	NOUN
dpc-4838	17	77	)	)	PUNCT
dpc-4838	18	1	[	[	X
dpc-4838	18	2	6	6	NUM
dpc-4838	18	3	]	]	PUNCT
dpc-4838	18	4	.	.	PUNCT
dpc-4838	19	1	secukinumab	secukinumab	NOUN
dpc-4838	19	2	,	,	PUNCT
dpc-4838	19	3	a	a	DET
dpc-4838	19	4	fully	fully	ADV
dpc-4838	19	5	human	human	ADJ
dpc-4838	19	6	monoclonal	monoclonal	NOUN
dpc-4838	19	7	antibody	antibody	NOUN
dpc-4838	19	8	targeting	target	VERB
dpc-4838	19	9	interleukin-17a	interleukin-17a	PROPN
dpc-4838	19	10	(	(	PUNCT
dpc-4838	19	11	il17a	il17a	PROPN
dpc-4838	19	12	)	)	PUNCT
dpc-4838	19	13	,	,	PUNCT
dpc-4838	19	14	was	be	AUX
dpc-4838	19	15	the	the	DET
dpc-4838	19	16	first	first	ADJ
dpc-4838	19	17	anti	anti	ADJ
dpc-4838	19	18	-	-	ADJ
dpc-4838	19	19	il17	il17	ADJ
dpc-4838	19	20	drug	drug	NOUN
dpc-4838	19	21	to	to	PART
dpc-4838	19	22	receive	receive	VERB
dpc-4838	19	23	the	the	DET
dpc-4838	19	24	fda	fda	PROPN
dpc-4838	19	25	and	and	CCONJ
dpc-4838	19	26	ema	ema	PROPN
dpc-4838	19	27	approval	approval	NOUN
dpc-4838	19	28	in	in	ADP
dpc-4838	19	29	2015	2015	NUM
dpc-4838	19	30	for	for	ADP
dpc-4838	19	31	the	the	DET
dpc-4838	19	32	treatment	treatment	NOUN
dpc-4838	19	33	of	of	ADP
dpc-4838	19	34	moderate	moderate	ADJ
dpc-4838	19	35	-	-	PUNCT
dpc-4838	19	36	to	to	ADP
dpc-4838	19	37	-	-	PUNCT
dpc-4838	19	38	severe	severe	ADJ
dpc-4838	19	39	forms	form	NOUN
dpc-4838	19	40	of	of	ADP
dpc-4838	19	41	psoriasis	psoriasis	NOUN
dpc-4838	19	42	[	[	X
dpc-4838	19	43	10	10	NUM
dpc-4838	19	44	]	]	PUNCT
dpc-4838	19	45	.	.	PUNCT
dpc-4838	20	1	in	in	ADP
dpc-4838	20	2	two	two	NUM
dpc-4838	20	3	phase	phase	NOUN
dpc-4838	20	4	iii	iii	NUM
dpc-4838	20	5	trials	trial	NOUN
dpc-4838	20	6	,	,	PUNCT
dpc-4838	20	7	secukinumab	secukinumab	NOUN
dpc-4838	20	8	showed	show	VERB
dpc-4838	20	9	superior	superior	ADJ
dpc-4838	20	10	efficacy	efficacy	NOUN
dpc-4838	20	11	and	and	CCONJ
dpc-4838	20	12	similar	similar	ADJ
dpc-4838	20	13	safety	safety	NOUN
dpc-4838	20	14	when	when	SCONJ
dpc-4838	20	15	compared	compare	VERB
dpc-4838	20	16	to	to	PART
dpc-4838	20	17	etanercept	etanercept	VERB
dpc-4838	20	18	[	[	X
dpc-4838	20	19	11	11	NUM
dpc-4838	20	20	]	]	PUNCT
dpc-4838	20	21	.	.	PUNCT
dpc-4838	21	1	secukinumab	secukinumab	NOUN
dpc-4838	21	2	also	also	ADV
dpc-4838	21	3	proved	prove	VERB
dpc-4838	21	4	superior	superior	ADJ
dpc-4838	21	5	in	in	ADP
dpc-4838	21	6	a	a	DET
dpc-4838	21	7	“	"	PUNCT
dpc-4838	21	8	head	head	NOUN
dpc-4838	21	9	-	-	PUNCT
dpc-4838	21	10	to	to	ADP
dpc-4838	21	11	-	-	PUNCT
dpc-4838	21	12	head	head	NOUN
dpc-4838	21	13	”	"	PUNCT
dpc-4838	21	14	comparison	comparison	NOUN
dpc-4838	21	15	with	with	ADP
dpc-4838	21	16	ustekinumab	ustekinumab	NOUN
dpc-4838	21	17	(	(	PUNCT
dpc-4838	21	18	an	an	DET
dpc-4838	21	19	anti	anti	ADJ
dpc-4838	21	20	-	-	ADJ
dpc-4838	21	21	il12	il12	ADJ
dpc-4838	21	22	/	/	SYM
dpc-4838	21	23	il23	il23	PROPN
dpc-4838	21	24	drug	drug	NOUN
dpc-4838	21	25	)	)	PUNCT
dpc-4838	21	26	,	,	PUNCT
dpc-4838	21	27	showing	show	VERB
dpc-4838	21	28	higher	high	ADJ
dpc-4838	21	29	rates	rate	NOUN
dpc-4838	21	30	of	of	ADP
dpc-4838	21	31	skin	skin	NOUN
dpc-4838	21	32	clearance	clearance	NOUN
dpc-4838	21	33	up	up	ADP
dpc-4838	21	34	to	to	PART
dpc-4838	21	35	1	1	NUM
dpc-4838	21	36	year	year	NOUN
dpc-4838	21	37	of	of	ADP
dpc-4838	21	38	treatment	treatment	NOUN
dpc-4838	21	39	[	[	X
dpc-4838	21	40	12	12	NUM
dpc-4838	21	41	]	]	PUNCT
dpc-4838	21	42	.	.	PUNCT
dpc-4838	22	1	risankizumab	risankizumab	PROPN
dpc-4838	22	2	,	,	PUNCT
dpc-4838	22	3	a	a	DET
dpc-4838	22	4	humanized	humanize	VERB
dpc-4838	22	5	monoclonal	monoclonal	NOUN
dpc-4838	22	6	antibody	antibody	NOUN
dpc-4838	22	7	that	that	PRON
dpc-4838	22	8	binds	bind	VERB
dpc-4838	22	9	with	with	ADP
dpc-4838	22	10	high	high	ADJ
dpc-4838	22	11	affinity	affinity	NOUN
dpc-4838	22	12	to	to	ADP
dpc-4838	22	13	the	the	DET
dpc-4838	22	14	p19	p19	ADJ
dpc-4838	22	15	subunit	subunit	NOUN
dpc-4838	22	16	of	of	ADP
dpc-4838	22	17	il23	il23	PROPN
dpc-4838	22	18	,	,	PUNCT
dpc-4838	22	19	also	also	ADV
dpc-4838	22	20	showed	show	VERB
dpc-4838	22	21	favorable	favorable	ADJ
dpc-4838	22	22	efficacy	efficacy	NOUN
dpc-4838	22	23	and	and	CCONJ
dpc-4838	22	24	safety	safety	NOUN
dpc-4838	22	25	profiles	profile	NOUN
dpc-4838	22	26	in	in	ADP
dpc-4838	22	27	several	several	ADJ
dpc-4838	22	28	phase	phase	NOUN
dpc-4838	22	29	iii	iii	NUM
dpc-4838	22	30	trials	trial	NOUN
dpc-4838	22	31	[	[	X
dpc-4838	22	32	13	13	NUM
dpc-4838	22	33	]	]	PUNCT
dpc-4838	22	34	,	,	PUNCT
dpc-4838	22	35	with	with	ADP
dpc-4838	22	36	higher	high	ADJ
dpc-4838	22	37	rates	rate	NOUN
dpc-4838	22	38	of	of	ADP
dpc-4838	22	39	skin	skin	NOUN
dpc-4838	22	40	clearance	clearance	NOUN
dpc-4838	22	41	than	than	ADP
dpc-4838	22	42	both	both	DET
dpc-4838	22	43	placebo	placebo	NOUN
dpc-4838	22	44	and	and	CCONJ
dpc-4838	22	45	ustekinumab	ustekinumab	NOUN
dpc-4838	22	46	and	and	CCONJ
dpc-4838	22	47	received	receive	VERB
dpc-4838	22	48	fda	fda	PROPN
dpc-4838	22	49	and	and	CCONJ
dpc-4838	22	50	ema	ema	PROPN
dpc-4838	22	51	approval	approval	NOUN
dpc-4838	22	52	in	in	ADP
dpc-4838	22	53	2019	2019	NUM
dpc-4838	22	54	[	[	X
dpc-4838	22	55	14	14	NUM
dpc-4838	22	56	]	]	PUNCT
dpc-4838	22	57	.	.	PUNCT
dpc-4838	23	1	of	of	ADP
dpc-4838	23	2	note	note	NOUN
dpc-4838	23	3	,	,	PUNCT
dpc-4838	23	4	in	in	ADP
dpc-4838	23	5	the	the	DET
dpc-4838	23	6	immerge	immerge	NOUN
dpc-4838	23	7	trial	trial	NOUN
dpc-4838	23	8	,	,	PUNCT
dpc-4838	23	9	a	a	DET
dpc-4838	23	10	“	"	PUNCT
dpc-4838	23	11	head	head	NOUN
dpc-4838	23	12	-	-	PUNCT
dpc-4838	23	13	to	to	ADP
dpc-4838	23	14	-	-	PUNCT
dpc-4838	23	15	head	head	NOUN
dpc-4838	23	16	”	"	PUNCT
dpc-4838	23	17	comparison	comparison	NOUN
dpc-4838	23	18	of	of	ADP
dpc-4838	23	19	risankizumab	risankizumab	NOUN
dpc-4838	23	20	vs	vs	ADP
dpc-4838	23	21	secukinumab	secukinumab	NOUN
dpc-4838	23	22	showed	show	VERB
dpc-4838	23	23	superior	superior	ADJ
dpc-4838	23	24	efficacy	efficacy	NOUN
dpc-4838	23	25	for	for	ADP
dpc-4838	23	26	the	the	DET
dpc-4838	23	27	former	former	ADJ
dpc-4838	23	28	,	,	PUNCT
dpc-4838	23	29	along	along	ADP
dpc-4838	23	30	with	with	ADP
dpc-4838	23	31	similar	similar	ADJ
dpc-4838	23	32	safety	safety	NOUN
dpc-4838	23	33	and	and	CCONJ
dpc-4838	23	34	a	a	DET
dpc-4838	23	35	more	more	ADV
dpc-4838	23	36	convenient	convenient	ADJ
dpc-4838	23	37	dosing	dose	VERB
dpc-4838	23	38	schedule	schedule	NOUN
dpc-4838	23	39	[	[	X
dpc-4838	23	40	15	15	NUM
dpc-4838	23	41	]	]	PUNCT
dpc-4838	23	42	.	.	PUNCT
dpc-4838	24	1	although	although	SCONJ
dpc-4838	24	2	the	the	DET
dpc-4838	24	3	efficacy	efficacy	NOUN
dpc-4838	24	4	and	and	CCONJ
dpc-4838	24	5	safety	safety	NOUN
dpc-4838	24	6	of	of	ADP
dpc-4838	24	7	these	these	DET
dpc-4838	24	8	drugs	drug	NOUN
dpc-4838	24	9	are	be	AUX
dpc-4838	24	10	well	well	ADV
dpc-4838	24	11	established	establish	VERB
dpc-4838	24	12	in	in	ADP
dpc-4838	24	13	randomized	randomized	ADJ
dpc-4838	24	14	clinical	clinical	ADJ
dpc-4838	24	15	trials	trial	NOUN
dpc-4838	24	16	(	(	PUNCT
dpc-4838	24	17	rcts	rct	NOUN
dpc-4838	24	18	)	)	PUNCT
dpc-4838	24	19	,	,	PUNCT
dpc-4838	24	20	there	there	PRON
dpc-4838	24	21	is	be	VERB
dpc-4838	24	22	little	little	ADJ
dpc-4838	24	23	data	datum	NOUN
dpc-4838	24	24	regarding	regard	VERB
dpc-4838	24	25	a	a	DET
dpc-4838	24	26	direct	direct	ADJ
dpc-4838	24	27	comparison	comparison	NOUN
dpc-4838	24	28	of	of	ADP
dpc-4838	24	29	risankizumab	risankizumab	NOUN
dpc-4838	24	30	and	and	CCONJ
dpc-4838	24	31	secukinumab	secukinumab	NOUN
dpc-4838	24	32	in	in	ADP
dpc-4838	24	33	a	a	DET
dpc-4838	24	34	real	real	ADJ
dpc-4838	24	35	-	-	PUNCT
dpc-4838	24	36	life	life	NOUN
dpc-4838	24	37	setting	setting	NOUN
dpc-4838	24	38	,	,	PUNCT
dpc-4838	24	39	except	except	SCONJ
dpc-4838	24	40	for	for	ADP
dpc-4838	24	41	indirect	indirect	ADJ
dpc-4838	24	42	comparisons	comparison	NOUN
dpc-4838	24	43	between	between	ADP
dpc-4838	24	44	different	different	ADJ
dpc-4838	24	45	anti	anti	ADJ
dpc-4838	24	46	-	-	ADJ
dpc-4838	24	47	interleukin	interleukin	ADJ
dpc-4838	24	48	agents	agent	NOUN
dpc-4838	24	49	in	in	ADP
dpc-4838	24	50	drug	drug	NOUN
dpc-4838	24	51	-	-	PUNCT
dpc-4838	24	52	survival	survival	NOUN
dpc-4838	24	53	studies	study	NOUN
dpc-4838	24	54	[	[	X
dpc-4838	24	55	16,17	16,17	NUM
dpc-4838	24	56	]	]	PUNCT
dpc-4838	24	57	.	.	PUNCT
dpc-4838	25	1	moreover	moreover	ADV
dpc-4838	25	2	,	,	PUNCT
dpc-4838	25	3	there	there	PRON
dpc-4838	25	4	are	be	VERB
dpc-4838	25	5	few	few	ADJ
dpc-4838	25	6	data	datum	NOUN
dpc-4838	25	7	comparing	compare	VERB
dpc-4838	25	8	the	the	DET
dpc-4838	25	9	economic	economic	ADJ
dpc-4838	25	10	impact	impact	NOUN
dpc-4838	25	11	of	of	ADP
dpc-4838	25	12	using	use	VERB
dpc-4838	25	13	secukinumab	secukinumab	NOUN
dpc-4838	25	14	or	or	CCONJ
dpc-4838	25	15	risankizumab	risankizumab	NOUN
dpc-4838	25	16	to	to	PART
dpc-4838	25	17	treat	treat	VERB
dpc-4838	25	18	moderate	moderate	ADJ
dpc-4838	25	19	-	-	PUNCT
dpc-4838	25	20	to	to	ADP
dpc-4838	25	21	-	-	PUNCT
dpc-4838	25	22	severe	severe	ADJ
dpc-4838	25	23	psoriasis	psoriasis	NOUN
dpc-4838	25	24	.	.	PUNCT
dpc-4838	26	1	in	in	ADP
dpc-4838	26	2	2021	2021	NUM
dpc-4838	26	3	,	,	PUNCT
dpc-4838	26	4	gisondi	gisondi	NOUN
dpc-4838	26	5	et	et	NOUN
dpc-4838	26	6	al	al	PROPN
dpc-4838	26	7	showed	show	VERB
dpc-4838	26	8	a	a	DET
dpc-4838	26	9	more	more	ADV
dpc-4838	26	10	favorable	favorable	ADJ
dpc-4838	26	11	economic	economic	ADJ
dpc-4838	26	12	profile	profile	NOUN
dpc-4838	26	13	for	for	ADP
dpc-4838	26	14	risankizumab	risankizumab	NOUN
dpc-4838	26	15	,	,	PUNCT
dpc-4838	26	16	in	in	ADP
dpc-4838	26	17	addition	addition	NOUN
dpc-4838	26	18	to	to	ADP
dpc-4838	26	19	its	its	PRON
dpc-4838	26	20	greater	great	ADJ
dpc-4838	26	21	efficacy	efficacy	NOUN
dpc-4838	26	22	,	,	PUNCT
dpc-4838	26	23	in	in	ADP
dpc-4838	26	24	an	an	DET
dpc-4838	26	25	analysis	analysis	NOUN
dpc-4838	26	26	aimed	aim	VERB
dpc-4838	26	27	at	at	ADP
dpc-4838	26	28	establishing	establish	VERB
dpc-4838	26	29	and	and	CCONJ
dpc-4838	26	30	comparing	compare	VERB
dpc-4838	26	31	the	the	DET
dpc-4838	26	32	cost	cost	NOUN
dpc-4838	26	33	per	per	ADP
dpc-4838	26	34	responder	responder	NOUN
dpc-4838	26	35	(	(	PUNCT
dpc-4838	26	36	ie	ie	X
dpc-4838	26	37	.	.	PUNCT
dpc-4838	27	1	the	the	DET
dpc-4838	27	2	evaluation	evaluation	NOUN
dpc-4838	27	3	of	of	ADP
dpc-4838	27	4	the	the	DET
dpc-4838	27	5	cost	cost	NOUN
dpc-4838	27	6	-	-	PUNCT
dpc-4838	27	7	effectiveness	effectiveness	NOUN
dpc-4838	27	8	of	of	ADP
dpc-4838	27	9	a	a	DET
dpc-4838	27	10	certain	certain	ADJ
dpc-4838	27	11	drug	drug	NOUN
dpc-4838	27	12	in	in	ADP
dpc-4838	27	13	treating	treat	VERB
dpc-4838	27	14	a	a	DET
dpc-4838	27	15	specific	specific	ADJ
dpc-4838	27	16	introduction	introduction	NOUN
dpc-4838	27	17	:	:	PUNCT
dpc-4838	27	18	risankizumab	risankizumab	NOUN
dpc-4838	27	19	and	and	CCONJ
dpc-4838	27	20	secukinumab	secukinumab	NOUN
dpc-4838	27	21	are	be	AUX
dpc-4838	27	22	effective	effective	ADJ
dpc-4838	27	23	treatment	treatment	NOUN
dpc-4838	27	24	options	option	NOUN
dpc-4838	27	25	for	for	ADP
dpc-4838	27	26	patients	patient	NOUN
dpc-4838	27	27	with	with	ADP
dpc-4838	27	28	moderate	moderate	ADJ
dpc-4838	27	29	to	to	ADP
dpc-4838	27	30	severe	severe	ADJ
dpc-4838	27	31	psoriasis	psoriasis	NOUN
dpc-4838	27	32	.	.	PUNCT
dpc-4838	28	1	objectives	objective	NOUN
dpc-4838	28	2	:	:	PUNCT
dpc-4838	28	3	we	we	PRON
dpc-4838	28	4	sought	seek	VERB
dpc-4838	28	5	to	to	PART
dpc-4838	28	6	estimate	estimate	VERB
dpc-4838	28	7	the	the	DET
dpc-4838	28	8	efficacy	efficacy	NOUN
dpc-4838	28	9	and	and	CCONJ
dpc-4838	28	10	the	the	DET
dpc-4838	28	11	cost	cost	NOUN
dpc-4838	28	12	per	per	ADP
dpc-4838	28	13	responder	responder	NOUN
dpc-4838	28	14	of	of	ADP
dpc-4838	28	15	risankizumab	risankizumab	NOUN
dpc-4838	28	16	and	and	CCONJ
dpc-4838	28	17	secukinumab	secukinumab	NOUN
dpc-4838	28	18	by	by	ADP
dpc-4838	28	19	comparing	compare	VERB
dpc-4838	28	20	these	these	DET
dpc-4838	28	21	two	two	NUM
dpc-4838	28	22	drugs	drug	NOUN
dpc-4838	28	23	in	in	ADP
dpc-4838	28	24	a	a	DET
dpc-4838	28	25	real	real	ADJ
dpc-4838	28	26	-	-	PUNCT
dpc-4838	28	27	life	life	NOUN
dpc-4838	28	28	setting	setting	NOUN
dpc-4838	28	29	.	.	PUNCT
dpc-4838	29	1	methods	method	NOUN
dpc-4838	29	2	:	:	PUNCT
dpc-4838	29	3	a	a	DET
dpc-4838	29	4	multicentric	multicentric	ADJ
dpc-4838	29	5	retrospective	retrospective	ADJ
dpc-4838	29	6	study	study	NOUN
dpc-4838	29	7	was	be	AUX
dpc-4838	29	8	conducted	conduct	VERB
dpc-4838	29	9	in	in	ADP
dpc-4838	29	10	patients	patient	NOUN
dpc-4838	29	11	from	from	ADP
dpc-4838	29	12	the	the	DET
dpc-4838	29	13	lazio	lazio	PROPN
dpc-4838	29	14	region	region	NOUN
dpc-4838	29	15	of	of	ADP
dpc-4838	29	16	italy	italy	PROPN
dpc-4838	29	17	affected	affect	VERB
dpc-4838	29	18	by	by	ADP
dpc-4838	29	19	moderate	moderate	ADJ
dpc-4838	29	20	-	-	PUNCT
dpc-4838	29	21	to	to	ADP
dpc-4838	29	22	-	-	PUNCT
dpc-4838	29	23	severe	severe	ADJ
dpc-4838	29	24	psoriasis	psoriasis	NOUN
dpc-4838	29	25	who	who	PRON
dpc-4838	29	26	initiated	initiate	VERB
dpc-4838	29	27	risankizumab	risankizumab	NOUN
dpc-4838	29	28	or	or	CCONJ
dpc-4838	29	29	secukinumab	secukinumab	NOUN
dpc-4838	29	30	between	between	ADP
dpc-4838	29	31	september	september	PROPN
dpc-4838	29	32	2020	2020	NUM
dpc-4838	29	33	to	to	ADP
dpc-4838	29	34	september	september	PROPN
dpc-4838	29	35	2022	2022	NUM
dpc-4838	29	36	.	.	PUNCT
dpc-4838	30	1	psoriasis	psoriasis	NOUN
dpc-4838	30	2	area	area	NOUN
dpc-4838	30	3	and	and	CCONJ
dpc-4838	30	4	severity	severity	NOUN
dpc-4838	30	5	index	index	NOUN
dpc-4838	30	6	(	(	PUNCT
dpc-4838	30	7	pasi	pasi	NOUN
dpc-4838	30	8	)	)	PUNCT
dpc-4838	30	9	was	be	AUX
dpc-4838	30	10	measured	measure	VERB
dpc-4838	30	11	at	at	ADP
dpc-4838	30	12	baseline	baseline	NOUN
dpc-4838	30	13	and	and	CCONJ
dpc-4838	30	14	after	after	ADP
dpc-4838	30	15	16	16	NUM
dpc-4838	30	16	,	,	PUNCT
dpc-4838	30	17	52	52	NUM
dpc-4838	30	18	,	,	PUNCT
dpc-4838	30	19	and	and	CCONJ
dpc-4838	30	20	78	78	NUM
dpc-4838	30	21	weeks	week	NOUN
dpc-4838	30	22	.	.	PUNCT
dpc-4838	31	1	clinical	clinical	ADJ
dpc-4838	31	2	responses	response	NOUN
dpc-4838	31	3	were	be	AUX
dpc-4838	31	4	evaluated	evaluate	VERB
dpc-4838	31	5	by	by	ADP
dpc-4838	31	6	pasi90	pasi90	NOUN
dpc-4838	31	7	and	and	CCONJ
dpc-4838	31	8	pasi100	pasi100	PROPN
dpc-4838	31	9	responses	response	NOUN
dpc-4838	31	10	at	at	ADP
dpc-4838	31	11	the	the	DET
dpc-4838	31	12	same	same	ADJ
dpc-4838	31	13	timepoints	timepoint	NOUN
dpc-4838	31	14	.	.	PUNCT
dpc-4838	32	1	the	the	DET
dpc-4838	32	2	cost	cost	NOUN
dpc-4838	32	3	per	per	ADP
dpc-4838	32	4	responder	responder	NOUN
dpc-4838	32	5	at	at	ADP
dpc-4838	32	6	week	week	NOUN
dpc-4838	32	7	16	16	NUM
dpc-4838	32	8	and	and	CCONJ
dpc-4838	32	9	52	52	NUM
dpc-4838	32	10	was	be	AUX
dpc-4838	32	11	adopted	adopt	VERB
dpc-4838	32	12	as	as	ADP
dpc-4838	32	13	a	a	DET
dpc-4838	32	14	cost	cost	NOUN
dpc-4838	32	15	-	-	PUNCT
dpc-4838	32	16	effectiveness	effectiveness	NOUN
dpc-4838	32	17	indicator	indicator	NOUN
dpc-4838	32	18	.	.	PUNCT
dpc-4838	33	1	results	result	NOUN
dpc-4838	33	2	:	:	PUNCT
dpc-4838	33	3	included	include	VERB
dpc-4838	33	4	were	be	AUX
dpc-4838	33	5	141	141	NUM
dpc-4838	33	6	patients	patient	NOUN
dpc-4838	33	7	,	,	PUNCT
dpc-4838	33	8	74	74	NUM
dpc-4838	33	9	(	(	PUNCT
dpc-4838	33	10	52.5	52.5	NUM
dpc-4838	33	11	%	%	NOUN
dpc-4838	33	12	)	)	PUNCT
dpc-4838	33	13	treated	treat	VERB
dpc-4838	33	14	with	with	ADP
dpc-4838	33	15	risankizumab	risankizumab	NOUN
dpc-4838	33	16	and	and	CCONJ
dpc-4838	33	17	67	67	NUM
dpc-4838	33	18	(	(	PUNCT
dpc-4838	33	19	47.5	47.5	NUM
dpc-4838	33	20	%	%	NOUN
dpc-4838	33	21	)	)	PUNCT
dpc-4838	33	22	treated	treat	VERB
dpc-4838	33	23	with	with	ADP
dpc-4838	33	24	secukinumab	secukinumab	NOUN
dpc-4838	33	25	.	.	PUNCT
dpc-4838	34	1	pasi90	pasi90	NOUN
dpc-4838	34	2	responses	response	VERB
dpc-4838	34	3	in	in	ADP
dpc-4838	34	4	risankizumab	risankizumab	NOUN
dpc-4838	34	5	-	-	PUNCT
dpc-4838	34	6	treated	treat	VERB
dpc-4838	34	7	patients	patient	NOUN
dpc-4838	34	8	were	be	AUX
dpc-4838	34	9	higher	high	ADJ
dpc-4838	34	10	than	than	ADP
dpc-4838	34	11	those	those	PRON
dpc-4838	34	12	observed	observe	VERB
dpc-4838	34	13	in	in	ADP
dpc-4838	34	14	patients	patient	NOUN
dpc-4838	34	15	treated	treat	VERB
dpc-4838	34	16	with	with	ADP
dpc-4838	34	17	secukinumab	secukinumab	NOUN
dpc-4838	34	18	at	at	ADP
dpc-4838	34	19	both	both	DET
dpc-4838	34	20	weeks	week	NOUN
dpc-4838	34	21	16	16	NUM
dpc-4838	34	22	and	and	CCONJ
dpc-4838	34	23	52	52	NUM
dpc-4838	34	24	(	(	PUNCT
dpc-4838	34	25	79.7	79.7	NUM
dpc-4838	34	26	%	%	NOUN
dpc-4838	34	27	versus	versus	ADP
dpc-4838	34	28	64.2	64.2	NUM
dpc-4838	34	29	%	%	NOUN
dpc-4838	34	30	(	(	PUNCT
dpc-4838	34	31	p	p	NOUN
dpc-4838	34	32	=	=	NOUN
dpc-4838	34	33	0.041	0.041	NUM
dpc-4838	34	34	)	)	PUNCT
dpc-4838	34	35	and	and	CCONJ
dpc-4838	34	36	98.6	98.6	NUM
dpc-4838	34	37	%	%	NOUN
dpc-4838	34	38	versus	versus	ADP
dpc-4838	34	39	83.6	83.6	NUM
dpc-4838	34	40	%	%	NOUN
dpc-4838	34	41	(	(	PUNCT
dpc-4838	34	42	p	p	X
dpc-4838	34	43	=	=	NOUN
dpc-4838	34	44	0.003	0.003	NUM
dpc-4838	34	45	)	)	PUNCT
dpc-4838	34	46	,	,	PUNCT
dpc-4838	34	47	respectively	respectively	ADV
dpc-4838	34	48	)	)	PUNCT
dpc-4838	34	49	.	.	PUNCT
dpc-4838	35	1	risankizumab	risankizumab	PROPN
dpc-4838	35	2	also	also	ADV
dpc-4838	35	3	showed	show	VERB
dpc-4838	35	4	superior	superior	ADJ
dpc-4838	35	5	pasi100	pasi100	PROPN
dpc-4838	35	6	rates	rate	NOUN
dpc-4838	35	7	at	at	ADP
dpc-4838	35	8	week	week	NOUN
dpc-4838	35	9	52	52	NUM
dpc-4838	35	10	(	(	PUNCT
dpc-4838	35	11	85.5	85.5	NUM
dpc-4838	35	12	%	%	NOUN
dpc-4838	35	13	versus	versus	ADP
dpc-4838	35	14	65.6	65.6	NUM
dpc-4838	35	15	%	%	NOUN
dpc-4838	35	16	,	,	PUNCT
dpc-4838	35	17	p	p	X
dpc-4838	35	18	=	=	NOUN
dpc-4838	35	19	0.009	0.009	NUM
dpc-4838	35	20	)	)	PUNCT
dpc-4838	35	21	.	.	PUNCT
dpc-4838	36	1	no	no	DET
dpc-4838	36	2	statistically	statistically	ADV
dpc-4838	36	3	significant	significant	ADJ
dpc-4838	36	4	differences	difference	NOUN
dpc-4838	36	5	were	be	AUX
dpc-4838	36	6	observed	observe	VERB
dpc-4838	36	7	in	in	ADP
dpc-4838	36	8	pasi90	pasi90	NOUN
dpc-4838	36	9	and	and	CCONJ
dpc-4838	36	10	pasi100	pasi100	PROPN
dpc-4838	36	11	rates	rate	NOUN
dpc-4838	36	12	between	between	ADP
dpc-4838	36	13	the	the	DET
dpc-4838	36	14	2	2	NUM
dpc-4838	36	15	groups	group	NOUN
dpc-4838	36	16	at	at	ADP
dpc-4838	36	17	week	week	NOUN
dpc-4838	36	18	78	78	NUM
dpc-4838	36	19	.	.	PUNCT
dpc-4838	37	1	the	the	DET
dpc-4838	37	2	cost	cost	NOUN
dpc-4838	37	3	per	per	ADP
dpc-4838	37	4	pasi90	pasi90	NOUN
dpc-4838	37	5	and	and	CCONJ
dpc-4838	37	6	pasi100	pasi100	PROPN
dpc-4838	37	7	responder	responder	NOUN
dpc-4838	37	8	for	for	ADP
dpc-4838	37	9	risankizumab	risankizumab	NOUN
dpc-4838	37	10	was	be	AUX
dpc-4838	37	11	lower	low	ADJ
dpc-4838	37	12	at	at	ADP
dpc-4838	37	13	both	both	DET
dpc-4838	37	14	weeks	week	NOUN
dpc-4838	37	15	16	16	NUM
dpc-4838	37	16	(	(	PUNCT
dpc-4838	37	17	€	€	SYM
dpc-4838	37	18	5833.66	5833.66	NUM
dpc-4838	37	19	and	and	CCONJ
dpc-4838	37	20	€	€	SYM
dpc-4838	37	21	8394.78	8394.78	NUM
dpc-4838	37	22	,	,	PUNCT
dpc-4838	37	23	compared	compare	VERB
dpc-4838	37	24	to	to	ADP
dpc-4838	37	25	€	€	SYM
dpc-4838	37	26	8747.18	8747.18	NUM
dpc-4838	37	27	and	and	CCONJ
dpc-4838	37	28	€	€	SYM
dpc-4838	37	29	10746.53	10746.53	NUM
dpc-4838	37	30	for	for	ADP
dpc-4838	37	31	secukinumab	secukinumab	NOUN
dpc-4838	37	32	)	)	PUNCT
dpc-4838	37	33	and	and	CCONJ
dpc-4838	37	34	52	52	NUM
dpc-4838	37	35	(	(	PUNCT
dpc-4838	37	36	€	€	SYM
dpc-4838	37	37	11798.90	11798.90	NUM
dpc-4838	37	38	and	and	CCONJ
dpc-4838	37	39	€	€	SYM
dpc-4838	37	40	13598.73	13598.73	NUM
dpc-4838	37	41	vs	vs	ADP
dpc-4838	37	42	€	€	SYM
dpc-4838	37	43	15347.70	15347.70	NUM
dpc-4838	37	44	and	and	CCONJ
dpc-4838	37	45	€	€	SYM
dpc-4838	37	46	19568.31	19568.31	NUM
dpc-4838	37	47	,	,	PUNCT
dpc-4838	37	48	respectively	respectively	ADV
dpc-4838	37	49	)	)	PUNCT
dpc-4838	37	50	.	.	PUNCT
dpc-4838	38	1	conclusions	conclusion	NOUN
dpc-4838	38	2	:	:	PUNCT
dpc-4838	38	3	risankizumab	risankizumab	PROPN
dpc-4838	38	4	showed	show	VERB
dpc-4838	38	5	superior	superior	ADJ
dpc-4838	38	6	efficacy	efficacy	NOUN
dpc-4838	38	7	than	than	ADP
dpc-4838	38	8	secukinumab	secukinumab	NOUN
dpc-4838	38	9	and	and	CCONJ
dpc-4838	38	10	a	a	DET
dpc-4838	38	11	lower	low	ADJ
dpc-4838	38	12	cost	cost	NOUN
dpc-4838	38	13	per	per	ADP
dpc-4838	38	14	responder	responder	NOUN
dpc-4838	38	15	.	.	PUNCT
dpc-4838	39	1	abstract	abstract	ADJ
dpc-4838	39	2	original	original	ADJ
dpc-4838	39	3	article	article	NOUN
dpc-4838	39	4	|	|	ADV
dpc-4838	39	5	dermatol	dermatol	ADJ
dpc-4838	39	6	pract	pract	NOUN
dpc-4838	39	7	concept	concept	NOUN
dpc-4838	39	8	.	.	PUNCT
dpc-4838	40	1	2025;15(1):4838	2025;15(1):4838	NUM
dpc-4838	40	2	3	3	NUM
dpc-4838	40	3	condition	condition	NOUN
dpc-4838	40	4	)	)	PUNCT
dpc-4838	40	5	of	of	ADP
dpc-4838	40	6	these	these	DET
dpc-4838	40	7	two	two	NUM
dpc-4838	40	8	drugs	drug	NOUN
dpc-4838	40	9	,	,	PUNCT
dpc-4838	40	10	on	on	ADP
dpc-4838	40	11	the	the	DET
dpc-4838	40	12	basis	basis	NOUN
dpc-4838	40	13	of	of	ADP
dpc-4838	40	14	data	datum	NOUN
dpc-4838	40	15	retrieved	retrieve	VERB
dpc-4838	40	16	from	from	ADP
dpc-4838	40	17	immerge	immerge	ADJ
dpc-4838	40	18	trial	trial	NOUN
dpc-4838	40	19	[	[	X
dpc-4838	40	20	18	18	NUM
dpc-4838	40	21	]	]	PUNCT
dpc-4838	40	22	.	.	PUNCT
dpc-4838	41	1	further	further	ADJ
dpc-4838	41	2	data	datum	NOUN
dpc-4838	41	3	regarding	regard	VERB
dpc-4838	41	4	cost	cost	NOUN
dpc-4838	41	5	effectiveness	effectiveness	NOUN
dpc-4838	41	6	analyses	analysis	NOUN
dpc-4838	41	7	on	on	ADP
dpc-4838	41	8	risankizumab	risankizumab	NOUN
dpc-4838	41	9	and	and	CCONJ
dpc-4838	41	10	secukinumab	secukinumab	NOUN
dpc-4838	41	11	can	can	AUX
dpc-4838	41	12	be	be	AUX
dpc-4838	41	13	found	find	VERB
dpc-4838	41	14	in	in	ADP
dpc-4838	41	15	comparative	comparative	ADJ
dpc-4838	41	16	studies	study	NOUN
dpc-4838	41	17	of	of	ADP
dpc-4838	41	18	anti	anti	ADJ
dpc-4838	41	19	-	-	ADJ
dpc-4838	41	20	interleukin	interleukin	ADJ
dpc-4838	41	21	agents	agent	NOUN
dpc-4838	41	22	based	base	VERB
dpc-4838	41	23	on	on	ADP
dpc-4838	41	24	efficacy	efficacy	NOUN
dpc-4838	41	25	data	datum	NOUN
dpc-4838	41	26	from	from	ADP
dpc-4838	41	27	other	other	ADJ
dpc-4838	41	28	registrational	registrational	ADJ
dpc-4838	41	29	studies	study	NOUN
dpc-4838	41	30	or	or	CCONJ
dpc-4838	41	31	network	network	NOUN
dpc-4838	41	32	meta	meta	NOUN
dpc-4838	41	33	-	-	PUNCT
dpc-4838	41	34	analyses	analyse	VERB
dpc-4838	41	35	[	[	X
dpc-4838	41	36	19,20	19,20	X
dpc-4838	41	37	]	]	X
dpc-4838	41	38	,	,	PUNCT
dpc-4838	41	39	without	without	ADP
dpc-4838	41	40	any	any	DET
dpc-4838	41	41	experience	experience	NOUN
dpc-4838	41	42	in	in	ADP
dpc-4838	41	43	a	a	DET
dpc-4838	41	44	real	real	ADJ
dpc-4838	41	45	-	-	PUNCT
dpc-4838	41	46	world	world	NOUN
dpc-4838	41	47	setting	setting	NOUN
dpc-4838	41	48	.	.	PUNCT
dpc-4838	42	1	objectives	objective	VERB
dpc-4838	42	2	the	the	DET
dpc-4838	42	3	objective	objective	NOUN
dpc-4838	42	4	of	of	ADP
dpc-4838	42	5	this	this	DET
dpc-4838	42	6	retrospective	retrospective	NOUN
dpc-4838	42	7	,	,	PUNCT
dpc-4838	42	8	multicenter	multicenter	ADJ
dpc-4838	42	9	study	study	NOUN
dpc-4838	42	10	is	be	AUX
dpc-4838	42	11	to	to	PART
dpc-4838	42	12	perform	perform	VERB
dpc-4838	42	13	a	a	DET
dpc-4838	42	14	real	real	ADJ
dpc-4838	42	15	-	-	PUNCT
dpc-4838	42	16	world	world	NOUN
dpc-4838	42	17	analysis	analysis	NOUN
dpc-4838	42	18	to	to	PART
dpc-4838	42	19	estimate	estimate	VERB
dpc-4838	42	20	the	the	DET
dpc-4838	42	21	efficacy	efficacy	NOUN
dpc-4838	42	22	and	and	CCONJ
dpc-4838	42	23	the	the	DET
dpc-4838	42	24	cost	cost	NOUN
dpc-4838	42	25	per	per	ADP
dpc-4838	42	26	responder	responder	NOUN
dpc-4838	42	27	of	of	ADP
dpc-4838	42	28	risankizumab	risankizumab	NOUN
dpc-4838	42	29	and	and	CCONJ
dpc-4838	42	30	secukinumab	secukinumab	NOUN
dpc-4838	42	31	by	by	ADP
dpc-4838	42	32	comparing	compare	VERB
dpc-4838	42	33	these	these	DET
dpc-4838	42	34	two	two	NUM
dpc-4838	42	35	drugs	drug	NOUN
dpc-4838	42	36	in	in	ADP
dpc-4838	42	37	a	a	DET
dpc-4838	42	38	population	population	NOUN
dpc-4838	42	39	of	of	ADP
dpc-4838	42	40	patients	patient	NOUN
dpc-4838	42	41	from	from	ADP
dpc-4838	42	42	the	the	DET
dpc-4838	42	43	lazio	lazio	PROPN
dpc-4838	42	44	region	region	NOUN
dpc-4838	42	45	of	of	ADP
dpc-4838	42	46	italy	italy	PROPN
dpc-4838	42	47	affected	affect	VERB
dpc-4838	42	48	by	by	ADP
dpc-4838	42	49	moderate	moderate	ADJ
dpc-4838	42	50	-	-	PUNCT
dpc-4838	42	51	to	to	ADP
dpc-4838	42	52	-	-	PUNCT
dpc-4838	42	53	severe	severe	ADJ
dpc-4838	42	54	psoriasis	psoriasis	NOUN
dpc-4838	42	55	.	.	PUNCT
dpc-4838	43	1	methods	method	NOUN
dpc-4838	43	2	a	a	DET
dpc-4838	43	3	retrospective	retrospective	ADJ
dpc-4838	43	4	analysis	analysis	NOUN
dpc-4838	43	5	was	be	AUX
dpc-4838	43	6	performed	perform	VERB
dpc-4838	43	7	in	in	ADP
dpc-4838	43	8	a	a	DET
dpc-4838	43	9	cohort	cohort	NOUN
dpc-4838	43	10	of	of	ADP
dpc-4838	43	11	patients	patient	NOUN
dpc-4838	43	12	affected	affect	VERB
dpc-4838	43	13	by	by	ADP
dpc-4838	43	14	chronic	chronic	ADJ
dpc-4838	43	15	plaque	plaque	NOUN
dpc-4838	43	16	psoriasis	psoriasis	NOUN
dpc-4838	43	17	who	who	PRON
dpc-4838	43	18	started	start	VERB
dpc-4838	43	19	treatment	treatment	NOUN
dpc-4838	43	20	with	with	ADP
dpc-4838	43	21	risankizumab	risankizumab	NOUN
dpc-4838	43	22	or	or	CCONJ
dpc-4838	43	23	secukinumab	secukinumab	NOUN
dpc-4838	43	24	between	between	ADP
dpc-4838	43	25	september	september	PROPN
dpc-4838	43	26	2020	2020	NUM
dpc-4838	43	27	and	and	CCONJ
dpc-4838	43	28	september	september	PROPN
dpc-4838	43	29	2022	2022	NUM
dpc-4838	43	30	.	.	PUNCT
dpc-4838	44	1	the	the	DET
dpc-4838	44	2	study	study	NOUN
dpc-4838	44	3	population	population	NOUN
dpc-4838	44	4	consisted	consist	VERB
dpc-4838	44	5	of	of	ADP
dpc-4838	44	6	patients	patient	NOUN
dpc-4838	44	7	attending	attend	VERB
dpc-4838	44	8	the	the	DET
dpc-4838	44	9	outpatient	outpatient	NOUN
dpc-4838	44	10	clinics	clinic	NOUN
dpc-4838	44	11	of	of	ADP
dpc-4838	44	12	the	the	DET
dpc-4838	44	13	5	5	NUM
dpc-4838	44	14	participating	participate	VERB
dpc-4838	44	15	centers	center	NOUN
dpc-4838	44	16	(	(	PUNCT
dpc-4838	44	17	fondazione	fondazione	X
dpc-4838	44	18	policlinico	policlinico	PROPN
dpc-4838	44	19	universitario	universitario	PROPN
dpc-4838	44	20	a.	a.	PROPN
dpc-4838	44	21	gemelli	gemelli	PROPN
dpc-4838	44	22	irccs	irccs	PROPN
dpc-4838	44	23	;	;	PUNCT
dpc-4838	44	24	fondazione	fondazione	NOUN
dpc-4838	44	25	policlinico	policlinico	NOUN
dpc-4838	44	26	tor	tor	NOUN
dpc-4838	44	27	vergata	vergata	NOUN
dpc-4838	44	28	;	;	PUNCT
dpc-4838	44	29	policlinico	policlinico	NOUN
dpc-4838	44	30	umberto	umberto	NOUN
dpc-4838	45	1	i	i	PRON
dpc-4838	45	2	;	;	PUNCT
dpc-4838	45	3	a.o.u	a.o.u	ADV
dpc-4838	45	4	.	.	PUNCT
dpc-4838	45	5	sant’andrea	sant’andrea	PROPN
dpc-4838	45	6	–	–	PUNCT
dpc-4838	45	7	sapienza	sapienza	PROPN
dpc-4838	45	8	,	,	PUNCT
dpc-4838	45	9	università	università	PROPN
dpc-4838	45	10	di	di	PROPN
dpc-4838	45	11	roma	roma	PROPN
dpc-4838	45	12	;	;	PUNCT
dpc-4838	45	13	p.o	p.o	PROPN
dpc-4838	45	14	.	.	PROPN
dpc-4838	45	15	centro	centro	PROPN
dpc-4838	45	16	“	"	PUNCT
dpc-4838	45	17	a.	a.	NOUN
dpc-4838	45	18	fiorini	fiorini	PROPN
dpc-4838	45	19	”	"	PUNCT
dpc-4838	45	20	of	of	ADP
dpc-4838	45	21	terracina	terracina	PROPN
dpc-4838	45	22	sapienza	sapienza	PROPN
dpc-4838	45	23	,	,	PUNCT
dpc-4838	45	24	università	università	PROPN
dpc-4838	45	25	di	di	PROPN
dpc-4838	45	26	roma	roma	PROPN
dpc-4838	45	27	polo	polo	PROPN
dpc-4838	45	28	pontino	pontino	PROPN
dpc-4838	45	29	)	)	PUNCT
dpc-4838	45	30	in	in	ADP
dpc-4838	45	31	lazio	lazio	PROPN
dpc-4838	45	32	,	,	PUNCT
dpc-4838	45	33	italy	italy	PROPN
dpc-4838	45	34	.	.	PUNCT
dpc-4838	46	1	all	all	DET
dpc-4838	46	2	enrolled	enrol	VERB
dpc-4838	46	3	patients	patient	NOUN
dpc-4838	46	4	were	be	AUX
dpc-4838	46	5	>	>	X
dpc-4838	46	6	18	18	NUM
dpc-4838	46	7	years	year	NOUN
dpc-4838	46	8	old	old	ADJ
dpc-4838	46	9	.	.	PUNCT
dpc-4838	47	1	patients	patient	NOUN
dpc-4838	47	2	affected	affect	VERB
dpc-4838	47	3	by	by	ADP
dpc-4838	47	4	generalized	generalized	ADJ
dpc-4838	47	5	or	or	CCONJ
dpc-4838	47	6	palmoplantar	palmoplantar	NOUN
dpc-4838	47	7	pustular	pustular	ADJ
dpc-4838	47	8	psoriasis	psoriasis	NOUN
dpc-4838	47	9	,	,	PUNCT
dpc-4838	47	10	erythrodermic	erythrodermic	ADJ
dpc-4838	47	11	psoriasis	psoriasis	NOUN
dpc-4838	47	12	or	or	CCONJ
dpc-4838	47	13	who	who	PRON
dpc-4838	47	14	had	have	AUX
dpc-4838	47	15	started	start	VERB
dpc-4838	47	16	treatment	treatment	NOUN
dpc-4838	47	17	within	within	ADP
dpc-4838	47	18	a	a	DET
dpc-4838	47	19	clinical	clinical	ADJ
dpc-4838	47	20	trial	trial	NOUN
dpc-4838	47	21	were	be	AUX
dpc-4838	47	22	excluded	exclude	VERB
dpc-4838	47	23	,	,	PUNCT
dpc-4838	47	24	as	as	ADV
dpc-4838	47	25	well	well	ADV
dpc-4838	47	26	as	as	ADP
dpc-4838	47	27	patients	patient	NOUN
dpc-4838	47	28	concurrently	concurrently	ADV
dpc-4838	47	29	treated	treat	VERB
dpc-4838	47	30	with	with	ADP
dpc-4838	47	31	other	other	ADJ
dpc-4838	47	32	systemic	systemic	ADJ
dpc-4838	47	33	therapies	therapy	NOUN
dpc-4838	47	34	.	.	PUNCT
dpc-4838	48	1	moreover	moreover	ADV
dpc-4838	48	2	,	,	PUNCT
dpc-4838	48	3	in	in	ADP
dpc-4838	48	4	order	order	NOUN
dpc-4838	48	5	to	to	PART
dpc-4838	48	6	avoid	avoid	VERB
dpc-4838	48	7	influence	influence	NOUN
dpc-4838	48	8	of	of	ADP
dpc-4838	48	9	previous	previous	ADJ
dpc-4838	48	10	therapies	therapy	NOUN
dpc-4838	48	11	,	,	PUNCT
dpc-4838	48	12	patients	patient	NOUN
dpc-4838	48	13	treated	treat	VERB
dpc-4838	48	14	with	with	ADP
dpc-4838	48	15	secukinumab	secukinumab	NOUN
dpc-4838	48	16	and	and	CCONJ
dpc-4838	48	17	previously	previously	ADV
dpc-4838	48	18	treated	treat	VERB
dpc-4838	48	19	with	with	ADP
dpc-4838	48	20	risankizumab	risankizumab	NOUN
dpc-4838	48	21	or	or	CCONJ
dpc-4838	48	22	other	other	ADJ
dpc-4838	48	23	il23	il23	PROPN
dpc-4838	48	24	inhibitors	inhibitor	NOUN
dpc-4838	48	25	were	be	AUX
dpc-4838	48	26	excluded	exclude	VERB
dpc-4838	48	27	,	,	PUNCT
dpc-4838	48	28	as	as	ADV
dpc-4838	48	29	well	well	ADV
dpc-4838	48	30	as	as	SCONJ
dpc-4838	48	31	patients	patient	NOUN
dpc-4838	48	32	treated	treat	VERB
dpc-4838	48	33	with	with	ADP
dpc-4838	48	34	risankizumab	risankizumab	NOUN
dpc-4838	48	35	and	and	CCONJ
dpc-4838	48	36	previously	previously	ADV
dpc-4838	48	37	treated	treat	VERB
dpc-4838	48	38	with	with	ADP
dpc-4838	48	39	secukinumab	secukinumab	NOUN
dpc-4838	48	40	or	or	CCONJ
dpc-4838	48	41	other	other	ADJ
dpc-4838	48	42	il17	il17	PROPN
dpc-4838	48	43	inhibitors	inhibitor	NOUN
dpc-4838	48	44	.	.	PUNCT
dpc-4838	49	1	risankizumab	risankizumab	NOUN
dpc-4838	49	2	and	and	CCONJ
dpc-4838	49	3	secukinumab	secukinumab	NOUN
dpc-4838	49	4	were	be	AUX
dpc-4838	49	5	administered	administer	VERB
dpc-4838	49	6	at	at	ADP
dpc-4838	49	7	ema	ema	PROPN
dpc-4838	49	8	approved	approve	VERB
dpc-4838	49	9	dosage	dosage	NOUN
dpc-4838	49	10	,	,	PUNCT
dpc-4838	49	11	and	and	CCONJ
dpc-4838	49	12	no	no	DET
dpc-4838	49	13	dose	dose	NOUN
dpc-4838	49	14	or	or	CCONJ
dpc-4838	49	15	frequency	frequency	NOUN
dpc-4838	49	16	variations	variation	NOUN
dpc-4838	49	17	were	be	AUX
dpc-4838	49	18	permitted	permit	VERB
dpc-4838	49	19	.	.	PUNCT
dpc-4838	50	1	the	the	DET
dpc-4838	50	2	dosing	dose	VERB
dpc-4838	50	3	regimen	regiman	NOUN
dpc-4838	50	4	adopted	adopt	VERB
dpc-4838	50	5	for	for	ADP
dpc-4838	50	6	the	the	DET
dpc-4838	50	7	two	two	NUM
dpc-4838	50	8	treatments	treatment	NOUN
dpc-4838	50	9	in	in	ADP
dpc-4838	50	10	the	the	DET
dpc-4838	50	11	first	first	ADJ
dpc-4838	50	12	year	year	NOUN
dpc-4838	50	13	of	of	ADP
dpc-4838	50	14	observation	observation	NOUN
dpc-4838	50	15	includes	include	VERB
dpc-4838	50	16	the	the	DET
dpc-4838	50	17	induction	induction	NOUN
dpc-4838	50	18	phase	phase	NOUN
dpc-4838	50	19	(	(	PUNCT
dpc-4838	50	20	300	300	NUM
dpc-4838	50	21	mg	mg	NOUN
dpc-4838	50	22	and	and	CCONJ
dpc-4838	50	23	2100	2100	NUM
dpc-4838	50	24	mg	mg	PROPN
dpc-4838	50	25	for	for	ADP
dpc-4838	50	26	risankizumab	risankizumab	NOUN
dpc-4838	50	27	and	and	CCONJ
dpc-4838	50	28	secukinumab	secukinumab	NOUN
dpc-4838	50	29	,	,	PUNCT
dpc-4838	50	30	respectively	respectively	ADV
dpc-4838	50	31	,	,	PUNCT
dpc-4838	50	32	over	over	ADP
dpc-4838	50	33	a	a	DET
dpc-4838	50	34	period	period	NOUN
dpc-4838	50	35	of	of	ADP
dpc-4838	50	36	16	16	NUM
dpc-4838	50	37	weeks	week	NOUN
dpc-4838	50	38	)	)	PUNCT
dpc-4838	50	39	followed	follow	VERB
dpc-4838	50	40	by	by	ADP
dpc-4838	50	41	the	the	DET
dpc-4838	50	42	maintenance	maintenance	NOUN
dpc-4838	50	43	phase	phase	NOUN
dpc-4838	50	44	,	,	PUNCT
dpc-4838	50	45	with	with	ADP
dpc-4838	50	46	one	one	NUM
dpc-4838	50	47	administration	administration	NOUN
dpc-4838	50	48	(	(	PUNCT
dpc-4838	50	49	2	2	NUM
dpc-4838	50	50	75	75	NUM
dpc-4838	50	51	mg	mg	NOUN
dpc-4838	50	52	pens	pen	NOUN
dpc-4838	50	53	,	,	PUNCT
dpc-4838	50	54	total	total	NOUN
dpc-4838	50	55	150	150	NUM
dpc-4838	50	56	mg	mg	NOUN
dpc-4838	50	57	)	)	PUNCT
dpc-4838	50	58	every	every	DET
dpc-4838	50	59	12	12	NUM
dpc-4838	50	60	weeks	week	NOUN
dpc-4838	50	61	for	for	ADP
dpc-4838	50	62	risankizumab	risankizumab	NOUN
dpc-4838	50	63	and	and	CCONJ
dpc-4838	50	64	one	one	NUM
dpc-4838	50	65	administration	administration	NOUN
dpc-4838	50	66	(	(	PUNCT
dpc-4838	50	67	2	2	NUM
dpc-4838	50	68	150	150	NUM
dpc-4838	50	69	mg	mg	NOUN
dpc-4838	50	70	pens	pen	NOUN
dpc-4838	50	71	,	,	PUNCT
dpc-4838	50	72	total	total	VERB
dpc-4838	50	73	300	300	NUM
dpc-4838	50	74	mg	mg	NOUN
dpc-4838	50	75	)	)	PUNCT
dpc-4838	50	76	every	every	DET
dpc-4838	50	77	4	4	NUM
dpc-4838	50	78	weeks	week	NOUN
dpc-4838	50	79	for	for	ADP
dpc-4838	50	80	secukinumab	secukinumab	NOUN
dpc-4838	50	81	.	.	PUNCT
dpc-4838	51	1	for	for	ADP
dpc-4838	51	2	each	each	DET
dpc-4838	51	3	patient	patient	NOUN
dpc-4838	51	4	,	,	PUNCT
dpc-4838	51	5	demographic	demographic	ADJ
dpc-4838	51	6	and	and	CCONJ
dpc-4838	51	7	clinical	clinical	ADJ
dpc-4838	51	8	data	datum	NOUN
dpc-4838	51	9	(	(	PUNCT
dpc-4838	51	10	age	age	NOUN
dpc-4838	51	11	,	,	PUNCT
dpc-4838	51	12	sex	sex	NOUN
dpc-4838	51	13	,	,	PUNCT
dpc-4838	51	14	weight	weight	NOUN
dpc-4838	51	15	,	,	PUNCT
dpc-4838	51	16	age	age	NOUN
dpc-4838	51	17	of	of	ADP
dpc-4838	51	18	onset	onset	NOUN
dpc-4838	51	19	and	and	CCONJ
dpc-4838	51	20	duration	duration	NOUN
dpc-4838	51	21	of	of	ADP
dpc-4838	51	22	psoriasis	psoriasis	NOUN
dpc-4838	51	23	)	)	PUNCT
dpc-4838	51	24	,	,	PUNCT
dpc-4838	51	25	history	history	NOUN
dpc-4838	51	26	of	of	ADP
dpc-4838	51	27	previous	previous	ADJ
dpc-4838	51	28	biological	biological	ADJ
dpc-4838	51	29	therapies	therapy	NOUN
dpc-4838	51	30	and	and	CCONJ
dpc-4838	51	31	baseline	baseline	NOUN
dpc-4838	51	32	disease	disease	NOUN
dpc-4838	51	33	severity	severity	NOUN
dpc-4838	51	34	were	be	AUX
dpc-4838	51	35	collected	collect	VERB
dpc-4838	51	36	at	at	ADP
dpc-4838	51	37	the	the	DET
dpc-4838	51	38	time	time	NOUN
dpc-4838	51	39	of	of	ADP
dpc-4838	51	40	initiation	initiation	NOUN
dpc-4838	51	41	of	of	ADP
dpc-4838	51	42	risankizumab	risankizumab	NOUN
dpc-4838	51	43	or	or	CCONJ
dpc-4838	51	44	secukinumab	secukinumab	NOUN
dpc-4838	51	45	.	.	PUNCT
dpc-4838	52	1	data	datum	NOUN
dpc-4838	52	2	regarding	regard	VERB
dpc-4838	52	3	the	the	DET
dpc-4838	52	4	treatment	treatment	NOUN
dpc-4838	52	5	status	status	NOUN
dpc-4838	52	6	and	and	CCONJ
dpc-4838	52	7	potential	potential	ADJ
dpc-4838	52	8	drug	drug	NOUN
dpc-4838	52	9	withdrawal	withdrawal	NOUN
dpc-4838	52	10	were	be	AUX
dpc-4838	52	11	also	also	ADV
dpc-4838	52	12	collected	collect	VERB
dpc-4838	52	13	.	.	PUNCT
dpc-4838	53	1	the	the	DET
dpc-4838	53	2	severity	severity	NOUN
dpc-4838	53	3	of	of	ADP
dpc-4838	53	4	psoriasis	psoriasis	NOUN
dpc-4838	53	5	was	be	AUX
dpc-4838	53	6	estimated	estimate	VERB
dpc-4838	53	7	by	by	ADP
dpc-4838	53	8	psoriasis	psoriasis	NOUN
dpc-4838	53	9	area	area	NOUN
dpc-4838	53	10	and	and	CCONJ
dpc-4838	53	11	severity	severity	NOUN
dpc-4838	53	12	index	index	NOUN
dpc-4838	53	13	(	(	PUNCT
dpc-4838	53	14	pasi	pasi	NOUN
dpc-4838	53	15	)	)	PUNCT
dpc-4838	54	1	[	[	X
dpc-4838	54	2	21	21	NUM
dpc-4838	54	3	]	]	PUNCT
dpc-4838	54	4	measured	measure	VERB
dpc-4838	54	5	at	at	ADP
dpc-4838	54	6	baseline	baseline	NOUN
dpc-4838	54	7	and	and	CCONJ
dpc-4838	54	8	after	after	ADP
dpc-4838	54	9	16	16	NUM
dpc-4838	54	10	,	,	PUNCT
dpc-4838	54	11	52	52	NUM
dpc-4838	54	12	and	and	CCONJ
dpc-4838	54	13	78	78	NUM
dpc-4838	54	14	weeks	week	NOUN
dpc-4838	54	15	,	,	PUNCT
dpc-4838	54	16	respectively	respectively	ADV
dpc-4838	54	17	.	.	PUNCT
dpc-4838	55	1	data	datum	NOUN
dpc-4838	55	2	were	be	AUX
dpc-4838	55	3	recorded	record	VERB
dpc-4838	55	4	on	on	ADP
dpc-4838	55	5	potential	potential	ADJ
dpc-4838	55	6	safety	safety	NOUN
dpc-4838	55	7	issues	issue	NOUN
dpc-4838	55	8	and	and	CCONJ
dpc-4838	55	9	adverse	adverse	ADJ
dpc-4838	55	10	events	event	NOUN
dpc-4838	55	11	(	(	PUNCT
dpc-4838	55	12	aes	aes	NOUN
dpc-4838	55	13	)	)	PUNCT
dpc-4838	55	14	,	,	PUNCT
dpc-4838	55	15	including	include	VERB
dpc-4838	55	16	both	both	CCONJ
dpc-4838	55	17	serious	serious	ADJ
dpc-4838	55	18	and	and	CCONJ
dpc-4838	55	19	mild	mild	ADJ
dpc-4838	55	20	aes	aes	NOUN
dpc-4838	55	21	.	.	PUNCT
dpc-4838	56	1	the	the	DET
dpc-4838	56	2	entire	entire	ADJ
dpc-4838	56	3	study	study	NOUN
dpc-4838	56	4	was	be	AUX
dpc-4838	56	5	conducted	conduct	VERB
dpc-4838	56	6	according	accord	VERB
dpc-4838	56	7	to	to	ADP
dpc-4838	56	8	the	the	DET
dpc-4838	56	9	principles	principle	NOUN
dpc-4838	56	10	of	of	ADP
dpc-4838	56	11	the	the	DET
dpc-4838	56	12	helsinki	helsinki	PROPN
dpc-4838	56	13	declaration	declaration	PROPN
dpc-4838	56	14	.	.	PUNCT
dpc-4838	57	1	statistical	statistical	ADJ
dpc-4838	57	2	analysis	analysis	NOUN
dpc-4838	57	3	descriptive	descriptive	ADJ
dpc-4838	57	4	data	datum	NOUN
dpc-4838	57	5	were	be	AUX
dpc-4838	57	6	reported	report	VERB
dpc-4838	57	7	using	use	VERB
dpc-4838	57	8	absolute	absolute	ADJ
dpc-4838	57	9	and	and	CCONJ
dpc-4838	57	10	relative	relative	ADJ
dpc-4838	57	11	(	(	PUNCT
dpc-4838	57	12	%	%	INTJ
dpc-4838	57	13	)	)	PUNCT
dpc-4838	57	14	frequencies	frequency	NOUN
dpc-4838	57	15	for	for	ADP
dpc-4838	57	16	categorical	categorical	ADJ
dpc-4838	57	17	variables	variable	NOUN
dpc-4838	57	18	,	,	PUNCT
dpc-4838	57	19	and	and	CCONJ
dpc-4838	57	20	mean	mean	VERB
dpc-4838	57	21	values	value	NOUN
dpc-4838	57	22	and	and	CCONJ
dpc-4838	57	23	standard	standard	ADJ
dpc-4838	57	24	deviations	deviation	NOUN
dpc-4838	57	25	when	when	SCONJ
dpc-4838	57	26	appropriate	appropriate	ADJ
dpc-4838	57	27	.	.	PUNCT
dpc-4838	58	1	efficacy	efficacy	NOUN
dpc-4838	58	2	analysis	analysis	NOUN
dpc-4838	58	3	was	be	AUX
dpc-4838	58	4	performed	perform	VERB
dpc-4838	58	5	by	by	ADP
dpc-4838	58	6	assessing	assess	VERB
dpc-4838	58	7	the	the	DET
dpc-4838	58	8	percentage	percentage	NOUN
dpc-4838	58	9	of	of	ADP
dpc-4838	58	10	achieving	achieve	VERB
dpc-4838	58	11	a	a	DET
dpc-4838	58	12	pasi90	pasi90	NOUN
dpc-4838	58	13	or	or	CCONJ
dpc-4838	58	14	pasi100	pasi100	PROPN
dpc-4838	58	15	response	response	NOUN
dpc-4838	58	16	(	(	PUNCT
dpc-4838	58	17	i.e.	i.e.	X
dpc-4838	58	18	whether	whether	SCONJ
dpc-4838	58	19	patients	patient	NOUN
dpc-4838	58	20	reached	reach	VERB
dpc-4838	58	21	an	an	DET
dpc-4838	58	22	improvement	improvement	NOUN
dpc-4838	58	23	of	of	ADP
dpc-4838	58	24	90	90	NUM
dpc-4838	58	25	%	%	NOUN
dpc-4838	58	26	or	or	CCONJ
dpc-4838	58	27	100	100	NUM
dpc-4838	58	28	%	%	NOUN
dpc-4838	58	29	from	from	ADP
dpc-4838	58	30	baseline	baseline	NOUN
dpc-4838	58	31	to	to	ADP
dpc-4838	58	32	weeks	week	NOUN
dpc-4838	58	33	16	16	NUM
dpc-4838	58	34	,	,	PUNCT
dpc-4838	58	35	52	52	NUM
dpc-4838	58	36	or	or	CCONJ
dpc-4838	58	37	78	78	NUM
dpc-4838	58	38	)	)	PUNCT
dpc-4838	58	39	in	in	ADP
dpc-4838	58	40	the	the	DET
dpc-4838	58	41	study	study	NOUN
dpc-4838	58	42	population	population	NOUN
dpc-4838	58	43	.	.	PUNCT
dpc-4838	59	1	student	student	PROPN
dpc-4838	59	2	t	t	PROPN
dpc-4838	59	3	-	-	PUNCT
dpc-4838	59	4	test	test	NOUN
dpc-4838	59	5	was	be	AUX
dpc-4838	59	6	used	use	VERB
dpc-4838	59	7	to	to	PART
dpc-4838	59	8	establish	establish	VERB
dpc-4838	59	9	clinical	clinical	ADJ
dpc-4838	59	10	significance	significance	NOUN
dpc-4838	59	11	of	of	ADP
dpc-4838	59	12	pasi	pasi	NOUN
dpc-4838	59	13	variations	variation	NOUN
dpc-4838	59	14	.	.	PUNCT
dpc-4838	60	1	the	the	DET
dpc-4838	60	2	cost	cost	NOUN
dpc-4838	60	3	per	per	ADP
dpc-4838	60	4	responder	responder	NOUN
dpc-4838	60	5	at	at	ADP
dpc-4838	60	6	week	week	NOUN
dpc-4838	60	7	16	16	NUM
dpc-4838	60	8	and	and	CCONJ
dpc-4838	60	9	52	52	NUM
dpc-4838	60	10	was	be	AUX
dpc-4838	60	11	adopted	adopt	VERB
dpc-4838	60	12	as	as	ADP
dpc-4838	60	13	a	a	DET
dpc-4838	60	14	cost	cost	NOUN
dpc-4838	60	15	effectiveness	effectiveness	NOUN
dpc-4838	60	16	indicator	indicator	NOUN
dpc-4838	60	17	.	.	PUNCT
dpc-4838	61	1	due	due	ADP
dpc-4838	61	2	to	to	ADP
dpc-4838	61	3	the	the	DET
dpc-4838	61	4	smaller	small	ADJ
dpc-4838	61	5	number	number	NOUN
dpc-4838	61	6	of	of	ADP
dpc-4838	61	7	patients	patient	NOUN
dpc-4838	61	8	reaching	reach	VERB
dpc-4838	61	9	week	week	NOUN
dpc-4838	61	10	78	78	NUM
dpc-4838	61	11	,	,	PUNCT
dpc-4838	61	12	the	the	DET
dpc-4838	61	13	cost	cost	NOUN
dpc-4838	61	14	per	per	ADP
dpc-4838	61	15	responder	responder	NOUN
dpc-4838	61	16	was	be	AUX
dpc-4838	61	17	not	not	PART
dpc-4838	61	18	evaluated	evaluate	VERB
dpc-4838	61	19	at	at	ADP
dpc-4838	61	20	this	this	DET
dpc-4838	61	21	time	time	NOUN
dpc-4838	61	22	-	-	PUNCT
dpc-4838	61	23	point	point	NOUN
dpc-4838	61	24	.	.	PUNCT
dpc-4838	62	1	a	a	DET
dpc-4838	62	2	purchase	purchase	NOUN
dpc-4838	62	3	price	price	NOUN
dpc-4838	62	4	of	of	ADP
dpc-4838	62	5	€	€	SYM
dpc-4838	62	6	1162.79	1162.79	NUM
dpc-4838	62	7	for	for	ADP
dpc-4838	62	8	a	a	DET
dpc-4838	62	9	75	75	NUM
dpc-4838	62	10	-	-	PUNCT
dpc-4838	62	11	mg	mg	NOUN
dpc-4838	62	12	pen	pen	NOUN
dpc-4838	62	13	of	of	ADP
dpc-4838	62	14	risankizumab	risankizumab	NOUN
dpc-4838	62	15	and	and	CCONJ
dpc-4838	62	16	€	€	SYM
dpc-4838	62	17	400.99	400.99	NUM
dpc-4838	62	18	for	for	ADP
dpc-4838	62	19	a	a	DET
dpc-4838	62	20	150	150	NUM
dpc-4838	62	21	-	-	PUNCT
dpc-4838	62	22	mg	mg	NOUN
dpc-4838	62	23	pen	pen	NOUN
dpc-4838	62	24	of	of	ADP
dpc-4838	62	25	secukinumab	secukinumab	NOUN
dpc-4838	62	26	,	,	PUNCT
dpc-4838	62	27	resulting	result	VERB
dpc-4838	62	28	from	from	ADP
dpc-4838	62	29	the	the	DET
dpc-4838	62	30	average	average	NOUN
dpc-4838	62	31	of	of	ADP
dpc-4838	62	32	the	the	DET
dpc-4838	62	33	purchase	purchase	NOUN
dpc-4838	62	34	prices	price	NOUN
dpc-4838	62	35	provided	provide	VERB
dpc-4838	62	36	by	by	ADP
dpc-4838	62	37	the	the	DET
dpc-4838	62	38	hospital	hospital	NOUN
dpc-4838	62	39	pharmacies	pharmacy	NOUN
dpc-4838	62	40	of	of	ADP
dpc-4838	62	41	the	the	DET
dpc-4838	62	42	respective	respective	ADJ
dpc-4838	62	43	participating	participate	VERB
dpc-4838	62	44	centers	center	NOUN
dpc-4838	62	45	,	,	PUNCT
dpc-4838	62	46	was	be	AUX
dpc-4838	62	47	considered	consider	VERB
dpc-4838	62	48	.	.	PUNCT
dpc-4838	63	1	the	the	DET
dpc-4838	63	2	cost	cost	NOUN
dpc-4838	63	3	per	per	ADP
dpc-4838	63	4	responder	responder	NOUN
dpc-4838	63	5	was	be	AUX
dpc-4838	63	6	calculated	calculate	VERB
dpc-4838	63	7	by	by	ADP
dpc-4838	63	8	dividing	divide	VERB
dpc-4838	63	9	the	the	DET
dpc-4838	63	10	total	total	ADJ
dpc-4838	63	11	cost	cost	NOUN
dpc-4838	63	12	of	of	ADP
dpc-4838	63	13	treatment	treatment	NOUN
dpc-4838	63	14	after	after	ADP
dpc-4838	63	15	16	16	NUM
dpc-4838	63	16	and	and	CCONJ
dpc-4838	63	17	52	52	NUM
dpc-4838	63	18	weeks	week	NOUN
dpc-4838	63	19	by	by	ADP
dpc-4838	63	20	the	the	DET
dpc-4838	63	21	relative	relative	ADJ
dpc-4838	63	22	efficacy	efficacy	PROPN
dpc-4838	63	23	data	datum	NOUN
dpc-4838	63	24	(	(	PUNCT
dpc-4838	63	25	pasi90	pasi90	NOUN
dpc-4838	63	26	,	,	PUNCT
dpc-4838	63	27	pasi100	pasi100	PROPN
dpc-4838	63	28	)	)	PUNCT
dpc-4838	63	29	collected	collect	VERB
dpc-4838	63	30	in	in	ADP
dpc-4838	63	31	the	the	DET
dpc-4838	63	32	retrospective	retrospective	ADJ
dpc-4838	63	33	real	real	ADJ
dpc-4838	63	34	-	-	PUNCT
dpc-4838	63	35	world	world	NOUN
dpc-4838	63	36	analysis	analysis	NOUN
dpc-4838	63	37	.	.	PUNCT
dpc-4838	64	1	statistical	statistical	ADJ
dpc-4838	64	2	significance	significance	NOUN
dpc-4838	64	3	was	be	AUX
dpc-4838	64	4	set	set	VERB
dpc-4838	64	5	at	at	ADP
dpc-4838	64	6	p	p	NOUN
dpc-4838	64	7	value	value	NOUN
dpc-4838	64	8	<	<	NOUN
dpc-4838	64	9	0.05	0.05	NUM
dpc-4838	64	10	.	.	PUNCT
dpc-4838	65	1	analyses	analysis	NOUN
dpc-4838	65	2	were	be	AUX
dpc-4838	65	3	performed	perform	VERB
dpc-4838	65	4	by	by	ADP
dpc-4838	65	5	using	use	VERB
dpc-4838	65	6	stata	stata	NOUN
dpc-4838	65	7	13.0	13.0	NUM
dpc-4838	65	8	software	software	NOUN
dpc-4838	65	9	(	(	PUNCT
dpc-4838	65	10	statacorp	statacorp	PROPN
dpc-4838	65	11	,	,	PUNCT
dpc-4838	65	12	texas	texas	PROPN
dpc-4838	65	13	)	)	PUNCT
dpc-4838	65	14	.	.	PUNCT
dpc-4838	66	1	results	result	VERB
dpc-4838	66	2	a	a	DET
dpc-4838	66	3	total	total	NOUN
dpc-4838	66	4	of	of	ADP
dpc-4838	66	5	141	141	NUM
dpc-4838	66	6	patients	patient	NOUN
dpc-4838	66	7	were	be	AUX
dpc-4838	66	8	enrolled	enrol	VERB
dpc-4838	66	9	in	in	ADP
dpc-4838	66	10	the	the	DET
dpc-4838	66	11	study	study	NOUN
dpc-4838	66	12	,	,	PUNCT
dpc-4838	66	13	74	74	NUM
dpc-4838	66	14	(	(	PUNCT
dpc-4838	66	15	52.5	52.5	NUM
dpc-4838	66	16	%	%	NOUN
dpc-4838	66	17	)	)	PUNCT
dpc-4838	66	18	treated	treat	VERB
dpc-4838	66	19	with	with	ADP
dpc-4838	66	20	risankizumab	risankizumab	NOUN
dpc-4838	66	21	and	and	CCONJ
dpc-4838	66	22	67	67	NUM
dpc-4838	66	23	(	(	PUNCT
dpc-4838	66	24	47.5	47.5	NUM
dpc-4838	66	25	%	%	NOUN
dpc-4838	66	26	)	)	PUNCT
dpc-4838	66	27	treated	treat	VERB
dpc-4838	66	28	with	with	ADP
dpc-4838	66	29	secukinumab	secukinumab	NOUN
dpc-4838	66	30	.	.	PUNCT
dpc-4838	67	1	mean	mean	ADJ
dpc-4838	67	2	age	age	NOUN
dpc-4838	67	3	was	be	AUX
dpc-4838	67	4	51.2	51.2	NUM
dpc-4838	67	5	±	±	NUM
dpc-4838	67	6	16.4	16.4	NUM
dpc-4838	67	7	and	and	CCONJ
dpc-4838	67	8	50.9	50.9	NUM
dpc-4838	67	9	±	±	NUM
dpc-4838	67	10	14.3	14.3	NUM
dpc-4838	67	11	for	for	ADP
dpc-4838	67	12	the	the	DET
dpc-4838	67	13	risankizumab	risankizumab	NOUN
dpc-4838	67	14	and	and	CCONJ
dpc-4838	67	15	secukinumab	secukinumab	PROPN
dpc-4838	67	16	group	group	NOUN
dpc-4838	67	17	,	,	PUNCT
dpc-4838	67	18	respectively	respectively	ADV
dpc-4838	67	19	.	.	PUNCT
dpc-4838	68	1	the	the	DET
dpc-4838	68	2	percentage	percentage	NOUN
dpc-4838	68	3	of	of	ADP
dpc-4838	68	4	patients	patient	NOUN
dpc-4838	68	5	with	with	ADP
dpc-4838	68	6	history	history	NOUN
dpc-4838	68	7	of	of	ADP
dpc-4838	68	8	previous	previous	ADJ
dpc-4838	68	9	biological	biological	ADJ
dpc-4838	68	10	therapies	therapy	NOUN
dpc-4838	68	11	was	be	AUX
dpc-4838	68	12	77.0	77.0	NUM
dpc-4838	68	13	%	%	NOUN
dpc-4838	68	14	for	for	ADP
dpc-4838	68	15	risankizumab	risankizumab	NOUN
dpc-4838	68	16	and	and	CCONJ
dpc-4838	68	17	41.8	41.8	NUM
dpc-4838	68	18	%	%	NOUN
dpc-4838	68	19	for	for	ADP
dpc-4838	68	20	secukinumab	secukinumab	NOUN
dpc-4838	68	21	(	(	PUNCT
dpc-4838	68	22	p	p	X
dpc-4838	68	23	=	=	NOUN
dpc-4838	68	24	0.00005	0.00005	NUM
dpc-4838	68	25	)	)	PUNCT
dpc-4838	68	26	,	,	PUNCT
dpc-4838	68	27	with	with	ADP
dpc-4838	68	28	a	a	DET
dpc-4838	68	29	mean	mean	ADJ
dpc-4838	68	30	number	number	NOUN
dpc-4838	68	31	of	of	ADP
dpc-4838	68	32	prior	prior	ADJ
dpc-4838	68	33	biological	biological	ADJ
dpc-4838	68	34	therapies	therapy	NOUN
dpc-4838	68	35	of	of	ADP
dpc-4838	68	36	1.3	1.3	NUM
dpc-4838	68	37	±	±	NUM
dpc-4838	68	38	1.3	1.3	NUM
dpc-4838	68	39	and	and	CCONJ
dpc-4838	68	40	0.6	0.6	NUM
dpc-4838	68	41	±	±	NUM
dpc-4838	68	42	0.89	0.89	NUM
dpc-4838	68	43	,	,	PUNCT
dpc-4838	68	44	respectively	respectively	ADV
dpc-4838	68	45	(	(	PUNCT
dpc-4838	68	46	p	p	X
dpc-4838	68	47	=	=	NOUN
dpc-4838	68	48	0.001	0.001	NUM
dpc-4838	68	49	)	)	PUNCT
dpc-4838	68	50	.	.	PUNCT
dpc-4838	69	1	baseline	baseline	PROPN
dpc-4838	69	2	pasi	pasi	PROPN
dpc-4838	69	3	was	be	AUX
dpc-4838	69	4	similar	similar	ADJ
dpc-4838	69	5	between	between	ADP
dpc-4838	69	6	the	the	DET
dpc-4838	69	7	two	two	NUM
dpc-4838	69	8	subgroups	subgroup	NOUN
dpc-4838	69	9	(	(	PUNCT
dpc-4838	69	10	17.0	17.0	NUM
dpc-4838	69	11	and	and	CCONJ
dpc-4838	69	12	17.2	17.2	NUM
dpc-4838	69	13	for	for	ADP
dpc-4838	69	14	risankizumab	risankizumab	NOUN
dpc-4838	69	15	and	and	CCONJ
dpc-4838	69	16	secukinumab	secukinumab	NOUN
dpc-4838	69	17	,	,	PUNCT
dpc-4838	69	18	respectively	respectively	ADV
dpc-4838	69	19	)	)	PUNCT
dpc-4838	69	20	.	.	PUNCT
dpc-4838	70	1	further	far	ADV
dpc-4838	70	2	demographic	demographic	ADJ
dpc-4838	70	3	and	and	CCONJ
dpc-4838	70	4	clinical	clinical	ADJ
dpc-4838	70	5	data	datum	NOUN
dpc-4838	70	6	of	of	ADP
dpc-4838	70	7	enrolled	enrol	VERB
dpc-4838	70	8	patients	patient	NOUN
dpc-4838	70	9	are	be	AUX
dpc-4838	70	10	reported	report	VERB
dpc-4838	70	11	in	in	ADP
dpc-4838	70	12	table	table	NOUN
dpc-4838	70	13	1	1	NUM
dpc-4838	70	14	.	.	PUNCT
dpc-4838	71	1	patients	patient	NOUN
dpc-4838	71	2	were	be	AUX
dpc-4838	71	3	followed	follow	VERB
dpc-4838	71	4	at	at	ADP
dpc-4838	71	5	weeks	week	NOUN
dpc-4838	71	6	16	16	NUM
dpc-4838	71	7	,	,	PUNCT
dpc-4838	71	8	52	52	NUM
dpc-4838	71	9	and	and	CCONJ
dpc-4838	71	10	78	78	NUM
dpc-4838	71	11	for	for	ADP
dpc-4838	71	12	risankizumab	risankizumab	NOUN
dpc-4838	71	13	and	and	CCONJ
dpc-4838	71	14	secukinumab	secukinumab	NOUN
dpc-4838	71	15	.	.	PUNCT
dpc-4838	72	1	treatment	treatment	NOUN
dpc-4838	72	2	suspension	suspension	NOUN
dpc-4838	72	3	was	be	AUX
dpc-4838	72	4	recorded	record	VERB
dpc-4838	72	5	in	in	ADP
dpc-4838	72	6	2	2	NUM
dpc-4838	72	7	(	(	PUNCT
dpc-4838	72	8	2.9	2.9	NUM
dpc-4838	72	9	%	%	NOUN
dpc-4838	72	10	)	)	PUNCT
dpc-4838	72	11	secukinumab	secukinumab	NOUN
dpc-4838	72	12	-	-	PUNCT
dpc-4838	72	13	treated	treat	VERB
dpc-4838	72	14	patients	patient	NOUN
dpc-4838	72	15	;	;	PUNCT
dpc-4838	72	16	both	both	DET
dpc-4838	72	17	subjects	subject	NOUN
dpc-4838	72	18	experienced	experience	VERB
dpc-4838	72	19	primary	primary	ADJ
dpc-4838	72	20	inefficacy	inefficacy	NOUN
dpc-4838	72	21	and	and	CCONJ
dpc-4838	72	22	suspended	suspend	VERB
dpc-4838	72	23	the	the	DET
dpc-4838	72	24	treatment	treatment	NOUN
dpc-4838	72	25	at	at	ADP
dpc-4838	72	26	weeks	week	NOUN
dpc-4838	72	27	17	17	NUM
dpc-4838	72	28	and	and	CCONJ
dpc-4838	72	29	19	19	NUM
dpc-4838	72	30	,	,	PUNCT
dpc-4838	72	31	respectively	respectively	ADV
dpc-4838	72	32	.	.	PUNCT
dpc-4838	73	1	no	no	DET
dpc-4838	73	2	mild	mild	ADJ
dpc-4838	73	3	or	or	CCONJ
dpc-4838	73	4	serious	serious	ADJ
dpc-4838	73	5	safety	safety	NOUN
dpc-4838	73	6	issues	issue	NOUN
dpc-4838	73	7	or	or	CCONJ
dpc-4838	73	8	discontinuations	discontinuation	NOUN
dpc-4838	73	9	related	relate	VERB
dpc-4838	73	10	to	to	ADP
dpc-4838	73	11	aes	aes	PROPN
dpc-4838	73	12	were	be	AUX
dpc-4838	73	13	reported	report	VERB
dpc-4838	73	14	.	.	PUNCT
dpc-4838	74	1	4	4	NUM
dpc-4838	74	2	original	original	ADJ
dpc-4838	74	3	article	article	NOUN
dpc-4838	74	4	|	|	ADV
dpc-4838	74	5	dermatol	dermatol	ADJ
dpc-4838	74	6	pract	pract	NOUN
dpc-4838	74	7	concept	concept	NOUN
dpc-4838	74	8	.	.	PUNCT
dpc-4838	75	1	2025;15(1):4838	2025;15(1):4838	NUM
dpc-4838	75	2	clinical	clinical	ADJ
dpc-4838	75	3	efficacy	efficacy	NOUN
dpc-4838	75	4	in	in	ADP
dpc-4838	75	5	our	our	PRON
dpc-4838	75	6	population	population	NOUN
dpc-4838	75	7	,	,	PUNCT
dpc-4838	75	8	79.7	79.7	NUM
dpc-4838	75	9	%	%	NOUN
dpc-4838	75	10	versus	versus	ADP
dpc-4838	75	11	64.2	64.2	NUM
dpc-4838	75	12	%	%	NOUN
dpc-4838	75	13	of	of	ADP
dpc-4838	75	14	patients	patient	NOUN
dpc-4838	75	15	treated	treat	VERB
dpc-4838	75	16	respectively	respectively	ADV
dpc-4838	75	17	with	with	ADP
dpc-4838	75	18	risankizumab	risankizumab	NOUN
dpc-4838	75	19	or	or	CCONJ
dpc-4838	75	20	secukinumab	secukinumab	NOUN
dpc-4838	75	21	achieved	achieve	VERB
dpc-4838	75	22	a	a	DET
dpc-4838	75	23	pasi90	pasi90	NOUN
dpc-4838	75	24	response	response	NOUN
dpc-4838	75	25	at	at	ADP
dpc-4838	75	26	week	week	NOUN
dpc-4838	75	27	16	16	NUM
dpc-4838	75	28	(	(	PUNCT
dpc-4838	75	29	p	p	X
dpc-4838	75	30	=	=	NOUN
dpc-4838	75	31	0.041	0.041	NUM
dpc-4838	75	32	)	)	PUNCT
dpc-4838	75	33	,	,	PUNCT
dpc-4838	75	34	while	while	SCONJ
dpc-4838	75	35	the	the	DET
dpc-4838	75	36	difference	difference	NOUN
dpc-4838	75	37	in	in	ADP
dpc-4838	75	38	pasi100	pasi100	PROPN
dpc-4838	75	39	at	at	ADP
dpc-4838	75	40	week	week	NOUN
dpc-4838	75	41	16	16	NUM
dpc-4838	75	42	was	be	AUX
dpc-4838	75	43	not	not	PART
dpc-4838	75	44	statistically	statistically	ADV
dpc-4838	75	45	significant	significant	ADJ
dpc-4838	75	46	between	between	ADP
dpc-4838	75	47	the	the	DET
dpc-4838	75	48	2	2	NUM
dpc-4838	75	49	groups	group	NOUN
dpc-4838	75	50	.	.	PUNCT
dpc-4838	76	1	at	at	ADP
dpc-4838	76	2	week	week	NOUN
dpc-4838	76	3	52	52	NUM
dpc-4838	76	4	,	,	PUNCT
dpc-4838	76	5	pasi	pasi	NOUN
dpc-4838	76	6	90	90	NUM
dpc-4838	76	7	was	be	AUX
dpc-4838	76	8	achieved	achieve	VERB
dpc-4838	76	9	by	by	ADP
dpc-4838	76	10	98.6	98.6	NUM
dpc-4838	76	11	%	%	NOUN
dpc-4838	76	12	of	of	ADP
dpc-4838	76	13	patients	patient	NOUN
dpc-4838	76	14	in	in	ADP
dpc-4838	76	15	the	the	DET
dpc-4838	76	16	risankizumab	risankizumab	NOUN
dpc-4838	76	17	group	group	NOUN
dpc-4838	76	18	and	and	CCONJ
dpc-4838	76	19	by	by	ADP
dpc-4838	76	20	83.6	83.6	NUM
dpc-4838	76	21	%	%	NOUN
dpc-4838	76	22	of	of	ADP
dpc-4838	76	23	patients	patient	NOUN
dpc-4838	76	24	treated	treat	VERB
dpc-4838	76	25	with	with	ADP
dpc-4838	76	26	secukinumab	secukinumab	NOUN
dpc-4838	76	27	(	(	PUNCT
dpc-4838	76	28	p	p	X
dpc-4838	76	29	=	=	NOUN
dpc-4838	76	30	0.003	0.003	NUM
dpc-4838	76	31	)	)	PUNCT
dpc-4838	76	32	.	.	PUNCT
dpc-4838	77	1	risankizumab	risankizumab	PROPN
dpc-4838	77	2	also	also	ADV
dpc-4838	77	3	showed	show	VERB
dpc-4838	77	4	superior	superior	ADJ
dpc-4838	77	5	pasi100	pasi100	PROPN
dpc-4838	77	6	rates	rate	NOUN
dpc-4838	77	7	at	at	ADP
dpc-4838	77	8	week	week	NOUN
dpc-4838	77	9	52	52	NUM
dpc-4838	77	10	(	(	PUNCT
dpc-4838	77	11	85.5	85.5	NUM
dpc-4838	77	12	%	%	NOUN
dpc-4838	77	13	versus	versus	ADP
dpc-4838	77	14	65.6	65.6	NUM
dpc-4838	77	15	%	%	NOUN
dpc-4838	77	16	,	,	PUNCT
dpc-4838	77	17	p=0.009	p=0.009	NOUN
dpc-4838	77	18	)	)	PUNCT
dpc-4838	77	19	.	.	PUNCT
dpc-4838	78	1	no	no	DET
dpc-4838	78	2	statistically	statistically	ADV
dpc-4838	78	3	significant	significant	ADJ
dpc-4838	78	4	differences	difference	NOUN
dpc-4838	78	5	were	be	AUX
dpc-4838	78	6	observed	observe	VERB
dpc-4838	78	7	in	in	ADP
dpc-4838	78	8	pasi90	pasi90	NOUN
dpc-4838	78	9	and	and	CCONJ
dpc-4838	78	10	pasi100	pasi100	PROPN
dpc-4838	78	11	rates	rate	NOUN
dpc-4838	78	12	between	between	ADP
dpc-4838	78	13	the	the	DET
dpc-4838	78	14	2	2	NUM
dpc-4838	78	15	groups	group	NOUN
dpc-4838	78	16	at	at	ADP
dpc-4838	78	17	week	week	NOUN
dpc-4838	78	18	78	78	NUM
dpc-4838	78	19	,	,	PUNCT
dpc-4838	78	20	although	although	SCONJ
dpc-4838	78	21	risankizumab	risankizumab	NOUN
dpc-4838	78	22	showed	show	VERB
dpc-4838	78	23	higher	high	ADJ
dpc-4838	78	24	rates	rate	NOUN
dpc-4838	78	25	of	of	ADP
dpc-4838	78	26	pasi90	pasi90	NOUN
dpc-4838	78	27	and	and	CCONJ
dpc-4838	78	28	pasi100	pasi100	PROPN
dpc-4838	78	29	(	(	PUNCT
dpc-4838	78	30	95.16	95.16	NUM
dpc-4838	78	31	%	%	NOUN
dpc-4838	78	32	and	and	CCONJ
dpc-4838	78	33	82.26	82.26	NUM
dpc-4838	78	34	%	%	NOUN
dpc-4838	78	35	versus	versus	ADP
dpc-4838	78	36	89.83	89.83	NUM
dpc-4838	78	37	%	%	NOUN
dpc-4838	78	38	and	and	CCONJ
dpc-4838	78	39	72.88	72.88	NUM
dpc-4838	78	40	%	%	NOUN
dpc-4838	78	41	,	,	PUNCT
dpc-4838	78	42	respectively	respectively	ADV
dpc-4838	78	43	)	)	PUNCT
dpc-4838	78	44	.	.	PUNCT
dpc-4838	79	1	the	the	DET
dpc-4838	79	2	proportions	proportion	NOUN
dpc-4838	79	3	of	of	ADP
dpc-4838	79	4	patients	patient	NOUN
dpc-4838	79	5	reaching	reach	VERB
dpc-4838	79	6	pasi90	pasi90	NOUN
dpc-4838	79	7	and	and	CCONJ
dpc-4838	79	8	pasi100	pasi100	PROPN
dpc-4838	79	9	response	response	NOUN
dpc-4838	79	10	at	at	ADP
dpc-4838	79	11	the	the	DET
dpc-4838	79	12	different	different	ADJ
dpc-4838	79	13	time	time	NOUN
dpc-4838	79	14	-	-	PUNCT
dpc-4838	79	15	points	point	NOUN
dpc-4838	79	16	are	be	AUX
dpc-4838	79	17	represented	represent	VERB
dpc-4838	79	18	in	in	ADP
dpc-4838	79	19	table	table	NOUN
dpc-4838	79	20	2	2	NUM
dpc-4838	79	21	and	and	CCONJ
dpc-4838	79	22	figure	figure	NOUN
dpc-4838	79	23	1	1	NUM
dpc-4838	79	24	.	.	PUNCT
dpc-4838	80	1	cost	cost	NOUN
dpc-4838	80	2	per	per	ADP
dpc-4838	80	3	responder	responder	NOUN
dpc-4838	80	4	analysis	analysis	NOUN
dpc-4838	80	5	the	the	DET
dpc-4838	80	6	cost	cost	NOUN
dpc-4838	80	7	per	per	ADP
dpc-4838	80	8	responder	responder	NOUN
dpc-4838	80	9	for	for	ADP
dpc-4838	80	10	risankizumab	risankizumab	NOUN
dpc-4838	80	11	and	and	CCONJ
dpc-4838	80	12	secukinumab	secukinumab	NOUN
dpc-4838	80	13	was	be	AUX
dpc-4838	80	14	calculated	calculate	VERB
dpc-4838	80	15	using	use	VERB
dpc-4838	80	16	pasi90	pasi90	NOUN
dpc-4838	80	17	and	and	CCONJ
dpc-4838	80	18	pasi100	pasi100	PROPN
dpc-4838	80	19	rates	rate	NOUN
dpc-4838	80	20	at	at	ADP
dpc-4838	80	21	weeks	week	NOUN
dpc-4838	80	22	table	table	NOUN
dpc-4838	80	23	1	1	NUM
dpc-4838	80	24	.	.	PUNCT
dpc-4838	81	1	clinical	clinical	ADJ
dpc-4838	81	2	and	and	CCONJ
dpc-4838	81	3	demographic	demographic	ADJ
dpc-4838	81	4	characteristics	characteristic	NOUN
dpc-4838	81	5	of	of	ADP
dpc-4838	81	6	the	the	DET
dpc-4838	81	7	study	study	NOUN
dpc-4838	81	8	population	population	NOUN
dpc-4838	81	9	.	.	PUNCT
dpc-4838	82	1	characteristics	characteristics	PROPN
dpc-4838	82	2	risankizumab	risankizumab	PROPN
dpc-4838	82	3	secukinumab	secukinumab	PROPN
dpc-4838	82	4	p	p	NOUN
dpc-4838	82	5	value	value	NOUN
dpc-4838	82	6	patients	patient	NOUN
dpc-4838	82	7	(	(	PUNCT
dpc-4838	82	8	n	n	CCONJ
dpc-4838	82	9	)	)	PUNCT
dpc-4838	82	10	74	74	NUM
dpc-4838	82	11	67	67	NUM
dpc-4838	82	12	mean	mean	NOUN
dpc-4838	82	13	age	age	NOUN
dpc-4838	82	14	(	(	PUNCT
dpc-4838	82	15	years	year	NOUN
dpc-4838	82	16	±	±	NUM
dpc-4838	82	17	sd	sd	NOUN
dpc-4838	82	18	)	)	PUNCT
dpc-4838	82	19	51.2	51.2	NUM
dpc-4838	82	20	±	±	NUM
dpc-4838	82	21	16.4	16.4	NUM
dpc-4838	82	22	50.9	50.9	NUM
dpc-4838	82	23	±	±	NUM
dpc-4838	82	24	14.3	14.3	NUM
dpc-4838	82	25	0.862	0.862	NUM
dpc-4838	82	26	gender	gender	NOUN
dpc-4838	82	27	(	(	PUNCT
dpc-4838	82	28	%	%	NOUN
dpc-4838	82	29	male	male	NOUN
dpc-4838	82	30	)	)	PUNCT
dpc-4838	82	31	55.4	55.4	NUM
dpc-4838	82	32	%	%	NOUN
dpc-4838	82	33	67.2	67.2	NUM
dpc-4838	82	34	%	%	NOUN
dpc-4838	82	35	0.137	0.137	NUM
dpc-4838	82	36	weight	weight	NOUN
dpc-4838	82	37	(	(	PUNCT
dpc-4838	82	38	kg	kg	PROPN
dpc-4838	82	39	±	±	NUM
dpc-4838	82	40	sd	sd	NOUN
dpc-4838	82	41	)	)	PUNCT
dpc-4838	82	42	77.8	77.8	NUM
dpc-4838	82	43	±	±	NUM
dpc-4838	82	44	15.8	15.8	NUM
dpc-4838	82	45	78.8	78.8	NUM
dpc-4838	82	46	±	±	NUM
dpc-4838	82	47	15.7	15.7	NUM
dpc-4838	82	48	0.400	0.400	NUM
dpc-4838	82	49	duration	duration	NOUN
dpc-4838	82	50	of	of	ADP
dpc-4838	82	51	disease	disease	NOUN
dpc-4838	82	52	(	(	PUNCT
dpc-4838	82	53	years	year	NOUN
dpc-4838	82	54	±	±	NUM
dpc-4838	82	55	sd	sd	NOUN
dpc-4838	82	56	)	)	PUNCT
dpc-4838	82	57	21.1	21.1	NUM
dpc-4838	82	58	±	±	NUM
dpc-4838	82	59	14.8	14.8	NUM
dpc-4838	82	60	17.3	17.3	NUM
dpc-4838	82	61	±	±	NUM
dpc-4838	82	62	11.6	11.6	NUM
dpc-4838	82	63	0.079	0.079	NUM
dpc-4838	82	64	bio	bio	NOUN
dpc-4838	82	65	-	-	PUNCT
dpc-4838	82	66	exposed	exposed	ADJ
dpc-4838	82	67	(	(	PUNCT
dpc-4838	82	68	%	%	INTJ
dpc-4838	82	69	)	)	PUNCT
dpc-4838	82	70	77.0	77.0	NUM
dpc-4838	82	71	%	%	NOUN
dpc-4838	82	72	41.8	41.8	NUM
dpc-4838	82	73	%	%	NOUN
dpc-4838	82	74	0.00005a	0.00005a	PROPN
dpc-4838	82	75	n.	n.	PROPN
dpc-4838	82	76	previous	previous	ADJ
dpc-4838	82	77	biologics	biologic	NOUN
dpc-4838	82	78	(	(	PUNCT
dpc-4838	82	79	mean	mean	PROPN
dpc-4838	82	80	±	±	NUM
dpc-4838	82	81	sd	sd	NOUN
dpc-4838	82	82	)	)	PUNCT
dpc-4838	82	83	1.3	1.3	NUM
dpc-4838	82	84	±	±	NUM
dpc-4838	82	85	1.2	1.2	NUM
dpc-4838	82	86	0.6	0.6	NUM
dpc-4838	82	87	±	±	NUM
dpc-4838	82	88	0.8	0.8	NUM
dpc-4838	82	89	0.001	0.001	NUM
dpc-4838	82	90	a	a	DET
dpc-4838	82	91	baseline	baseline	ADJ
dpc-4838	82	92	pasi	pasi	NOUN
dpc-4838	82	93	(	(	PUNCT
dpc-4838	82	94	mean	mean	PROPN
dpc-4838	82	95	±	±	NUM
dpc-4838	82	96	sd	sd	NOUN
dpc-4838	82	97	)	)	PUNCT
dpc-4838	82	98	17.0	17.0	NUM
dpc-4838	82	99	±	±	NUM
dpc-4838	82	100	6.8	6.8	NUM
dpc-4838	82	101	17.2	17.2	NUM
dpc-4838	82	102	±	±	NUM
dpc-4838	82	103	8.4	8.4	NUM
dpc-4838	82	104	0.899	0.899	NUM
dpc-4838	82	105	pasi	pasi	NOUN
dpc-4838	82	106	=	=	SYM
dpc-4838	82	107	psoriasis	psoriasis	NOUN
dpc-4838	82	108	area	area	NOUN
dpc-4838	82	109	and	and	CCONJ
dpc-4838	82	110	severity	severity	NOUN
dpc-4838	82	111	index	index	NOUN
dpc-4838	82	112	;	;	PUNCT
dpc-4838	82	113	sd	sd	NOUN
dpc-4838	82	114	=	=	SYM
dpc-4838	82	115	standard	standard	ADJ
dpc-4838	82	116	deviation	deviation	NOUN
dpc-4838	82	117	.	.	PUNCT
dpc-4838	83	1	a	a	DET
dpc-4838	83	2	statistically	statistically	ADV
dpc-4838	83	3	significant	significant	ADJ
dpc-4838	83	4	table	table	NOUN
dpc-4838	83	5	2	2	NUM
dpc-4838	83	6	.	.	PUNCT
dpc-4838	83	7	pasi90	pasi90	NOUN
dpc-4838	83	8	and	and	CCONJ
dpc-4838	83	9	pasi100	pasi100	PROPN
dpc-4838	83	10	rates	rate	NOUN
dpc-4838	83	11	at	at	ADP
dpc-4838	83	12	weeks	week	NOUN
dpc-4838	83	13	16	16	NUM
dpc-4838	83	14	,	,	PUNCT
dpc-4838	83	15	52	52	NUM
dpc-4838	83	16	and	and	CCONJ
dpc-4838	83	17	78	78	NUM
dpc-4838	83	18	.	.	PUNCT
dpc-4838	84	1	pasi	pasi	PROPN
dpc-4838	84	2	risankizumab	risankizumab	PROPN
dpc-4838	84	3	secukinumab	secukinumab	PROPN
dpc-4838	84	4	delta	delta	PROPN
dpc-4838	84	5	risankizumab	risankizumab	PROPN
dpc-4838	84	6	vs	vs	ADP
dpc-4838	84	7	secukinumab	secukinumab	NOUN
dpc-4838	84	8	p	p	NOUN
dpc-4838	84	9	value	value	NOUN
dpc-4838	84	10	patients	patient	NOUN
dpc-4838	84	11	(	(	PUNCT
dpc-4838	84	12	n	n	CCONJ
dpc-4838	84	13	)	)	PUNCT
dpc-4838	84	14	74	74	NUM
dpc-4838	84	15	67	67	NUM
dpc-4838	84	16	pasi	pasi	NOUN
dpc-4838	84	17	90	90	NUM
dpc-4838	84	18	week	week	NOUN
dpc-4838	84	19	16	16	NUM
dpc-4838	84	20	79.7	79.7	NUM
dpc-4838	84	21	%	%	NOUN
dpc-4838	84	22	64.2	64.2	NUM
dpc-4838	84	23	%	%	NOUN
dpc-4838	84	24	15.6	15.6	NUM
dpc-4838	84	25	%	%	NOUN
dpc-4838	84	26	0.041	0.041	NUM
dpc-4838	84	27	a	a	DET
dpc-4838	84	28	pasi	pasi	NOUN
dpc-4838	84	29	100	100	NUM
dpc-4838	84	30	week	week	NOUN
dpc-4838	84	31	16	16	NUM
dpc-4838	84	32	55.4	55.4	NUM
dpc-4838	84	33	%	%	NOUN
dpc-4838	84	34	52.2	52.2	NUM
dpc-4838	84	35	%	%	NOUN
dpc-4838	84	36	3.2	3.2	NUM
dpc-4838	84	37	%	%	NOUN
dpc-4838	84	38	0.707	0.707	NUM
dpc-4838	84	39	patients	patient	NOUN
dpc-4838	84	40	(	(	PUNCT
dpc-4838	84	41	n	n	CCONJ
dpc-4838	84	42	)	)	PUNCT
dpc-4838	84	43	69	69	NUM
dpc-4838	84	44	61	61	NUM
dpc-4838	84	45	pasi	pasi	NOUN
dpc-4838	84	46	90	90	NUM
dpc-4838	84	47	week	week	NOUN
dpc-4838	84	48	52	52	NUM
dpc-4838	84	49	98.6	98.6	NUM
dpc-4838	84	50	%	%	NOUN
dpc-4838	84	51	83.6	83.6	NUM
dpc-4838	84	52	%	%	NOUN
dpc-4838	84	53	14.9	14.9	NUM
dpc-4838	84	54	%	%	NOUN
dpc-4838	84	55	0.003	0.003	NUM
dpc-4838	84	56	a	a	DET
dpc-4838	84	57	pasi	pasi	NOUN
dpc-4838	84	58	100	100	NUM
dpc-4838	84	59	week	week	NOUN
dpc-4838	84	60	52	52	NUM
dpc-4838	84	61	85.5	85.5	NUM
dpc-4838	84	62	%	%	NOUN
dpc-4838	84	63	65.6	65.6	NUM
dpc-4838	84	64	%	%	NOUN
dpc-4838	84	65	19.9	19.9	NUM
dpc-4838	84	66	%	%	NOUN
dpc-4838	84	67	0.009	0.009	NUM
dpc-4838	84	68	a	a	DET
dpc-4838	84	69	patients	patient	NOUN
dpc-4838	84	70	(	(	PUNCT
dpc-4838	84	71	n	n	CCONJ
dpc-4838	84	72	)	)	PUNCT
dpc-4838	84	73	62	62	NUM
dpc-4838	84	74	59	59	NUM
dpc-4838	84	75	pasi	pasi	NOUN
dpc-4838	84	76	90	90	NUM
dpc-4838	84	77	week	week	NOUN
dpc-4838	84	78	78	78	NUM
dpc-4838	84	79	95.16	95.16	NUM
dpc-4838	84	80	%	%	NOUN
dpc-4838	84	81	89.83	89.83	NUM
dpc-4838	84	82	%	%	NOUN
dpc-4838	84	83	5.3	5.3	NUM
dpc-4838	84	84	%	%	NOUN
dpc-4838	84	85	0.266	0.266	NUM
dpc-4838	84	86	pasi	pasi	NOUN
dpc-4838	84	87	100	100	NUM
dpc-4838	84	88	week	week	NOUN
dpc-4838	84	89	78	78	NUM
dpc-4838	84	90	82.26	82.26	NUM
dpc-4838	84	91	%	%	NOUN
dpc-4838	84	92	72.88	72.88	NUM
dpc-4838	84	93	%	%	NOUN
dpc-4838	84	94	9.4	9.4	NUM
dpc-4838	84	95	%	%	NOUN
dpc-4838	84	96	0.218	0.218	NUM
dpc-4838	84	97	pasi	pasi	NOUN
dpc-4838	84	98	=	=	SYM
dpc-4838	84	99	psoriasis	psoriasis	NOUN
dpc-4838	84	100	area	area	NOUN
dpc-4838	84	101	and	and	CCONJ
dpc-4838	84	102	severity	severity	NOUN
dpc-4838	84	103	index	index	NOUN
dpc-4838	84	104	.	.	PUNCT
dpc-4838	85	1	a	a	DET
dpc-4838	85	2	statistically	statistically	ADV
dpc-4838	85	3	significant	significant	ADJ
dpc-4838	85	4	16	16	NUM
dpc-4838	85	5	and	and	CCONJ
dpc-4838	85	6	52	52	NUM
dpc-4838	85	7	,	,	PUNCT
dpc-4838	85	8	respectively	respectively	ADV
dpc-4838	85	9	(	(	PUNCT
dpc-4838	85	10	table	table	NOUN
dpc-4838	85	11	3	3	NUM
dpc-4838	85	12	)	)	PUNCT
dpc-4838	85	13	.	.	PUNCT
dpc-4838	86	1	at	at	ADP
dpc-4838	86	2	week	week	NOUN
dpc-4838	86	3	16	16	NUM
dpc-4838	86	4	,	,	PUNCT
dpc-4838	86	5	the	the	DET
dpc-4838	86	6	cost	cost	NOUN
dpc-4838	86	7	per	per	ADP
dpc-4838	86	8	responder	responder	NOUN
dpc-4838	86	9	calculated	calculate	VERB
dpc-4838	86	10	using	use	VERB
dpc-4838	86	11	pasi90	pasi90	NOUN
dpc-4838	86	12	index	index	NOUN
dpc-4838	86	13	was	be	AUX
dpc-4838	86	14	€	€	SYM
dpc-4838	86	15	5833.66	5833.66	NUM
dpc-4838	86	16	for	for	ADP
dpc-4838	86	17	risankizumab	risankizumab	NOUN
dpc-4838	86	18	and	and	CCONJ
dpc-4838	86	19	€	€	SYM
dpc-4838	86	20	8747.18	8747.18	NUM
dpc-4838	86	21	for	for	ADP
dpc-4838	86	22	secukinumab	secukinumab	NOUN
dpc-4838	86	23	,	,	PUNCT
dpc-4838	86	24	whereas	whereas	SCONJ
dpc-4838	86	25	the	the	DET
dpc-4838	86	26	cost	cost	NOUN
dpc-4838	86	27	per	per	ADP
dpc-4838	86	28	responder	responder	NOUN
dpc-4838	86	29	calculated	calculate	VERB
dpc-4838	86	30	with	with	ADP
dpc-4838	86	31	pasi100	pasi100	PROPN
dpc-4838	86	32	index	index	NOUN
dpc-4838	86	33	was	be	AUX
dpc-4838	86	34	€	€	SYM
dpc-4838	86	35	8394.78	8394.78	NUM
dpc-4838	86	36	for	for	ADP
dpc-4838	86	37	risankizumab	risankizumab	NOUN
dpc-4838	86	38	and	and	CCONJ
dpc-4838	86	39	€	€	SYM
dpc-4838	86	40	10746.53	10746.53	NUM
dpc-4838	86	41	for	for	ADP
dpc-4838	86	42	secukinumab	secukinumab	NOUN
dpc-4838	86	43	.	.	PUNCT
dpc-4838	87	1	risankizumab	risankizumab	PROPN
dpc-4838	87	2	also	also	ADV
dpc-4838	87	3	had	have	VERB
dpc-4838	87	4	lower	low	ADJ
dpc-4838	87	5	costs	cost	NOUN
dpc-4838	87	6	per	per	ADP
dpc-4838	87	7	responder	responder	NOUN
dpc-4838	87	8	than	than	ADP
dpc-4838	87	9	secukinumab	secukinumab	NOUN
dpc-4838	87	10	at	at	ADP
dpc-4838	87	11	week	week	NOUN
dpc-4838	87	12	52	52	NUM
dpc-4838	87	13	,	,	PUNCT
dpc-4838	87	14	with	with	ADP
dpc-4838	87	15	pasi90	pasi90	NOUN
dpc-4838	87	16	and	and	CCONJ
dpc-4838	87	17	pasi100	pasi100	PROPN
dpc-4838	87	18	costs	cost	NOUN
dpc-4838	87	19	per	per	ADP
dpc-4838	87	20	responder	responder	NOUN
dpc-4838	87	21	of	of	ADP
dpc-4838	87	22	€	€	SYM
dpc-4838	87	23	11798.90	11798.90	NUM
dpc-4838	87	24	and	and	CCONJ
dpc-4838	87	25	€	€	SYM
dpc-4838	87	26	13598.73	13598.73	NUM
dpc-4838	87	27	versus	versus	ADP
dpc-4838	87	28	€	€	SYM
dpc-4838	87	29	15347.70	15347.70	NUM
dpc-4838	87	30	and	and	CCONJ
dpc-4838	87	31	€	€	SYM
dpc-4838	87	32	19568.31	19568.31	NUM
dpc-4838	87	33	,	,	PUNCT
dpc-4838	87	34	respectively	respectively	ADV
dpc-4838	87	35	.	.	PUNCT
dpc-4838	88	1	the	the	DET
dpc-4838	88	2	results	result	NOUN
dpc-4838	88	3	of	of	ADP
dpc-4838	88	4	the	the	DET
dpc-4838	88	5	cost	cost	NOUN
dpc-4838	88	6	per	per	ADP
dpc-4838	88	7	responder	responder	NOUN
dpc-4838	88	8	analysis	analysis	NOUN
dpc-4838	88	9	are	be	AUX
dpc-4838	88	10	shown	show	VERB
dpc-4838	88	11	in	in	ADP
dpc-4838	88	12	figure	figure	NOUN
dpc-4838	88	13	2	2	NUM
dpc-4838	88	14	.	.	PUNCT
dpc-4838	88	15	conclusions	conclusion	NOUN
dpc-4838	88	16	this	this	DET
dpc-4838	88	17	retrospective	retrospective	NOUN
dpc-4838	88	18	,	,	PUNCT
dpc-4838	88	19	multicenter	multicenter	ADJ
dpc-4838	88	20	study	study	NOUN
dpc-4838	88	21	analyzed	analyze	VERB
dpc-4838	88	22	a	a	DET
dpc-4838	88	23	cohort	cohort	NOUN
dpc-4838	88	24	of	of	ADP
dpc-4838	88	25	patients	patient	NOUN
dpc-4838	88	26	from	from	ADP
dpc-4838	88	27	the	the	DET
dpc-4838	88	28	lazio	lazio	PROPN
dpc-4838	88	29	region	region	NOUN
dpc-4838	88	30	of	of	ADP
dpc-4838	88	31	italy	italy	PROPN
dpc-4838	88	32	affected	affect	VERB
dpc-4838	88	33	by	by	ADP
dpc-4838	88	34	moderate	moderate	ADJ
dpc-4838	88	35	-	-	PUNCT
dpc-4838	88	36	to	to	ADP
dpc-4838	88	37	-	-	PUNCT
dpc-4838	88	38	severe	severe	ADJ
dpc-4838	88	39	psoriasis	psoriasis	NOUN
dpc-4838	88	40	and	and	CCONJ
dpc-4838	88	41	treated	treat	VERB
dpc-4838	88	42	with	with	ADP
dpc-4838	88	43	risankizumab	risankizumab	NOUN
dpc-4838	88	44	or	or	CCONJ
dpc-4838	88	45	secukinumab	secukinumab	NOUN
dpc-4838	88	46	.	.	PUNCT
dpc-4838	89	1	the	the	DET
dpc-4838	89	2	maximum	maximum	ADJ
dpc-4838	89	3	follow	follow	VERB
dpc-4838	89	4	-	-	PUNCT
dpc-4838	89	5	up	up	NOUN
dpc-4838	89	6	period	period	NOUN
dpc-4838	89	7	was	be	AUX
dpc-4838	89	8	78	78	NUM
dpc-4838	89	9	weeks	week	NOUN
dpc-4838	89	10	.	.	PUNCT
dpc-4838	90	1	the	the	DET
dpc-4838	90	2	results	result	NOUN
dpc-4838	90	3	of	of	ADP
dpc-4838	90	4	the	the	DET
dpc-4838	90	5	study	study	NOUN
dpc-4838	90	6	confirm	confirm	VERB
dpc-4838	90	7	the	the	DET
dpc-4838	90	8	efficacy	efficacy	NOUN
dpc-4838	90	9	and	and	CCONJ
dpc-4838	90	10	safety	safety	NOUN
dpc-4838	90	11	of	of	ADP
dpc-4838	90	12	both	both	DET
dpc-4838	90	13	risankizumab	risankizumab	NOUN
dpc-4838	90	14	and	and	CCONJ
dpc-4838	90	15	secukinumab	secukinumab	NOUN
dpc-4838	90	16	in	in	ADP
dpc-4838	90	17	patients	patient	NOUN
dpc-4838	90	18	with	with	ADP
dpc-4838	90	19	psoriasis	psoriasis	NOUN
dpc-4838	90	20	,	,	PUNCT
dpc-4838	90	21	consistent	consistent	ADJ
dpc-4838	90	22	with	with	ADP
dpc-4838	90	23	the	the	DET
dpc-4838	90	24	results	result	NOUN
dpc-4838	90	25	of	of	ADP
dpc-4838	90	26	the	the	DET
dpc-4838	90	27	rcts	rct	NOUN
dpc-4838	90	28	.	.	PUNCT
dpc-4838	91	1	original	original	ADJ
dpc-4838	91	2	article	article	NOUN
dpc-4838	91	3	|	|	ADV
dpc-4838	91	4	dermatol	dermatol	ADJ
dpc-4838	91	5	pract	pract	NOUN
dpc-4838	91	6	concept	concept	NOUN
dpc-4838	91	7	.	.	PUNCT
dpc-4838	92	1	2025;15(1):4838	2025;15(1):4838	NUM
dpc-4838	92	2	5	5	NUM
dpc-4838	92	3	figure	figure	NOUN
dpc-4838	92	4	1	1	NUM
dpc-4838	92	5	.	.	PUNCT
dpc-4838	93	1	proportions	proportion	NOUN
dpc-4838	93	2	(	(	PUNCT
dpc-4838	93	3	%	%	INTJ
dpc-4838	93	4	)	)	PUNCT
dpc-4838	93	5	of	of	ADP
dpc-4838	93	6	patients	patient	NOUN
dpc-4838	93	7	achieving	achieve	VERB
dpc-4838	93	8	psoriasis	psoriasis	NOUN
dpc-4838	93	9	area	area	NOUN
dpc-4838	93	10	and	and	CCONJ
dpc-4838	93	11	severity	severity	NOUN
dpc-4838	93	12	index	index	NOUN
dpc-4838	93	13	(	(	PUNCT
dpc-4838	93	14	pasi)90	pasi)90	PROPN
dpc-4838	93	15	and	and	CCONJ
dpc-4838	93	16	pasi100	pasi100	PROPN
dpc-4838	93	17	responses	response	NOUN
dpc-4838	93	18	at	at	ADP
dpc-4838	93	19	weeks	week	NOUN
dpc-4838	93	20	16	16	NUM
dpc-4838	93	21	,	,	PUNCT
dpc-4838	93	22	52	52	NUM
dpc-4838	93	23	and	and	CCONJ
dpc-4838	93	24	78	78	NUM
dpc-4838	93	25	.	.	PUNCT
dpc-4838	94	1	table	table	NOUN
dpc-4838	94	2	3	3	NUM
dpc-4838	94	3	.	.	PUNCT
dpc-4838	95	1	cost	cost	NOUN
dpc-4838	95	2	per	per	ADP
dpc-4838	95	3	pasi90	pasi90	NOUN
dpc-4838	95	4	and	and	CCONJ
dpc-4838	95	5	pasi100	pasi100	PROPN
dpc-4838	95	6	responder	responder	NOUN
dpc-4838	95	7	at	at	ADP
dpc-4838	95	8	weeks	week	NOUN
dpc-4838	95	9	16	16	NUM
dpc-4838	95	10	and	and	CCONJ
dpc-4838	95	11	52	52	NUM
dpc-4838	95	12	.	.	PUNCT
dpc-4838	96	1	cost	cost	NOUN
dpc-4838	96	2	per	per	ADP
dpc-4838	96	3	responder	responder	NOUN
dpc-4838	96	4	risankizumab	risankizumab	VERB
dpc-4838	96	5	a	a	DET
dpc-4838	96	6	secukinumabb	secukinumabb	ADJ
dpc-4838	96	7	delta	delta	NOUN
dpc-4838	96	8	risankizumab	risankizumab	NOUN
dpc-4838	96	9	versus	versus	ADP
dpc-4838	96	10	secukinumab	secukinumab	PROPN
dpc-4838	96	11	pasi	pasi	NOUN
dpc-4838	96	12	90	90	NUM
dpc-4838	96	13	week	week	NOUN
dpc-4838	96	14	16	16	NUM
dpc-4838	96	15	€	€	SYM
dpc-4838	96	16	5833.66	5833.66	NUM
dpc-4838	96	17	€	€	SYM
dpc-4838	96	18	8747.18	8747.18	NUM
dpc-4838	96	19	-€	-€	PRON
dpc-4838	96	20	2913.52	2913.52	NUM
dpc-4838	96	21	pasi	pasi	NOUN
dpc-4838	96	22	100	100	NUM
dpc-4838	96	23	week	week	NOUN
dpc-4838	96	24	16	16	NUM
dpc-4838	96	25	€	€	SYM
dpc-4838	96	26	8394.78	8394.78	NUM
dpc-4838	96	27	€	€	SYM
dpc-4838	96	28	10746.53	10746.53	NUM
dpc-4838	96	29	-€	-€	PRON
dpc-4838	96	30	2351.76	2351.76	NUM
dpc-4838	96	31	pasi	pasi	NOUN
dpc-4838	96	32	90	90	NUM
dpc-4838	96	33	week	week	NOUN
dpc-4838	96	34	52	52	NUM
dpc-4838	96	35	€	€	SYM
dpc-4838	96	36	11798.90	11798.90	NUM
dpc-4838	96	37	€	€	SYM
dpc-4838	96	38	15347.70	15347.70	NUM
dpc-4838	96	39	-€	-€	SYM
dpc-4838	96	40	3548.80	3548.80	NUM
dpc-4838	96	41	pasi	pasi	NOUN
dpc-4838	96	42	100	100	NUM
dpc-4838	96	43	week	week	NOUN
dpc-4838	96	44	52	52	NUM
dpc-4838	96	45	€	€	SYM
dpc-4838	96	46	13598.73	13598.73	NUM
dpc-4838	96	47	€	€	SYM
dpc-4838	96	48	19568.31	19568.31	NUM
dpc-4838	96	49	-€	-€	SYM
dpc-4838	96	50	5969.58	5969.58	NUM
dpc-4838	96	51	aa	aa	NOUN
dpc-4838	96	52	purchase	purchase	NOUN
dpc-4838	96	53	price	price	NOUN
dpc-4838	96	54	of	of	ADP
dpc-4838	96	55	€	€	SYM
dpc-4838	96	56	1162.79	1162.79	NUM
dpc-4838	96	57	for	for	ADP
dpc-4838	96	58	a	a	DET
dpc-4838	96	59	75	75	NUM
dpc-4838	96	60	-	-	PUNCT
dpc-4838	96	61	mg	mg	NOUN
dpc-4838	96	62	pen	pen	NOUN
dpc-4838	96	63	of	of	ADP
dpc-4838	96	64	risankizumab	risankizumab	NOUN
dpc-4838	96	65	was	be	AUX
dpc-4838	96	66	considered	consider	VERB
dpc-4838	96	67	ba	ba	NOUN
dpc-4838	96	68	purchase	purchase	NOUN
dpc-4838	96	69	price	price	NOUN
dpc-4838	96	70	of	of	ADP
dpc-4838	96	71	€	€	SYM
dpc-4838	96	72	400.99	400.99	NUM
dpc-4838	96	73	for	for	ADP
dpc-4838	96	74	a	a	DET
dpc-4838	96	75	150	150	NUM
dpc-4838	96	76	-	-	PUNCT
dpc-4838	96	77	mg	mg	NOUN
dpc-4838	96	78	pen	pen	NOUN
dpc-4838	96	79	of	of	ADP
dpc-4838	96	80	secukinumab	secukinumab	NOUN
dpc-4838	96	81	was	be	AUX
dpc-4838	96	82	considered	consider	VERB
dpc-4838	96	83	pasi	pasi	NOUN
dpc-4838	96	84	=	=	NOUN
dpc-4838	96	85	psoriasis	psoriasis	NOUN
dpc-4838	96	86	area	area	NOUN
dpc-4838	96	87	and	and	CCONJ
dpc-4838	96	88	severity	severity	NOUN
dpc-4838	96	89	index	index	NOUN
dpc-4838	96	90	.	.	PUNCT
dpc-4838	97	1	significant	significant	ADJ
dpc-4838	97	2	reductions	reduction	NOUN
dpc-4838	97	3	in	in	ADP
dpc-4838	97	4	pasi	pasi	NOUN
dpc-4838	97	5	scores	score	NOUN
dpc-4838	97	6	were	be	AUX
dpc-4838	97	7	observed	observe	VERB
dpc-4838	97	8	at	at	ADP
dpc-4838	97	9	the	the	DET
dpc-4838	97	10	time	time	NOUN
dpc-4838	97	11	points	point	NOUN
dpc-4838	97	12	of	of	ADP
dpc-4838	97	13	interest	interest	NOUN
dpc-4838	97	14	,	,	PUNCT
dpc-4838	97	15	and	and	CCONJ
dpc-4838	97	16	no	no	DET
dpc-4838	97	17	safety	safety	NOUN
dpc-4838	97	18	issues	issue	NOUN
dpc-4838	97	19	were	be	AUX
dpc-4838	97	20	reported	report	VERB
dpc-4838	97	21	.	.	PUNCT
dpc-4838	98	1	in	in	ADP
dpc-4838	98	2	our	our	PRON
dpc-4838	98	3	study	study	NOUN
dpc-4838	98	4	population	population	NOUN
dpc-4838	98	5	,	,	PUNCT
dpc-4838	98	6	risankizumab	risankizumab	NOUN
dpc-4838	98	7	pasi90	pasi90	NOUN
dpc-4838	98	8	and	and	CCONJ
dpc-4838	98	9	pasi100	pasi100	PROPN
dpc-4838	98	10	responses	response	VERB
dpc-4838	98	11	rates	rate	NOUN
dpc-4838	98	12	at	at	ADP
dpc-4838	98	13	week	week	NOUN
dpc-4838	98	14	16	16	NUM
dpc-4838	98	15	(	(	PUNCT
dpc-4838	98	16	79.7	79.7	NUM
dpc-4838	98	17	%	%	NOUN
dpc-4838	98	18	and	and	CCONJ
dpc-4838	98	19	55.4	55.4	NUM
dpc-4838	98	20	%	%	NOUN
dpc-4838	98	21	)	)	PUNCT
dpc-4838	98	22	and	and	CCONJ
dpc-4838	98	23	week	week	NOUN
dpc-4838	98	24	52	52	NUM
dpc-4838	98	25	(	(	PUNCT
dpc-4838	98	26	98.6	98.6	NUM
dpc-4838	98	27	%	%	NOUN
dpc-4838	98	28	and	and	CCONJ
dpc-4838	98	29	85.5	85.5	NUM
dpc-4838	98	30	%	%	NOUN
dpc-4838	98	31	)	)	PUNCT
dpc-4838	98	32	are	be	AUX
dpc-4838	98	33	similar	similar	ADJ
dpc-4838	98	34	to	to	ADP
dpc-4838	98	35	those	those	PRON
dpc-4838	98	36	reported	report	VERB
dpc-4838	98	37	in	in	ADP
dpc-4838	98	38	rcts	rct	NOUN
dpc-4838	98	39	,	,	PUNCT
dpc-4838	98	40	although	although	SCONJ
dpc-4838	98	41	slightly	slightly	ADV
dpc-4838	98	42	higher	high	ADJ
dpc-4838	98	43	at	at	ADP
dpc-4838	98	44	week	week	NOUN
dpc-4838	98	45	52	52	NUM
dpc-4838	98	46	in	in	ADP
dpc-4838	98	47	our	our	PRON
dpc-4838	98	48	study	study	NOUN
dpc-4838	98	49	respect	respect	NOUN
dpc-4838	98	50	to	to	ADP
dpc-4838	98	51	data	datum	NOUN
dpc-4838	98	52	described	describe	VERB
dpc-4838	98	53	in	in	ADP
dpc-4838	98	54	ultimma-1	ultimma-1	NUM
dpc-4838	98	55	and	and	CCONJ
dpc-4838	98	56	-2	-2	NOUN
dpc-4838	98	57	trials	trial	NOUN
dpc-4838	98	58	[	[	X
dpc-4838	98	59	13	13	NUM
dpc-4838	98	60	]	]	PUNCT
dpc-4838	98	61	.	.	PUNCT
dpc-4838	99	1	the	the	DET
dpc-4838	99	2	small	small	ADJ
dpc-4838	99	3	sample	sample	NOUN
dpc-4838	99	4	size	size	NOUN
dpc-4838	99	5	of	of	ADP
dpc-4838	99	6	our	our	PRON
dpc-4838	99	7	study	study	NOUN
dpc-4838	99	8	compared	compare	VERB
dpc-4838	99	9	to	to	ADP
dpc-4838	99	10	rcts	rct	NOUN
dpc-4838	99	11	may	may	AUX
dpc-4838	99	12	be	be	AUX
dpc-4838	99	13	a	a	DET
dpc-4838	99	14	possible	possible	ADJ
dpc-4838	99	15	explanation	explanation	NOUN
dpc-4838	99	16	for	for	ADP
dpc-4838	99	17	this	this	DET
dpc-4838	99	18	discrepancy	discrepancy	NOUN
dpc-4838	99	19	.	.	PUNCT
dpc-4838	100	1	on	on	ADP
dpc-4838	100	2	the	the	DET
dpc-4838	100	3	other	other	ADJ
dpc-4838	100	4	hand	hand	NOUN
dpc-4838	100	5	,	,	PUNCT
dpc-4838	100	6	the	the	DET
dpc-4838	100	7	secukinumab	secukinumab	NOUN
dpc-4838	100	8	-	-	PUNCT
dpc-4838	100	9	treated	treat	VERB
dpc-4838	100	10	population	population	NOUN
dpc-4838	100	11	showed	show	VERB
dpc-4838	100	12	pasi90	pasi90	NOUN
dpc-4838	100	13	and	and	CCONJ
dpc-4838	100	14	pasi100	pasi100	PROPN
dpc-4838	100	15	rates	rate	NOUN
dpc-4838	100	16	of	of	ADP
dpc-4838	100	17	64.2	64.2	NUM
dpc-4838	100	18	%	%	NOUN
dpc-4838	100	19	and	and	CCONJ
dpc-4838	100	20	52.2	52.2	NUM
dpc-4838	100	21	%	%	NOUN
dpc-4838	100	22	at	at	ADP
dpc-4838	100	23	week	week	NOUN
dpc-4838	100	24	16	16	NUM
dpc-4838	100	25	and	and	CCONJ
dpc-4838	100	26	83.6	83.6	NUM
dpc-4838	100	27	%	%	NOUN
dpc-4838	100	28	and	and	CCONJ
dpc-4838	100	29	65.6	65.6	NUM
dpc-4838	100	30	%	%	NOUN
dpc-4838	100	31	at	at	ADP
dpc-4838	100	32	week	week	NOUN
dpc-4838	100	33	52	52	NUM
dpc-4838	100	34	,	,	PUNCT
dpc-4838	100	35	similar	similar	ADJ
dpc-4838	100	36	to	to	ADP
dpc-4838	100	37	those	those	PRON
dpc-4838	100	38	reported	report	VERB
dpc-4838	100	39	in	in	ADP
dpc-4838	100	40	erasure	erasure	NOUN
dpc-4838	100	41	and	and	CCONJ
dpc-4838	100	42	fixture	fixture	ADJ
dpc-4838	100	43	studies	study	NOUN
dpc-4838	100	44	[	[	X
dpc-4838	100	45	11	11	NUM
dpc-4838	100	46	]	]	PUNCT
dpc-4838	100	47	.	.	PUNCT
dpc-4838	101	1	several	several	ADJ
dpc-4838	101	2	real	real	ADJ
dpc-4838	101	3	-	-	PUNCT
dpc-4838	101	4	world	world	NOUN
dpc-4838	101	5	studies	study	NOUN
dpc-4838	101	6	have	have	AUX
dpc-4838	101	7	also	also	ADV
dpc-4838	101	8	evaluated	evaluate	VERB
dpc-4838	101	9	the	the	DET
dpc-4838	101	10	efficacy	efficacy	NOUN
dpc-4838	101	11	of	of	ADP
dpc-4838	101	12	risankizumab	risankizumab	PROPN
dpc-4838	101	13	and	and	CCONJ
dpc-4838	101	14	secukinumab	secukinumab	NOUN
dpc-4838	101	15	,	,	PUNCT
dpc-4838	101	16	highlighting	highlight	VERB
dpc-4838	101	17	their	their	PRON
dpc-4838	101	18	overall	overall	ADJ
dpc-4838	101	19	superiority	superiority	NOUN
dpc-4838	101	20	over	over	ADP
dpc-4838	101	21	anti	anti	ADJ
dpc-4838	101	22	-	-	NOUN
dpc-4838	101	23	tnfs	tnfs	NOUN
dpc-4838	101	24	in	in	ADP
dpc-4838	101	25	terms	term	NOUN
dpc-4838	101	26	of	of	ADP
dpc-4838	101	27	disease	disease	NOUN
dpc-4838	101	28	activity	activity	NOUN
dpc-4838	101	29	reduction	reduction	NOUN
dpc-4838	101	30	[	[	X
dpc-4838	101	31	22	22	NUM
dpc-4838	101	32	-	-	SYM
dpc-4838	101	33	25	25	NUM
dpc-4838	101	34	]	]	PUNCT
dpc-4838	101	35	.	.	PUNCT
dpc-4838	102	1	however	however	ADV
dpc-4838	102	2	,	,	PUNCT
dpc-4838	102	3	as	as	SCONJ
dpc-4838	102	4	previously	previously	ADV
dpc-4838	102	5	stated	state	VERB
dpc-4838	102	6	,	,	PUNCT
dpc-4838	102	7	few	few	ADJ
dpc-4838	102	8	data	datum	NOUN
dpc-4838	102	9	are	be	AUX
dpc-4838	102	10	available	available	ADJ
dpc-4838	102	11	regarding	regard	VERB
dpc-4838	102	12	a	a	DET
dpc-4838	102	13	direct	direct	ADJ
dpc-4838	102	14	comparison	comparison	NOUN
dpc-4838	102	15	of	of	ADP
dpc-4838	102	16	efficacy	efficacy	NOUN
dpc-4838	102	17	and	and	CCONJ
dpc-4838	102	18	safety	safety	NOUN
dpc-4838	102	19	of	of	ADP
dpc-4838	102	20	risankizumab	risankizumab	NOUN
dpc-4838	102	21	and	and	CCONJ
dpc-4838	102	22	secukinumab	secukinumab	NOUN
dpc-4838	102	23	in	in	ADP
dpc-4838	102	24	a	a	DET
dpc-4838	102	25	real	real	ADJ
dpc-4838	102	26	-	-	PUNCT
dpc-4838	102	27	life	life	NOUN
dpc-4838	102	28	setting	setting	NOUN
dpc-4838	102	29	,	,	PUNCT
dpc-4838	102	30	except	except	SCONJ
dpc-4838	102	31	for	for	ADP
dpc-4838	102	32	data	datum	NOUN
dpc-4838	102	33	from	from	ADP
dpc-4838	102	34	comparisons	comparison	NOUN
dpc-4838	102	35	between	between	ADP
dpc-4838	102	36	classes	class	NOUN
dpc-4838	102	37	of	of	ADP
dpc-4838	102	38	drugs	drug	NOUN
dpc-4838	102	39	(	(	PUNCT
dpc-4838	102	40	eg	eg	NOUN
dpc-4838	102	41	anti	anti	PROPN
dpc-4838	102	42	-	-	PROPN
dpc-4838	102	43	il23	il23	PROPN
dpc-4838	102	44	vs.	vs.	ADP
dpc-4838	102	45	anti	anti	ADJ
dpc-4838	102	46	-	-	ADJ
dpc-4838	102	47	il17	il17	PROPN
dpc-4838	102	48	)	)	PUNCT
dpc-4838	102	49	in	in	ADP
dpc-4838	102	50	single	single	ADJ
dpc-4838	102	51	-	-	PUNCT
dpc-4838	102	52	center	center	NOUN
dpc-4838	102	53	experiences	experience	NOUN
dpc-4838	102	54	[	[	X
dpc-4838	102	55	26,27	26,27	NUM
dpc-4838	102	56	]	]	PUNCT
dpc-4838	102	57	and	and	CCONJ
dpc-4838	102	58	drug	drug	NOUN
dpc-4838	102	59	survival	survival	NOUN
dpc-4838	102	60	studies	study	NOUN
dpc-4838	102	61	[	[	X
dpc-4838	102	62	16,17	16,17	NUM
dpc-4838	102	63	]	]	PUNCT
dpc-4838	102	64	.	.	PUNCT
dpc-4838	103	1	in	in	ADP
dpc-4838	103	2	our	our	PRON
dpc-4838	103	3	real	real	ADJ
dpc-4838	103	4	-	-	PUNCT
dpc-4838	103	5	life	life	NOUN
dpc-4838	103	6	comparison	comparison	NOUN
dpc-4838	103	7	,	,	PUNCT
dpc-4838	103	8	risankizumab	risankizumab	PROPN
dpc-4838	103	9	outperformed	outperform	VERB
dpc-4838	103	10	secukinumab	secukinumab	NOUN
dpc-4838	103	11	,	,	PUNCT
dpc-4838	103	12	showing	show	VERB
dpc-4838	103	13	higher	high	ADJ
dpc-4838	103	14	pasi90	pasi90	NOUN
dpc-4838	103	15	and	and	CCONJ
dpc-4838	103	16	pasi100	pasi100	PROPN
dpc-4838	103	17	rates	rate	NOUN
dpc-4838	103	18	at	at	ADP
dpc-4838	103	19	every	every	DET
dpc-4838	103	20	time	time	NOUN
dpc-4838	103	21	point	point	NOUN
dpc-4838	103	22	examined	examine	VERB
dpc-4838	103	23	.	.	PUNCT
dpc-4838	104	1	in	in	ADP
dpc-4838	104	2	particular	particular	ADJ
dpc-4838	104	3	,	,	PUNCT
dpc-4838	104	4	at	at	ADP
dpc-4838	104	5	over	over	ADP
dpc-4838	104	6	1	1	NUM
dpc-4838	104	7	year	year	NOUN
dpc-4838	104	8	of	of	ADP
dpc-4838	104	9	treatment	treatment	NOUN
dpc-4838	104	10	,	,	PUNCT
dpc-4838	104	11	98.6	98.6	NUM
dpc-4838	104	12	%	%	NOUN
dpc-4838	104	13	of	of	ADP
dpc-4838	104	14	the	the	DET
dpc-4838	104	15	risankizumab	risankizumab	NOUN
dpc-4838	104	16	-	-	PUNCT
dpc-4838	104	17	treated	treat	VERB
dpc-4838	104	18	population	population	NOUN
dpc-4838	104	19	achieved	achieve	VERB
dpc-4838	104	20	a	a	DET
dpc-4838	104	21	pasi90	pasi90	NOUN
dpc-4838	104	22	response	response	NOUN
dpc-4838	104	23	,	,	PUNCT
dpc-4838	104	24	in	in	ADP
dpc-4838	104	25	contrast	contrast	NOUN
dpc-4838	104	26	with	with	ADP
dpc-4838	104	27	the	the	DET
dpc-4838	104	28	secukinumab	secukinumab	NOUN
dpc-4838	104	29	-	-	PUNCT
dpc-4838	104	30	treated	treat	VERB
dpc-4838	104	31	population	population	NOUN
dpc-4838	104	32	in	in	ADP
dpc-4838	104	33	which	which	PRON
dpc-4838	104	34	83.6	83.6	NUM
dpc-4838	104	35	%	%	NOUN
dpc-4838	104	36	of	of	ADP
dpc-4838	104	37	patients	patient	NOUN
dpc-4838	104	38	met	meet	VERB
dpc-4838	104	39	this	this	DET
dpc-4838	104	40	efficacy	efficacy	NOUN
dpc-4838	104	41	endpoint	endpoint	NOUN
dpc-4838	104	42	.	.	PUNCT
dpc-4838	105	1	these	these	DET
dpc-4838	105	2	results	result	NOUN
dpc-4838	105	3	are	be	AUX
dpc-4838	105	4	consistent	consistent	ADJ
dpc-4838	105	5	with	with	ADP
dpc-4838	105	6	those	those	PRON
dpc-4838	105	7	reported	report	VERB
dpc-4838	105	8	in	in	ADP
dpc-4838	105	9	the	the	DET
dpc-4838	105	10	immerge	immerge	ADJ
dpc-4838	105	11	study	study	NOUN
dpc-4838	105	12	,	,	PUNCT
dpc-4838	105	13	where	where	SCONJ
dpc-4838	105	14	a	a	DET
dpc-4838	105	15	head	head	NOUN
dpc-4838	105	16	-	-	PUNCT
dpc-4838	105	17	to	to	ADP
dpc-4838	105	18	-	-	PUNCT
dpc-4838	105	19	head	head	NOUN
dpc-4838	105	20	comparison	comparison	NOUN
dpc-4838	105	21	between	between	ADP
dpc-4838	105	22	risankizumab	risankizumab	NOUN
dpc-4838	105	23	and	and	CCONJ
dpc-4838	105	24	secukinumab	secukinumab	NOUN
dpc-4838	105	25	showed	show	VERB
dpc-4838	105	26	superiority	superiority	NOUN
dpc-4838	105	27	in	in	ADP
dpc-4838	105	28	the	the	DET
dpc-4838	105	29	short	short	ADJ
dpc-4838	105	30	and	and	CCONJ
dpc-4838	105	31	long	long	ADJ
dpc-4838	105	32	term	term	NOUN
dpc-4838	105	33	for	for	ADP
dpc-4838	105	34	the	the	DET
dpc-4838	105	35	il23	il23	PROPN
dpc-4838	105	36	inhibitor	inhibitor	NOUN
dpc-4838	105	37	,	,	PUNCT
dpc-4838	105	38	with	with	ADP
dpc-4838	105	39	similar	similar	ADJ
dpc-4838	105	40	safety	safety	NOUN
dpc-4838	105	41	profiles	profile	NOUN
dpc-4838	105	42	.	.	PUNCT
dpc-4838	106	1	notably	notably	ADV
dpc-4838	106	2	,	,	PUNCT
dpc-4838	106	3	in	in	ADP
dpc-4838	106	4	a	a	DET
dpc-4838	106	5	subsequent	subsequent	ADJ
dpc-4838	106	6	subgroup	subgroup	NOUN
dpc-4838	106	7	analysis	analysis	NOUN
dpc-4838	106	8	of	of	ADP
dpc-4838	106	9	the	the	DET
dpc-4838	106	10	population	population	NOUN
dpc-4838	106	11	enrolled	enrol	VERB
dpc-4838	106	12	in	in	ADP
dpc-4838	106	13	the	the	DET
dpc-4838	106	14	immerge	immerge	NOUN
dpc-4838	106	15	trial	trial	NOUN
dpc-4838	106	16	,	,	PUNCT
dpc-4838	106	17	risankizumab	risankizumab	PROPN
dpc-4838	106	18	demonstrated	demonstrate	VERB
dpc-4838	106	19	superior	superior	ADJ
dpc-4838	106	20	efficacy	efficacy	NOUN
dpc-4838	106	21	rates	rate	NOUN
dpc-4838	106	22	over	over	ADP
dpc-4838	106	23	6	6	NUM
dpc-4838	106	24	original	original	ADJ
dpc-4838	106	25	article	article	NOUN
dpc-4838	106	26	|	|	ADV
dpc-4838	106	27	dermatol	dermatol	ADJ
dpc-4838	106	28	pract	pract	NOUN
dpc-4838	106	29	concept	concept	NOUN
dpc-4838	106	30	.	.	PUNCT
dpc-4838	107	1	2025;15(1):4838	2025;15(1):4838	NUM
dpc-4838	107	2	clinical	clinical	ADJ
dpc-4838	107	3	trials	trial	NOUN
dpc-4838	107	4	(	(	PUNCT
dpc-4838	107	5	rcts	rct	NOUN
dpc-4838	107	6	)	)	PUNCT
dpc-4838	107	7	may	may	AUX
dpc-4838	107	8	not	not	PART
dpc-4838	107	9	be	be	AUX
dpc-4838	107	10	fully	fully	ADV
dpc-4838	107	11	representative	representative	ADJ
dpc-4838	107	12	of	of	ADP
dpc-4838	107	13	daily	daily	ADJ
dpc-4838	107	14	clinical	clinical	ADJ
dpc-4838	107	15	practice	practice	NOUN
dpc-4838	107	16	,	,	PUNCT
dpc-4838	107	17	in	in	ADP
dpc-4838	107	18	which	which	PRON
dpc-4838	107	19	a	a	DET
dpc-4838	107	20	greater	great	ADJ
dpc-4838	107	21	variability	variability	NOUN
dpc-4838	107	22	in	in	ADP
dpc-4838	107	23	the	the	DET
dpc-4838	107	24	demographic	demographic	ADJ
dpc-4838	107	25	and	and	CCONJ
dpc-4838	107	26	clinical	clinical	ADJ
dpc-4838	107	27	characteristics	characteristic	NOUN
dpc-4838	107	28	of	of	ADP
dpc-4838	107	29	treated	treat	VERB
dpc-4838	107	30	patients	patient	NOUN
dpc-4838	107	31	can	can	AUX
dpc-4838	107	32	be	be	AUX
dpc-4838	107	33	observed	observe	VERB
dpc-4838	107	34	.	.	PUNCT
dpc-4838	108	1	our	our	PRON
dpc-4838	108	2	results	result	NOUN
dpc-4838	108	3	are	be	AUX
dpc-4838	108	4	also	also	ADV
dpc-4838	108	5	in	in	ADP
dpc-4838	108	6	line	line	NOUN
dpc-4838	108	7	with	with	ADP
dpc-4838	108	8	a	a	DET
dpc-4838	108	9	recent	recent	ADJ
dpc-4838	108	10	japanese	japanese	ADJ
dpc-4838	108	11	study	study	NOUN
dpc-4838	108	12	in	in	ADP
dpc-4838	108	13	which	which	PRON
dpc-4838	108	14	the	the	DET
dpc-4838	108	15	authors	author	NOUN
dpc-4838	108	16	compared	compare	VERB
dpc-4838	108	17	the	the	DET
dpc-4838	108	18	cost	cost	NOUN
dpc-4838	108	19	-	-	PUNCT
dpc-4838	108	20	effectiveness	effectiveness	NOUN
dpc-4838	108	21	of	of	ADP
dpc-4838	108	22	risankizumab	risankizumab	NOUN
dpc-4838	108	23	with	with	ADP
dpc-4838	108	24	other	other	ADJ
dpc-4838	108	25	biologic	biologic	NOUN
dpc-4838	108	26	agents	agent	NOUN
dpc-4838	108	27	(	(	PUNCT
dpc-4838	108	28	adalimumab	adalimumab	PROPN
dpc-4838	108	29	,	,	PUNCT
dpc-4838	108	30	infliximab	infliximab	NOUN
dpc-4838	108	31	,	,	PUNCT
dpc-4838	108	32	ustekinumab	ustekinumab	NOUN
dpc-4838	108	33	,	,	PUNCT
dpc-4838	108	34	secukinumab	secukinumab	NOUN
dpc-4838	108	35	,	,	PUNCT
dpc-4838	108	36	brodalumab	brodalumab	NOUN
dpc-4838	108	37	,	,	PUNCT
dpc-4838	108	38	ixekizumab	ixekizumab	NOUN
dpc-4838	108	39	,	,	PUNCT
dpc-4838	108	40	and	and	CCONJ
dpc-4838	108	41	guselkumab	guselkumab	NOUN
dpc-4838	108	42	)	)	PUNCT
dpc-4838	108	43	.	.	PUNCT
dpc-4838	109	1	in	in	ADP
dpc-4838	109	2	this	this	DET
dpc-4838	109	3	context	context	NOUN
dpc-4838	109	4	,	,	PUNCT
dpc-4838	109	5	risankizumab	risankizumab	PROPN
dpc-4838	109	6	showed	show	VERB
dpc-4838	109	7	a	a	DET
dpc-4838	109	8	significantly	significantly	ADV
dpc-4838	109	9	more	more	ADV
dpc-4838	109	10	favorable	favorable	ADJ
dpc-4838	109	11	pharmaco	pharmaco	NOUN
dpc-4838	109	12	-	-	PUNCT
dpc-4838	109	13	economic	economic	ADJ
dpc-4838	109	14	profile	profile	NOUN
dpc-4838	109	15	than	than	ADP
dpc-4838	109	16	the	the	DET
dpc-4838	109	17	comparators	comparator	NOUN
dpc-4838	109	18	[	[	X
dpc-4838	109	19	32	32	NUM
dpc-4838	109	20	]	]	PUNCT
dpc-4838	109	21	.	.	PUNCT
dpc-4838	110	1	however	however	ADV
dpc-4838	110	2	,	,	PUNCT
dpc-4838	110	3	even	even	ADV
dpc-4838	110	4	in	in	ADP
dpc-4838	110	5	this	this	DET
dpc-4838	110	6	case	case	NOUN
dpc-4838	110	7	,	,	PUNCT
dpc-4838	110	8	much	much	ADJ
dpc-4838	110	9	of	of	ADP
dpc-4838	110	10	the	the	DET
dpc-4838	110	11	efficacy	efficacy	NOUN
dpc-4838	110	12	data	datum	NOUN
dpc-4838	110	13	on	on	ADP
dpc-4838	110	14	which	which	PRON
dpc-4838	110	15	the	the	DET
dpc-4838	110	16	cost	cost	NOUN
dpc-4838	110	17	-	-	PUNCT
dpc-4838	110	18	effectiveness	effectiveness	NOUN
dpc-4838	110	19	estimates	estimate	NOUN
dpc-4838	110	20	were	be	AUX
dpc-4838	110	21	based	base	VERB
dpc-4838	110	22	were	be	AUX
dpc-4838	110	23	obtained	obtain	VERB
dpc-4838	110	24	from	from	ADP
dpc-4838	110	25	registry	registry	NOUN
dpc-4838	110	26	studies	study	NOUN
dpc-4838	110	27	,	,	PUNCT
dpc-4838	110	28	while	while	SCONJ
dpc-4838	110	29	our	our	PRON
dpc-4838	110	30	study	study	NOUN
dpc-4838	110	31	was	be	AUX
dpc-4838	110	32	able	able	ADJ
dpc-4838	110	33	to	to	PART
dpc-4838	110	34	confirm	confirm	VERB
dpc-4838	110	35	these	these	DET
dpc-4838	110	36	findings	finding	NOUN
dpc-4838	110	37	in	in	ADP
dpc-4838	110	38	a	a	DET
dpc-4838	110	39	real	real	ADJ
dpc-4838	110	40	-	-	PUNCT
dpc-4838	110	41	life	life	NOUN
dpc-4838	110	42	setting	setting	NOUN
dpc-4838	110	43	.	.	PUNCT
dpc-4838	111	1	the	the	DET
dpc-4838	111	2	difference	difference	NOUN
dpc-4838	111	3	in	in	ADP
dpc-4838	111	4	purchase	purchase	NOUN
dpc-4838	111	5	price	price	NOUN
dpc-4838	111	6	per	per	ADP
dpc-4838	111	7	unit	unit	NOUN
dpc-4838	111	8	should	should	AUX
dpc-4838	111	9	also	also	ADV
dpc-4838	111	10	be	be	AUX
dpc-4838	111	11	considered	consider	VERB
dpc-4838	111	12	in	in	ADP
dpc-4838	111	13	the	the	DET
dpc-4838	111	14	comparison	comparison	NOUN
dpc-4838	111	15	of	of	ADP
dpc-4838	111	16	the	the	DET
dpc-4838	111	17	two	two	NUM
dpc-4838	111	18	drugs	drug	NOUN
dpc-4838	111	19	.	.	PUNCT
dpc-4838	112	1	secukinumab	secukinumab	NOUN
dpc-4838	112	2	,	,	PUNCT
dpc-4838	112	3	being	be	AUX
dpc-4838	112	4	on	on	ADP
dpc-4838	112	5	the	the	DET
dpc-4838	112	6	market	market	NOUN
dpc-4838	112	7	since	since	SCONJ
dpc-4838	112	8	its	its	PRON
dpc-4838	112	9	approval	approval	NOUN
dpc-4838	112	10	in	in	ADP
dpc-4838	112	11	2015	2015	NUM
dpc-4838	112	12	,	,	PUNCT
dpc-4838	112	13	to	to	ADP
dpc-4838	112	14	date	date	NOUN
dpc-4838	112	15	has	have	VERB
dpc-4838	112	16	a	a	DET
dpc-4838	112	17	lower	low	ADJ
dpc-4838	112	18	cost	cost	NOUN
dpc-4838	112	19	per	per	ADP
dpc-4838	112	20	single	single	ADJ
dpc-4838	112	21	150	150	NUM
dpc-4838	112	22	mg	mg	NOUN
dpc-4838	112	23	pen	pen	NOUN
dpc-4838	112	24	than	than	ADP
dpc-4838	112	25	a	a	DET
dpc-4838	112	26	75	75	NUM
dpc-4838	112	27	mg	mg	PROPN
dpc-4838	112	28	pen	pen	NOUN
dpc-4838	112	29	of	of	ADP
dpc-4838	112	30	risankizumab	risankizumab	NOUN
dpc-4838	112	31	(	(	PUNCT
dpc-4838	112	32	€	€	SYM
dpc-4838	112	33	400.99	400.99	NUM
dpc-4838	112	34	versus	versus	ADP
dpc-4838	112	35	€	€	SYM
dpc-4838	112	36	1162.79	1162.79	NUM
dpc-4838	112	37	,	,	PUNCT
dpc-4838	112	38	respectively	respectively	ADV
dpc-4838	112	39	)	)	PUNCT
dpc-4838	112	40	in	in	ADP
dpc-4838	112	41	the	the	DET
dpc-4838	112	42	italian	italian	ADJ
dpc-4838	112	43	healthcare	healthcare	NOUN
dpc-4838	112	44	system	system	NOUN
dpc-4838	112	45	.	.	PUNCT
dpc-4838	113	1	however	however	ADV
dpc-4838	113	2	,	,	PUNCT
dpc-4838	113	3	risankizumab	risankizumab	NOUN
dpc-4838	113	4	and	and	CCONJ
dpc-4838	113	5	secukinumab	secukinumab	NOUN
dpc-4838	113	6	differ	differ	VERB
dpc-4838	113	7	significantly	significantly	ADV
dpc-4838	113	8	in	in	ADP
dpc-4838	113	9	their	their	PRON
dpc-4838	113	10	respective	respective	ADJ
dpc-4838	113	11	dosing	dosing	ADJ
dpc-4838	113	12	regimens	regimen	NOUN
dpc-4838	113	13	.	.	PUNCT
dpc-4838	114	1	risankizumab	risankizumab	PROPN
dpc-4838	114	2	has	have	VERB
dpc-4838	114	3	a	a	DET
dpc-4838	114	4	significantly	significantly	ADV
dpc-4838	114	5	lower	low	ADJ
dpc-4838	114	6	total	total	ADJ
dpc-4838	114	7	number	number	NOUN
dpc-4838	114	8	of	of	ADP
dpc-4838	114	9	annual	annual	ADJ
dpc-4838	114	10	administrations	administration	NOUN
dpc-4838	114	11	than	than	ADP
dpc-4838	114	12	the	the	DET
dpc-4838	114	13	il17	il17	PROPN
dpc-4838	114	14	inhibitors	inhibitor	NOUN
dpc-4838	114	15	,	,	PUNCT
dpc-4838	114	16	similar	similar	ADJ
dpc-4838	114	17	to	to	ADP
dpc-4838	114	18	the	the	DET
dpc-4838	114	19	other	other	ADJ
dpc-4838	114	20	il23	il23	PROPN
dpc-4838	114	21	inhibitors	inhibitor	NOUN
dpc-4838	114	22	[	[	X
dpc-4838	114	23	33	33	NUM
dpc-4838	114	24	]	]	PUNCT
dpc-4838	114	25	.	.	PUNCT
dpc-4838	115	1	this	this	PRON
dpc-4838	115	2	certainly	certainly	ADV
dpc-4838	115	3	represents	represent	VERB
dpc-4838	115	4	a	a	DET
dpc-4838	115	5	pharmaco	pharmaco	NOUN
dpc-4838	115	6	-	-	PUNCT
dpc-4838	115	7	economic	economic	ADJ
dpc-4838	115	8	advantage	advantage	NOUN
dpc-4838	115	9	,	,	PUNCT
dpc-4838	115	10	as	as	SCONJ
dpc-4838	115	11	it	it	PRON
dpc-4838	115	12	allows	allow	VERB
dpc-4838	115	13	for	for	ADP
dpc-4838	115	14	a	a	DET
dpc-4838	115	15	lower	low	ADJ
dpc-4838	115	16	net	net	ADJ
dpc-4838	115	17	annual	annual	ADJ
dpc-4838	115	18	cost	cost	NOUN
dpc-4838	115	19	of	of	ADP
dpc-4838	115	20	therapy	therapy	NOUN
dpc-4838	115	21	and	and	CCONJ
dpc-4838	115	22	should	should	AUX
dpc-4838	115	23	be	be	AUX
dpc-4838	115	24	taken	take	VERB
dpc-4838	115	25	into	into	ADP
dpc-4838	115	26	consideration	consideration	NOUN
dpc-4838	115	27	when	when	SCONJ
dpc-4838	115	28	making	make	VERB
dpc-4838	115	29	therapeutic	therapeutic	ADJ
dpc-4838	115	30	decisions	decision	NOUN
dpc-4838	115	31	.	.	PUNCT
dpc-4838	116	1	indeed	indeed	ADV
dpc-4838	116	2	,	,	PUNCT
dpc-4838	116	3	in	in	ADP
dpc-4838	116	4	several	several	ADJ
dpc-4838	116	5	countries	country	NOUN
dpc-4838	116	6	,	,	PUNCT
dpc-4838	116	7	especially	especially	ADV
dpc-4838	116	8	after	after	ADP
dpc-4838	116	9	the	the	DET
dpc-4838	116	10	recent	recent	ADJ
dpc-4838	116	11	introduction	introduction	NOUN
dpc-4838	116	12	of	of	ADP
dpc-4838	116	13	their	their	PRON
dpc-4838	116	14	biosimilars	biosimilar	NOUN
dpc-4838	116	15	,	,	PUNCT
dpc-4838	116	16	anti	anti	ADJ
dpc-4838	116	17	-	-	ADJ
dpc-4838	116	18	tnf	tnf	ADJ
dpc-4838	116	19	drugs	drug	NOUN
dpc-4838	116	20	are	be	AUX
dpc-4838	116	21	often	often	ADV
dpc-4838	116	22	recommended	recommend	VERB
dpc-4838	116	23	as	as	ADP
dpc-4838	116	24	firstline	firstline	ADJ
dpc-4838	116	25	treatment	treatment	NOUN
dpc-4838	116	26	in	in	ADP
dpc-4838	116	27	patients	patient	NOUN
dpc-4838	116	28	with	with	ADP
dpc-4838	116	29	moderate	moderate	ADJ
dpc-4838	116	30	-	-	PUNCT
dpc-4838	116	31	to	to	ADP
dpc-4838	116	32	-	-	PUNCT
dpc-4838	116	33	severe	severe	ADJ
dpc-4838	116	34	psoriasis	psoriasis	NOUN
dpc-4838	116	35	for	for	ADP
dpc-4838	116	36	economic	economic	ADJ
dpc-4838	116	37	reasons	reason	NOUN
dpc-4838	116	38	(	(	PUNCT
dpc-4838	116	39	eg	eg	NOUN
dpc-4838	116	40	significantly	significantly	ADV
dpc-4838	116	41	lower	low	ADJ
dpc-4838	116	42	acquisition	acquisition	NOUN
dpc-4838	116	43	secukinumab	secukinumab	NOUN
dpc-4838	116	44	in	in	ADP
dpc-4838	116	45	different	different	ADJ
dpc-4838	116	46	categories	category	NOUN
dpc-4838	116	47	of	of	ADP
dpc-4838	116	48	patients	patient	NOUN
dpc-4838	116	49	,	,	PUNCT
dpc-4838	116	50	unaffected	unaffected	ADJ
dpc-4838	116	51	by	by	ADP
dpc-4838	116	52	variables	variable	NOUN
dpc-4838	116	53	such	such	ADJ
dpc-4838	116	54	as	as	ADP
dpc-4838	116	55	bmi	bmi	NOUN
dpc-4838	116	56	,	,	PUNCT
dpc-4838	116	57	prior	prior	ADJ
dpc-4838	116	58	therapies	therapy	NOUN
dpc-4838	116	59	or	or	CCONJ
dpc-4838	116	60	disease	disease	NOUN
dpc-4838	116	61	activity	activity	NOUN
dpc-4838	116	62	at	at	ADP
dpc-4838	116	63	baseline	baseline	NOUN
dpc-4838	116	64	[	[	X
dpc-4838	116	65	28	28	NUM
dpc-4838	116	66	]	]	PUNCT
dpc-4838	116	67	.	.	PUNCT
dpc-4838	117	1	although	although	SCONJ
dpc-4838	117	2	a	a	DET
dpc-4838	117	3	univariate	univariate	ADJ
dpc-4838	117	4	analysis	analysis	NOUN
dpc-4838	117	5	to	to	PART
dpc-4838	117	6	determine	determine	VERB
dpc-4838	117	7	the	the	DET
dpc-4838	117	8	influence	influence	NOUN
dpc-4838	117	9	,	,	PUNCT
dpc-4838	117	10	if	if	SCONJ
dpc-4838	117	11	any	any	PRON
dpc-4838	117	12	,	,	PUNCT
dpc-4838	117	13	of	of	ADP
dpc-4838	117	14	patient	patient	NOUN
dpc-4838	117	15	or	or	CCONJ
dpc-4838	117	16	disease	disease	NOUN
dpc-4838	117	17	-	-	PUNCT
dpc-4838	117	18	related	relate	VERB
dpc-4838	117	19	variables	variable	NOUN
dpc-4838	117	20	on	on	ADP
dpc-4838	117	21	the	the	DET
dpc-4838	117	22	clinical	clinical	ADJ
dpc-4838	117	23	efficacy	efficacy	NOUN
dpc-4838	117	24	of	of	ADP
dpc-4838	117	25	the	the	DET
dpc-4838	117	26	two	two	NUM
dpc-4838	117	27	drugs	drug	NOUN
dpc-4838	117	28	was	be	AUX
dpc-4838	117	29	not	not	PART
dpc-4838	117	30	performed	perform	VERB
dpc-4838	117	31	in	in	ADP
dpc-4838	117	32	our	our	PRON
dpc-4838	117	33	study	study	NOUN
dpc-4838	117	34	,	,	PUNCT
dpc-4838	117	35	it	it	PRON
dpc-4838	117	36	should	should	AUX
dpc-4838	117	37	be	be	AUX
dpc-4838	117	38	noted	note	VERB
dpc-4838	117	39	that	that	SCONJ
dpc-4838	117	40	the	the	DET
dpc-4838	117	41	risankizumab	risankizumab	NOUN
dpc-4838	117	42	-	-	PUNCT
dpc-4838	117	43	treated	treat	VERB
dpc-4838	117	44	population	population	NOUN
dpc-4838	117	45	had	have	VERB
dpc-4838	117	46	a	a	DET
dpc-4838	117	47	significantly	significantly	ADV
dpc-4838	117	48	higher	high	ADJ
dpc-4838	117	49	percentage	percentage	NOUN
dpc-4838	117	50	of	of	ADP
dpc-4838	117	51	patients	patient	NOUN
dpc-4838	117	52	previously	previously	ADV
dpc-4838	117	53	treated	treat	VERB
dpc-4838	117	54	with	with	ADP
dpc-4838	117	55	biologic	biologic	ADJ
dpc-4838	117	56	agents	agent	NOUN
dpc-4838	117	57	than	than	SCONJ
dpc-4838	117	58	the	the	DET
dpc-4838	117	59	secukinumab	secukinumab	NOUN
dpc-4838	117	60	treated	treat	VERB
dpc-4838	117	61	population	population	NOUN
dpc-4838	117	62	(	(	PUNCT
dpc-4838	117	63	77.0	77.0	NUM
dpc-4838	117	64	%	%	NOUN
dpc-4838	117	65	versus	versus	ADP
dpc-4838	117	66	41.8	41.8	NUM
dpc-4838	117	67	%	%	NOUN
dpc-4838	117	68	,	,	PUNCT
dpc-4838	117	69	respectively	respectively	ADV
dpc-4838	117	70	)	)	PUNCT
dpc-4838	117	71	,	,	PUNCT
dpc-4838	117	72	which	which	PRON
dpc-4838	117	73	could	could	AUX
dpc-4838	117	74	represent	represent	VERB
dpc-4838	117	75	a	a	DET
dpc-4838	117	76	potential	potential	ADJ
dpc-4838	117	77	negative	negative	ADJ
dpc-4838	117	78	predictive	predictive	ADJ
dpc-4838	117	79	factor	factor	NOUN
dpc-4838	117	80	of	of	ADP
dpc-4838	117	81	the	the	DET
dpc-4838	117	82	efficacy	efficacy	NOUN
dpc-4838	117	83	of	of	ADP
dpc-4838	117	84	a	a	DET
dpc-4838	117	85	biological	biological	ADJ
dpc-4838	117	86	drug	drug	NOUN
dpc-4838	117	87	[	[	X
dpc-4838	117	88	29,30	29,30	NUM
dpc-4838	117	89	]	]	PUNCT
dpc-4838	117	90	.	.	PUNCT
dpc-4838	118	1	despite	despite	SCONJ
dpc-4838	118	2	this	this	DET
dpc-4838	118	3	difference	difference	NOUN
dpc-4838	118	4	,	,	PUNCT
dpc-4838	118	5	risankizumab	risankizumab	NOUN
dpc-4838	118	6	offered	offer	VERB
dpc-4838	118	7	higher	high	ADJ
dpc-4838	118	8	pasi90	pasi90	NOUN
dpc-4838	118	9	and	and	CCONJ
dpc-4838	118	10	pasi100	pasi100	PROPN
dpc-4838	118	11	rates	rate	NOUN
dpc-4838	118	12	than	than	ADP
dpc-4838	118	13	secukinumab	secukinumab	NOUN
dpc-4838	118	14	,	,	PUNCT
dpc-4838	118	15	in	in	ADP
dpc-4838	118	16	line	line	NOUN
dpc-4838	118	17	with	with	ADP
dpc-4838	118	18	the	the	DET
dpc-4838	118	19	literature	literature	NOUN
dpc-4838	118	20	data	datum	NOUN
dpc-4838	118	21	highlighting	highlight	VERB
dpc-4838	118	22	the	the	DET
dpc-4838	118	23	low	low	ADJ
dpc-4838	118	24	incidence	incidence	NOUN
dpc-4838	118	25	of	of	ADP
dpc-4838	118	26	extraneous	extraneous	ADJ
dpc-4838	118	27	variables	variable	NOUN
dpc-4838	118	28	on	on	ADP
dpc-4838	118	29	its	its	PRON
dpc-4838	118	30	efficacy	efficacy	NOUN
dpc-4838	118	31	[	[	X
dpc-4838	118	32	22,31	22,31	NOUN
dpc-4838	118	33	]	]	X
dpc-4838	118	34	.	.	PUNCT
dpc-4838	119	1	moreover	moreover	ADV
dpc-4838	119	2	,	,	PUNCT
dpc-4838	119	3	in	in	ADP
dpc-4838	119	4	our	our	PRON
dpc-4838	119	5	study	study	NOUN
dpc-4838	119	6	,	,	PUNCT
dpc-4838	119	7	risankizumab	risankizumab	PROPN
dpc-4838	119	8	demonstrated	demonstrate	VERB
dpc-4838	119	9	a	a	DET
dpc-4838	119	10	faster	fast	ADJ
dpc-4838	119	11	onset	onset	NOUN
dpc-4838	119	12	of	of	ADP
dpc-4838	119	13	action	action	NOUN
dpc-4838	119	14	than	than	ADP
dpc-4838	119	15	secukinumab	secukinumab	NOUN
dpc-4838	119	16	and	and	CCONJ
dpc-4838	119	17	was	be	AUX
dpc-4838	119	18	superior	superior	ADJ
dpc-4838	119	19	in	in	ADP
dpc-4838	119	20	terms	term	NOUN
dpc-4838	119	21	of	of	ADP
dpc-4838	119	22	efficacy	efficacy	NOUN
dpc-4838	119	23	after	after	ADP
dpc-4838	119	24	only	only	ADV
dpc-4838	119	25	16	16	NUM
dpc-4838	119	26	weeks	week	NOUN
dpc-4838	119	27	of	of	ADP
dpc-4838	119	28	treatment	treatment	NOUN
dpc-4838	119	29	,	,	PUNCT
dpc-4838	119	30	confirming	confirm	VERB
dpc-4838	119	31	that	that	SCONJ
dpc-4838	119	32	anti	anti	ADJ
dpc-4838	119	33	-	-	ADJ
dpc-4838	119	34	il23	il23	ADJ
dpc-4838	119	35	inhibitors	inhibitor	NOUN
dpc-4838	119	36	may	may	AUX
dpc-4838	119	37	be	be	AUX
dpc-4838	119	38	equal	equal	ADJ
dpc-4838	119	39	to	to	ADP
dpc-4838	119	40	or	or	CCONJ
dpc-4838	119	41	superior	superior	ADJ
dpc-4838	119	42	to	to	ADP
dpc-4838	119	43	anti	anti	ADJ
dpc-4838	119	44	-	-	ADJ
dpc-4838	119	45	il17	il17	ADJ
dpc-4838	119	46	inhibitors	inhibitor	NOUN
dpc-4838	119	47	in	in	ADP
dpc-4838	119	48	terms	term	NOUN
dpc-4838	119	49	of	of	ADP
dpc-4838	119	50	rapidity	rapidity	NOUN
dpc-4838	119	51	in	in	ADP
dpc-4838	119	52	inducing	induce	VERB
dpc-4838	119	53	a	a	DET
dpc-4838	119	54	clinical	clinical	ADJ
dpc-4838	119	55	response	response	NOUN
dpc-4838	119	56	[	[	X
dpc-4838	119	57	15	15	NUM
dpc-4838	119	58	]	]	PUNCT
dpc-4838	119	59	.	.	PUNCT
dpc-4838	120	1	from	from	ADP
dpc-4838	120	2	a	a	DET
dpc-4838	120	3	pharmaco	pharmaco	NOUN
dpc-4838	120	4	-	-	PUNCT
dpc-4838	120	5	economic	economic	ADJ
dpc-4838	120	6	perspective	perspective	NOUN
dpc-4838	120	7	,	,	PUNCT
dpc-4838	120	8	risankizumab	risankizumab	PROPN
dpc-4838	120	9	had	have	VERB
dpc-4838	120	10	a	a	DET
dpc-4838	120	11	more	more	ADV
dpc-4838	120	12	favorable	favorable	ADJ
dpc-4838	120	13	cost	cost	NOUN
dpc-4838	120	14	-	-	PUNCT
dpc-4838	120	15	effectiveness	effectiveness	NOUN
dpc-4838	120	16	ratio	ratio	NOUN
dpc-4838	120	17	than	than	ADP
dpc-4838	120	18	secukinumab	secukinumab	NOUN
dpc-4838	120	19	in	in	ADP
dpc-4838	120	20	our	our	PRON
dpc-4838	120	21	cost	cost	NOUN
dpc-4838	120	22	-	-	PUNCT
dpc-4838	120	23	per	per	ADP
dpc-4838	120	24	-	-	PUNCT
dpc-4838	120	25	responder	responder	NOUN
dpc-4838	120	26	analysis	analysis	NOUN
dpc-4838	120	27	based	base	VERB
dpc-4838	120	28	on	on	ADP
dpc-4838	120	29	the	the	DET
dpc-4838	120	30	clinical	clinical	ADJ
dpc-4838	120	31	efficacy	efficacy	NOUN
dpc-4838	120	32	data	datum	NOUN
dpc-4838	120	33	just	just	ADV
dpc-4838	120	34	reported	report	VERB
dpc-4838	120	35	.	.	PUNCT
dpc-4838	121	1	this	this	PRON
dpc-4838	121	2	is	be	AUX
dpc-4838	121	3	consistent	consistent	ADJ
dpc-4838	121	4	with	with	ADP
dpc-4838	121	5	the	the	DET
dpc-4838	121	6	results	result	NOUN
dpc-4838	121	7	reported	report	VERB
dpc-4838	121	8	by	by	ADP
dpc-4838	121	9	gisondi	gisondi	NOUN
dpc-4838	121	10	et	et	NOUN
dpc-4838	121	11	al	al	PROPN
dpc-4838	122	1	[	[	X
dpc-4838	122	2	18	18	NUM
dpc-4838	122	3	]	]	PUNCT
dpc-4838	122	4	in	in	ADP
dpc-4838	122	5	which	which	PRON
dpc-4838	122	6	risankizumab	risankizumab	NOUN
dpc-4838	122	7	showed	show	VERB
dpc-4838	122	8	better	well	ADV
dpc-4838	122	9	clinical	clinical	ADJ
dpc-4838	122	10	and	and	CCONJ
dpc-4838	122	11	cost	cost	NOUN
dpc-4838	122	12	-	-	PUNCT
dpc-4838	122	13	effectiveness	effectiveness	NOUN
dpc-4838	122	14	performances	performance	NOUN
dpc-4838	122	15	than	than	ADP
dpc-4838	122	16	secukinumab	secukinumab	NOUN
dpc-4838	122	17	over	over	ADP
dpc-4838	122	18	an	an	DET
dpc-4838	122	19	observation	observation	NOUN
dpc-4838	122	20	period	period	NOUN
dpc-4838	122	21	of	of	ADP
dpc-4838	122	22	up	up	ADP
dpc-4838	122	23	to	to	PART
dpc-4838	122	24	2	2	NUM
dpc-4838	122	25	years	year	NOUN
dpc-4838	122	26	of	of	ADP
dpc-4838	122	27	treatment	treatment	NOUN
dpc-4838	122	28	.	.	PUNCT
dpc-4838	123	1	it	it	PRON
dpc-4838	123	2	should	should	AUX
dpc-4838	123	3	be	be	AUX
dpc-4838	123	4	noted	note	VERB
dpc-4838	123	5	,	,	PUNCT
dpc-4838	123	6	however	however	ADV
dpc-4838	123	7	,	,	PUNCT
dpc-4838	123	8	that	that	SCONJ
dpc-4838	123	9	this	this	DET
dpc-4838	123	10	analysis	analysis	NOUN
dpc-4838	123	11	was	be	AUX
dpc-4838	123	12	based	base	VERB
dpc-4838	123	13	on	on	ADP
dpc-4838	123	14	clinical	clinical	ADJ
dpc-4838	123	15	data	datum	NOUN
dpc-4838	123	16	derived	derive	VERB
dpc-4838	123	17	from	from	ADP
dpc-4838	123	18	the	the	DET
dpc-4838	123	19	population	population	NOUN
dpc-4838	123	20	enrolled	enrol	VERB
dpc-4838	123	21	in	in	ADP
dpc-4838	123	22	the	the	DET
dpc-4838	123	23	immerge	immerge	ADJ
dpc-4838	123	24	trial	trial	NOUN
dpc-4838	123	25	.	.	PUNCT
dpc-4838	124	1	population	population	NOUN
dpc-4838	124	2	of	of	ADP
dpc-4838	124	3	randomized	randomized	ADJ
dpc-4838	124	4	figure	figure	NOUN
dpc-4838	124	5	2	2	NUM
dpc-4838	124	6	.	.	PUNCT
dpc-4838	124	7	cost	cost	NOUN
dpc-4838	124	8	per	per	ADP
dpc-4838	124	9	psoriasis	psoriasis	NOUN
dpc-4838	124	10	area	area	NOUN
dpc-4838	124	11	and	and	CCONJ
dpc-4838	124	12	severity	severity	NOUN
dpc-4838	124	13	index	index	NOUN
dpc-4838	124	14	(	(	PUNCT
dpc-4838	124	15	pasi)90	pasi)90	PROPN
dpc-4838	124	16	and	and	CCONJ
dpc-4838	124	17	pasi100	pasi100	PROPN
dpc-4838	124	18	responder	responder	NOUN
dpc-4838	124	19	patient	patient	ADJ
dpc-4838	124	20	at	at	ADP
dpc-4838	124	21	weeks	week	NOUN
dpc-4838	124	22	16	16	NUM
dpc-4838	124	23	and	and	CCONJ
dpc-4838	124	24	52	52	NUM
dpc-4838	124	25	.	.	PUNCT
dpc-4838	125	1	original	original	ADJ
dpc-4838	125	2	article	article	NOUN
dpc-4838	125	3	|	|	ADV
dpc-4838	125	4	dermatol	dermatol	ADJ
dpc-4838	125	5	pract	pract	NOUN
dpc-4838	125	6	concept	concept	NOUN
dpc-4838	125	7	.	.	PUNCT
dpc-4838	126	1	2025;15(1):4838	2025;15(1):4838	NUM
dpc-4838	126	2	7	7	NUM
dpc-4838	126	3	2	2	NUM
dpc-4838	126	4	.	.	PUNCT
dpc-4838	126	5	gianfredi	gianfredi	PROPN
dpc-4838	126	6	v	v	PROPN
dpc-4838	126	7	,	,	PUNCT
dpc-4838	126	8	casu	casu	PROPN
dpc-4838	126	9	g	g	PROPN
dpc-4838	126	10	,	,	PUNCT
dpc-4838	126	11	bricchi	bricchi	PROPN
dpc-4838	126	12	l	l	NOUN
dpc-4838	126	13	,	,	PUNCT
dpc-4838	126	14	kacerik	kacerik	ADJ
dpc-4838	126	15	e	e	NOUN
dpc-4838	126	16	,	,	PUNCT
dpc-4838	126	17	rongioletti	rongioletti	PROPN
dpc-4838	126	18	f	f	PROPN
dpc-4838	126	19	,	,	PUNCT
dpc-4838	126	20	signorelli	signorelli	PROPN
dpc-4838	126	21	c.	c.	PROPN
dpc-4838	126	22	epidemiology	epidemiology	NOUN
dpc-4838	126	23	of	of	ADP
dpc-4838	126	24	psoriasis	psoriasis	NOUN
dpc-4838	126	25	in	in	ADP
dpc-4838	126	26	italy	italy	PROPN
dpc-4838	126	27	:	:	PUNCT
dpc-4838	126	28	burden	burden	NOUN
dpc-4838	126	29	,	,	PUNCT
dpc-4838	126	30	cost	cost	NOUN
dpc-4838	126	31	,	,	PUNCT
dpc-4838	126	32	comorbidities	comorbiditie	NOUN
dpc-4838	126	33	and	and	CCONJ
dpc-4838	126	34	patients	patient	NOUN
dpc-4838	126	35	’	'	PUNCT
dpc-4838	126	36	satisfaction	satisfaction	NOUN
dpc-4838	126	37	.	.	PUNCT
dpc-4838	127	1	a	a	DET
dpc-4838	127	2	systematic	systematic	ADJ
dpc-4838	127	3	review	review	NOUN
dpc-4838	127	4	.	.	PUNCT
dpc-4838	128	1	acta	acta	PROPN
dpc-4838	128	2	biomed	biome	VERB
dpc-4838	128	3	.	.	PUNCT
dpc-4838	129	1	2022;93(6):e2022332	2022;93(6):e2022332	NUM
dpc-4838	129	2	3	3	NUM
dpc-4838	129	3	.	.	PUNCT
dpc-4838	129	4	parisi	parisi	PROPN
dpc-4838	129	5	r	r	PROPN
dpc-4838	129	6	,	,	PUNCT
dpc-4838	129	7	iskandar	iskandar	PROPN
dpc-4838	129	8	iyk	iyk	PROPN
dpc-4838	129	9	,	,	PUNCT
dpc-4838	129	10	kontopantelis	kontopantelis	PROPN
dpc-4838	129	11	e	e	PROPN
dpc-4838	129	12	,	,	PUNCT
dpc-4838	129	13	augustin	augustin	PROPN
dpc-4838	129	14	m	m	PROPN
dpc-4838	129	15	,	,	PUNCT
dpc-4838	129	16	griffiths	griffiths	PROPN
dpc-4838	129	17	cem	cem	PROPN
dpc-4838	129	18	,	,	PUNCT
dpc-4838	129	19	ashcroft	ashcroft	PROPN
dpc-4838	129	20	dm	dm	PROPN
dpc-4838	129	21	;	;	PUNCT
dpc-4838	129	22	global	global	ADJ
dpc-4838	129	23	psoriasis	psoriasis	NOUN
dpc-4838	129	24	atlas	atlas	PROPN
dpc-4838	129	25	.	.	PUNCT
dpc-4838	130	1	national	national	ADJ
dpc-4838	130	2	,	,	PUNCT
dpc-4838	130	3	regional	regional	ADJ
dpc-4838	130	4	,	,	PUNCT
dpc-4838	130	5	and	and	CCONJ
dpc-4838	130	6	worldwide	worldwide	ADJ
dpc-4838	130	7	epidemiology	epidemiology	NOUN
dpc-4838	130	8	of	of	ADP
dpc-4838	130	9	psoriasis	psoriasis	NOUN
dpc-4838	130	10	:	:	PUNCT
dpc-4838	130	11	systematic	systematic	ADJ
dpc-4838	130	12	analysis	analysis	NOUN
dpc-4838	130	13	and	and	CCONJ
dpc-4838	130	14	modelling	model	VERB
dpc-4838	130	15	study	study	NOUN
dpc-4838	130	16	.	.	PUNCT
dpc-4838	131	1	bmj	bmj	PROPN
dpc-4838	131	2	.	.	PUNCT
dpc-4838	132	1	2020	2020	NUM
dpc-4838	132	2	may	may	AUX
dpc-4838	132	3	28;369	28;369	NUM
dpc-4838	132	4	:	:	PUNCT
dpc-4838	132	5	m1590	m1590	VERB
dpc-4838	132	6	4	4	NUM
dpc-4838	132	7	.	.	PUNCT
dpc-4838	133	1	armstrong	armstrong	PROPN
dpc-4838	133	2	aw	aw	PROPN
dpc-4838	133	3	,	,	PUNCT
dpc-4838	133	4	read	read	VERB
dpc-4838	133	5	c.	c.	PROPN
dpc-4838	133	6	pathophysiology	pathophysiology	NOUN
dpc-4838	133	7	,	,	PUNCT
dpc-4838	133	8	clinical	clinical	ADJ
dpc-4838	133	9	presentation	presentation	NOUN
dpc-4838	133	10	,	,	PUNCT
dpc-4838	133	11	and	and	CCONJ
dpc-4838	133	12	treatment	treatment	NOUN
dpc-4838	133	13	of	of	ADP
dpc-4838	133	14	psoriasis	psoriasis	NOUN
dpc-4838	133	15	:	:	PUNCT
dpc-4838	133	16	a	a	DET
dpc-4838	133	17	review	review	NOUN
dpc-4838	133	18	.	.	PUNCT
dpc-4838	134	1	jama	jama	PROPN
dpc-4838	134	2	.	.	PUNCT
dpc-4838	135	1	2020;323(19	2020;323(19	PROPN
dpc-4838	135	2	):	):	PUNCT
dpc-4838	135	3	1945	1945	NUM
dpc-4838	135	4	-	-	SYM
dpc-4838	135	5	1960	1960	NUM
dpc-4838	135	6	5	5	NUM
dpc-4838	135	7	.	.	PUNCT
dpc-4838	136	1	alwan	alwan	PROPN
dpc-4838	136	2	w	w	PROPN
dpc-4838	136	3	,	,	PUNCT
dpc-4838	136	4	nestle	nestle	PROPN
dpc-4838	136	5	fo	fo	PROPN
dpc-4838	136	6	.	.	PUNCT
dpc-4838	137	1	pathogenesis	pathogenesis	NOUN
dpc-4838	137	2	and	and	CCONJ
dpc-4838	137	3	treatment	treatment	NOUN
dpc-4838	137	4	of	of	ADP
dpc-4838	137	5	psoriasis	psoriasis	NOUN
dpc-4838	137	6	:	:	PUNCT
dpc-4838	137	7	exploiting	exploit	VERB
dpc-4838	137	8	pathophysiological	pathophysiological	ADJ
dpc-4838	137	9	pathways	pathway	NOUN
dpc-4838	137	10	for	for	ADP
dpc-4838	137	11	precision	precision	NOUN
dpc-4838	137	12	medicine	medicine	NOUN
dpc-4838	137	13	.	.	PUNCT
dpc-4838	138	1	clin	clin	PROPN
dpc-4838	138	2	exp	exp	NOUN
dpc-4838	138	3	rheumatol	rheumatol	NOUN
dpc-4838	138	4	.	.	PUNCT
dpc-4838	139	1	2015;33(5	2015;33(5	NUM
dpc-4838	139	2	suppl	suppl	ADJ
dpc-4838	139	3	93):s2	93):s2	NUM
dpc-4838	139	4	-	-	PUNCT
dpc-4838	139	5	s6	s6	PROPN
dpc-4838	139	6	6	6	NUM
dpc-4838	139	7	.	.	PUNCT
dpc-4838	139	8	kim	kim	PROPN
dpc-4838	139	9	j	j	PROPN
dpc-4838	139	10	,	,	PUNCT
dpc-4838	139	11	krueger	krueger	PROPN
dpc-4838	139	12	jg	jg	PROPN
dpc-4838	139	13	.	.	PUNCT
dpc-4838	140	1	highly	highly	ADV
dpc-4838	140	2	effective	effective	ADJ
dpc-4838	140	3	new	new	ADJ
dpc-4838	140	4	treatments	treatment	NOUN
dpc-4838	140	5	for	for	ADP
dpc-4838	140	6	psoriasis	psoriasis	NOUN
dpc-4838	140	7	target	target	VERB
dpc-4838	140	8	the	the	DET
dpc-4838	140	9	il-23	il-23	NOUN
dpc-4838	140	10	/	/	SYM
dpc-4838	140	11	type	type	NOUN
dpc-4838	140	12	17	17	NUM
dpc-4838	140	13	t	t	NOUN
dpc-4838	140	14	cell	cell	NOUN
dpc-4838	140	15	autoimmune	autoimmune	ADJ
dpc-4838	140	16	axis	axis	NOUN
dpc-4838	140	17	.	.	PUNCT
dpc-4838	141	1	annu	annu	PROPN
dpc-4838	141	2	rev	rev	VERB
dpc-4838	141	3	med	med	PROPN
dpc-4838	141	4	.	.	PROPN
dpc-4838	142	1	2017	2017	NUM
dpc-4838	142	2	jan	jan	NOUN
dpc-4838	142	3	14;68:255	14;68:255	NUM
dpc-4838	142	4	-	-	SYM
dpc-4838	142	5	269	269	NUM
dpc-4838	142	6	7	7	NUM
dpc-4838	142	7	.	.	PUNCT
dpc-4838	142	8	di	di	PROPN
dpc-4838	142	9	cesare	cesare	PROPN
dpc-4838	142	10	a	a	PROPN
dpc-4838	142	11	,	,	PUNCT
dpc-4838	142	12	di	di	NOUN
dpc-4838	142	13	meglio	meglio	NOUN
dpc-4838	142	14	p	p	X
dpc-4838	142	15	,	,	PUNCT
dpc-4838	142	16	nestle	nestle	PROPN
dpc-4838	142	17	fo	fo	PROPN
dpc-4838	142	18	.	.	PUNCT
dpc-4838	143	1	the	the	DET
dpc-4838	143	2	il-23	il-23	NOUN
dpc-4838	143	3	/	/	SYM
dpc-4838	143	4	th17	th17	PROPN
dpc-4838	143	5	axis	axis	NOUN
dpc-4838	143	6	in	in	ADP
dpc-4838	143	7	the	the	DET
dpc-4838	143	8	immunopathogenesis	immunopathogenesis	NOUN
dpc-4838	143	9	of	of	ADP
dpc-4838	143	10	psoriasis	psoriasis	NOUN
dpc-4838	143	11	.	.	PUNCT
dpc-4838	144	1	j	j	PROPN
dpc-4838	144	2	invest	invest	VERB
dpc-4838	144	3	dermatol	dermatol	NOUN
dpc-4838	144	4	.	.	PUNCT
dpc-4838	145	1	2009	2009	NUM
dpc-4838	145	2	jun;129(6):1339	jun;129(6):1339	NOUN
dpc-4838	145	3	-	-	PUNCT
dpc-4838	145	4	50	50	NUM
dpc-4838	145	5	8	8	NUM
dpc-4838	145	6	.	.	PUNCT
dpc-4838	146	1	rendon	rendon	PROPN
dpc-4838	146	2	a	a	PRON
dpc-4838	146	3	,	,	PUNCT
dpc-4838	146	4	schäkel	schäkel	PROPN
dpc-4838	146	5	k.	k.	PROPN
dpc-4838	146	6	psoriasis	psoriasis	NOUN
dpc-4838	146	7	pathogenesis	pathogenesis	NOUN
dpc-4838	146	8	and	and	CCONJ
dpc-4838	146	9	treatment	treatment	NOUN
dpc-4838	146	10	.	.	PUNCT
dpc-4838	147	1	int	int	PROPN
dpc-4838	147	2	j	j	PROPN
dpc-4838	147	3	mol	mol	ADP
dpc-4838	147	4	sci	sci	PROPN
dpc-4838	147	5	.	.	PROPN
dpc-4838	147	6	2019	2019	NUM
dpc-4838	147	7	mar	mar	PROPN
dpc-4838	147	8	23;20(6):1475	23;20(6):1475	NUM
dpc-4838	147	9	9	9	NUM
dpc-4838	147	10	.	.	PUNCT
dpc-4838	148	1	tokuyama	tokuyama	PROPN
dpc-4838	148	2	m	m	NOUN
dpc-4838	148	3	,	,	PUNCT
dpc-4838	148	4	mabuchi	mabuchi	PROPN
dpc-4838	148	5	t.	t.	NOUN
dpc-4838	148	6	new	new	ADJ
dpc-4838	148	7	treatment	treatment	NOUN
dpc-4838	148	8	addressing	address	VERB
dpc-4838	148	9	the	the	DET
dpc-4838	148	10	pathogenesis	pathogenesis	NOUN
dpc-4838	148	11	of	of	ADP
dpc-4838	148	12	psoriasis	psoriasis	NOUN
dpc-4838	148	13	.	.	PUNCT
dpc-4838	149	1	int	int	PROPN
dpc-4838	149	2	j	j	PROPN
dpc-4838	149	3	mol	mol	ADP
dpc-4838	149	4	sci	sci	PROPN
dpc-4838	149	5	.	.	PROPN
dpc-4838	149	6	2020	2020	NUM
dpc-4838	149	7	oct	oct	PROPN
dpc-4838	149	8	11;21(20):7488	11;21(20):7488	NUM
dpc-4838	149	9	10	10	NUM
dpc-4838	149	10	.	.	PUNCT
dpc-4838	150	1	sanford	sanford	PROPN
dpc-4838	150	2	m	m	PROPN
dpc-4838	150	3	,	,	PUNCT
dpc-4838	150	4	mckeage	mckeage	PROPN
dpc-4838	150	5	k.	k.	PROPN
dpc-4838	150	6	secukinumab	secukinumab	PROPN
dpc-4838	150	7	:	:	PUNCT
dpc-4838	150	8	first	first	ADJ
dpc-4838	150	9	global	global	ADJ
dpc-4838	150	10	approval	approval	NOUN
dpc-4838	150	11	.	.	PUNCT
dpc-4838	151	1	drugs	drug	NOUN
dpc-4838	151	2	.	.	PUNCT
dpc-4838	152	1	2015;75(3):329	2015;75(3):329	NUM
dpc-4838	152	2	-	-	PUNCT
dpc-4838	152	3	338	338	NUM
dpc-4838	152	4	11	11	NUM
dpc-4838	152	5	.	.	PUNCT
dpc-4838	153	1	langley	langley	PROPN
dpc-4838	153	2	rg	rg	PROPN
dpc-4838	153	3	,	,	PUNCT
dpc-4838	153	4	elewski	elewski	PROPN
dpc-4838	153	5	be	be	AUX
dpc-4838	153	6	,	,	PUNCT
dpc-4838	153	7	lebwohl	lebwohl	PROPN
dpc-4838	153	8	m	m	PROPN
dpc-4838	153	9	,	,	PUNCT
dpc-4838	153	10	et	et	PROPN
dpc-4838	153	11	al	al	PROPN
dpc-4838	153	12	.	.	PROPN
dpc-4838	153	13	secukinumab	secukinumab	PROPN
dpc-4838	153	14	in	in	ADP
dpc-4838	153	15	plaque	plaque	NOUN
dpc-4838	153	16	psoriasis	psoriasis	NOUN
dpc-4838	153	17	--	--	PUNCT
dpc-4838	153	18	results	result	NOUN
dpc-4838	153	19	of	of	ADP
dpc-4838	153	20	two	two	NUM
dpc-4838	153	21	phase	phase	NOUN
dpc-4838	153	22	3	3	NUM
dpc-4838	153	23	trials	trial	NOUN
dpc-4838	153	24	.	.	PUNCT
dpc-4838	154	1	n	n	PROPN
dpc-4838	154	2	engl	engl	PROPN
dpc-4838	154	3	j	j	PROPN
dpc-4838	154	4	med	med	PROPN
dpc-4838	154	5	.	.	PUNCT
dpc-4838	155	1	2014;371(4):326	2014;371(4):326	NUM
dpc-4838	155	2	-	-	SYM
dpc-4838	155	3	338	338	NUM
dpc-4838	155	4	12	12	NUM
dpc-4838	155	5	.	.	PUNCT
dpc-4838	156	1	blauvelt	blauvelt	VERB
dpc-4838	156	2	a	a	DET
dpc-4838	156	3	,	,	PUNCT
dpc-4838	156	4	reich	reich	PROPN
dpc-4838	156	5	k	k	PROPN
dpc-4838	156	6	,	,	PUNCT
dpc-4838	156	7	tsai	tsai	PROPN
dpc-4838	156	8	tf	tf	X
dpc-4838	156	9	,	,	PUNCT
dpc-4838	156	10	tyring	tyre	VERB
dpc-4838	156	11	s	s	PRON
dpc-4838	156	12	,	,	PUNCT
dpc-4838	156	13	vanaclocha	vanaclocha	PROPN
dpc-4838	156	14	f	f	PROPN
dpc-4838	156	15	,	,	PUNCT
dpc-4838	156	16	kingo	kingo	PROPN
dpc-4838	156	17	k	k	PROPN
dpc-4838	156	18	,	,	PUNCT
dpc-4838	156	19	et	et	PROPN
dpc-4838	156	20	al	al	PROPN
dpc-4838	156	21	.	.	PROPN
dpc-4838	156	22	secukinumab	secukinumab	PROPN
dpc-4838	156	23	is	be	AUX
dpc-4838	156	24	superior	superior	ADJ
dpc-4838	156	25	to	to	ADP
dpc-4838	156	26	ustekinumab	ustekinumab	NOUN
dpc-4838	156	27	in	in	ADP
dpc-4838	156	28	clearing	clear	VERB
dpc-4838	156	29	skin	skin	NOUN
dpc-4838	156	30	of	of	ADP
dpc-4838	156	31	subjects	subject	NOUN
dpc-4838	156	32	with	with	ADP
dpc-4838	156	33	moderate	moderate	ADJ
dpc-4838	156	34	-	-	PUNCT
dpc-4838	156	35	to	to	ADP
dpc-4838	156	36	-	-	PUNCT
dpc-4838	156	37	severe	severe	ADJ
dpc-4838	156	38	plaque	plaque	NOUN
dpc-4838	156	39	psoriasis	psoriasis	NOUN
dpc-4838	156	40	up	up	ADP
dpc-4838	156	41	to	to	PART
dpc-4838	156	42	1	1	NUM
dpc-4838	156	43	year	year	NOUN
dpc-4838	156	44	:	:	PUNCT
dpc-4838	156	45	results	result	VERB
dpc-4838	156	46	from	from	ADP
dpc-4838	156	47	the	the	DET
dpc-4838	156	48	clear	clear	ADJ
dpc-4838	156	49	study	study	NOUN
dpc-4838	156	50	.	.	PUNCT
dpc-4838	157	1	j	j	PROPN
dpc-4838	157	2	am	be	AUX
dpc-4838	157	3	acad	acad	ADJ
dpc-4838	157	4	dermatol	dermatol	NOUN
dpc-4838	157	5	.	.	PUNCT
dpc-4838	158	1	2017	2017	NUM
dpc-4838	158	2	jan;76((1)):60–69.e9	jan;76((1)):60–69.e9	NOUN
dpc-4838	158	3	13	13	NUM
dpc-4838	158	4	.	.	PUNCT
dpc-4838	159	1	gordon	gordon	PROPN
dpc-4838	159	2	kb	kb	PROPN
dpc-4838	159	3	,	,	PUNCT
dpc-4838	159	4	strober	strober	ADV
dpc-4838	159	5	b	b	NUM
dpc-4838	159	6	,	,	PUNCT
dpc-4838	159	7	lebwohl	lebwohl	PROPN
dpc-4838	159	8	m	m	PROPN
dpc-4838	159	9	,	,	PUNCT
dpc-4838	159	10	augustin	augustin	PROPN
dpc-4838	159	11	m	m	PROPN
dpc-4838	159	12	,	,	PUNCT
dpc-4838	159	13	blauvelt	blauvelt	VERB
dpc-4838	159	14	a	a	PRON
dpc-4838	159	15	,	,	PUNCT
dpc-4838	159	16	poulin	poulin	PROPN
dpc-4838	159	17	y	y	PROPN
dpc-4838	159	18	,	,	PUNCT
dpc-4838	159	19	papp	papp	PROPN
dpc-4838	159	20	ka	ka	PROPN
dpc-4838	159	21	,	,	PUNCT
dpc-4838	159	22	sofen	sofen	PROPN
dpc-4838	159	23	h	h	PROPN
dpc-4838	159	24	,	,	PUNCT
dpc-4838	159	25	puig	puig	PROPN
dpc-4838	159	26	l	l	NOUN
dpc-4838	159	27	,	,	PUNCT
dpc-4838	159	28	foley	foley	PROPN
dpc-4838	159	29	p	p	X
dpc-4838	159	30	,	,	PUNCT
dpc-4838	159	31	ohtsuki	ohtsuki	PROPN
dpc-4838	159	32	m	m	PROPN
dpc-4838	159	33	,	,	PUNCT
dpc-4838	159	34	flack	flack	NOUN
dpc-4838	159	35	m	m	PROPN
dpc-4838	159	36	,	,	PUNCT
dpc-4838	159	37	geng	geng	PROPN
dpc-4838	159	38	z	z	PROPN
dpc-4838	159	39	,	,	PUNCT
dpc-4838	159	40	gu	gu	PROPN
dpc-4838	159	41	y	y	PROPN
dpc-4838	159	42	,	,	PUNCT
dpc-4838	159	43	valdes	valde	VERB
dpc-4838	159	44	jm	jm	PROPN
dpc-4838	159	45	,	,	PUNCT
dpc-4838	159	46	thompson	thompson	PROPN
dpc-4838	159	47	ehz	ehz	PROPN
dpc-4838	159	48	,	,	PUNCT
dpc-4838	159	49	bachelez	bachelez	PROPN
dpc-4838	159	50	h.	h.	PROPN
dpc-4838	159	51	efficacy	efficacy	PROPN
dpc-4838	159	52	and	and	CCONJ
dpc-4838	159	53	safety	safety	NOUN
dpc-4838	159	54	of	of	ADP
dpc-4838	159	55	risankizumab	risankizumab	NOUN
dpc-4838	159	56	in	in	ADP
dpc-4838	159	57	moderate	moderate	ADJ
dpc-4838	159	58	-	-	PUNCT
dpc-4838	159	59	to	to	ADP
dpc-4838	159	60	-	-	PUNCT
dpc-4838	159	61	severe	severe	ADJ
dpc-4838	159	62	plaque	plaque	NOUN
dpc-4838	159	63	psoriasis	psoriasis	NOUN
dpc-4838	159	64	(	(	PUNCT
dpc-4838	159	65	ultimma-1	ultimma-1	NUM
dpc-4838	159	66	and	and	CCONJ
dpc-4838	159	67	ultimma-2	ultimma-2	NUM
dpc-4838	159	68	):	):	PUNCT
dpc-4838	159	69	results	result	NOUN
dpc-4838	159	70	from	from	ADP
dpc-4838	159	71	two	two	NUM
dpc-4838	159	72	double	double	ADJ
dpc-4838	159	73	-	-	PUNCT
dpc-4838	159	74	blind	blind	ADJ
dpc-4838	159	75	,	,	PUNCT
dpc-4838	159	76	randomised	randomise	VERB
dpc-4838	159	77	,	,	PUNCT
dpc-4838	159	78	placebo	placebo	NOUN
dpc-4838	159	79	-	-	PUNCT
dpc-4838	159	80	controlled	control	VERB
dpc-4838	159	81	and	and	CCONJ
dpc-4838	159	82	ustekinumab	ustekinumab	NOUN
dpc-4838	159	83	-	-	PUNCT
dpc-4838	159	84	controlled	control	VERB
dpc-4838	159	85	phase	phase	NOUN
dpc-4838	159	86	3	3	NUM
dpc-4838	159	87	trials	trial	NOUN
dpc-4838	159	88	.	.	PUNCT
dpc-4838	160	1	lancet	lancet	NOUN
dpc-4838	160	2	.	.	PUNCT
dpc-4838	161	1	2018	2018	NUM
dpc-4838	161	2	aug	aug	PROPN
dpc-4838	161	3	25;392(10148):650	25;392(10148):650	NUM
dpc-4838	161	4	-	-	SYM
dpc-4838	161	5	661	661	NUM
dpc-4838	161	6	14	14	NUM
dpc-4838	161	7	.	.	PUNCT
dpc-4838	161	8	mckeage	mckeage	PROPN
dpc-4838	161	9	k	k	PROPN
dpc-4838	161	10	,	,	PUNCT
dpc-4838	161	11	duggan	duggan	PROPN
dpc-4838	161	12	s.	s.	PROPN
dpc-4838	161	13	risankizumab	risankizumab	PROPN
dpc-4838	161	14	:	:	PUNCT
dpc-4838	161	15	first	first	ADJ
dpc-4838	161	16	global	global	ADJ
dpc-4838	161	17	approval	approval	NOUN
dpc-4838	161	18	.	.	PUNCT
dpc-4838	162	1	drugs	drug	NOUN
dpc-4838	162	2	.	.	PUNCT
dpc-4838	163	1	2019;79(8):893	2019;79(8):893	NUM
dpc-4838	163	2	-	-	SYM
dpc-4838	163	3	900	900	NUM
dpc-4838	163	4	15	15	NUM
dpc-4838	163	5	.	.	PUNCT
dpc-4838	164	1	warren	warren	PROPN
dpc-4838	164	2	rb	rb	PROPN
dpc-4838	164	3	,	,	PUNCT
dpc-4838	164	4	blauvelt	blauvelt	VERB
dpc-4838	164	5	a	a	PRON
dpc-4838	164	6	,	,	PUNCT
dpc-4838	164	7	poulin	poulin	PROPN
dpc-4838	164	8	y	y	PROPN
dpc-4838	164	9	,	,	PUNCT
dpc-4838	164	10	beeck	beeck	PROPN
dpc-4838	164	11	s	s	PROPN
dpc-4838	164	12	,	,	PUNCT
dpc-4838	164	13	kelly	kelly	PROPN
dpc-4838	164	14	m	m	PROPN
dpc-4838	164	15	,	,	PUNCT
dpc-4838	164	16	wu	wu	PROPN
dpc-4838	164	17	t	t	PROPN
dpc-4838	164	18	,	,	PUNCT
dpc-4838	164	19	geng	geng	PROPN
dpc-4838	164	20	z	z	PROPN
dpc-4838	164	21	,	,	PUNCT
dpc-4838	164	22	paul	paul	PROPN
dpc-4838	164	23	c.	c.	PROPN
dpc-4838	164	24	efficacy	efficacy	PROPN
dpc-4838	164	25	and	and	CCONJ
dpc-4838	164	26	safety	safety	NOUN
dpc-4838	164	27	of	of	ADP
dpc-4838	164	28	risankizumab	risankizumab	NOUN
dpc-4838	164	29	vs.	vs.	ADP
dpc-4838	164	30	secukinumab	secukinumab	NOUN
dpc-4838	164	31	in	in	ADP
dpc-4838	164	32	patients	patient	NOUN
dpc-4838	164	33	with	with	ADP
dpc-4838	164	34	moderate	moderate	ADJ
dpc-4838	164	35	-	-	PUNCT
dpc-4838	164	36	to	to	ADP
dpc-4838	164	37	-	-	PUNCT
dpc-4838	164	38	severe	severe	ADJ
dpc-4838	164	39	plaque	plaque	NOUN
dpc-4838	164	40	psoriasis	psoriasis	NOUN
dpc-4838	164	41	(	(	PUNCT
dpc-4838	164	42	immerge	immerge	ADJ
dpc-4838	164	43	):	):	PUNCT
dpc-4838	164	44	results	result	NOUN
dpc-4838	164	45	from	from	ADP
dpc-4838	164	46	a	a	DET
dpc-4838	164	47	phase	phase	NOUN
dpc-4838	164	48	iii	iii	NOUN
dpc-4838	164	49	,	,	PUNCT
dpc-4838	164	50	randomized	randomize	VERB
dpc-4838	164	51	,	,	PUNCT
dpc-4838	164	52	open	open	ADJ
dpc-4838	164	53	-	-	PUNCT
dpc-4838	164	54	label	label	NOUN
dpc-4838	164	55	,	,	PUNCT
dpc-4838	164	56	efficacy	efficacy	NOUN
dpc-4838	164	57	-assessorblinded	-assessorblinde	VERB
dpc-4838	164	58	clinical	clinical	ADJ
dpc-4838	164	59	trial	trial	NOUN
dpc-4838	164	60	.	.	PUNCT
dpc-4838	165	1	br	br	PROPN
dpc-4838	165	2	j	j	PROPN
dpc-4838	165	3	dermatol	dermatol	NOUN
dpc-4838	165	4	.	.	PUNCT
dpc-4838	166	1	2021	2021	NUM
dpc-4838	166	2	jan;184(1):50	jan;184(1):50	NOUN
dpc-4838	166	3	-	-	SYM
dpc-4838	166	4	59	59	NUM
dpc-4838	166	5	16	16	NUM
dpc-4838	166	6	.	.	PUNCT
dpc-4838	167	1	mastorino	mastorino	PROPN
dpc-4838	167	2	l	l	NOUN
dpc-4838	167	3	,	,	PUNCT
dpc-4838	167	4	dapavo	dapavo	VERB
dpc-4838	167	5	p	p	NOUN
dpc-4838	167	6	,	,	PUNCT
dpc-4838	167	7	susca	susca	PROPN
dpc-4838	167	8	s	s	PROPN
dpc-4838	167	9	,	,	PUNCT
dpc-4838	167	10	et	et	PROPN
dpc-4838	167	11	al	al	PROPN
dpc-4838	167	12	.	.	PROPN
dpc-4838	167	13	drug	drug	PROPN
dpc-4838	167	14	survival	survival	NOUN
dpc-4838	167	15	and	and	CCONJ
dpc-4838	167	16	clinical	clinical	ADJ
dpc-4838	167	17	effectiveness	effectiveness	NOUN
dpc-4838	167	18	of	of	ADP
dpc-4838	167	19	secukinumab	secukinumab	NOUN
dpc-4838	167	20	,	,	PUNCT
dpc-4838	167	21	ixekizumab	ixekizumab	NOUN
dpc-4838	167	22	,	,	PUNCT
dpc-4838	167	23	brodalumab	brodalumab	NOUN
dpc-4838	167	24	,	,	PUNCT
dpc-4838	167	25	guselkumab	guselkumab	NOUN
dpc-4838	167	26	,	,	PUNCT
dpc-4838	167	27	risankizumab	risankizumab	NOUN
dpc-4838	167	28	,	,	PUNCT
dpc-4838	167	29	tildrakizumab	tildrakizumab	NOUN
dpc-4838	167	30	for	for	ADP
dpc-4838	167	31	psoriasis	psoriasis	NOUN
dpc-4838	167	32	treatment	treatment	NOUN
dpc-4838	167	33	.	.	PUNCT
dpc-4838	168	1	j	j	PROPN
dpc-4838	168	2	dtsch	dtsch	PROPN
dpc-4838	168	3	dermatol	dermatol	NOUN
dpc-4838	168	4	ges	ge	NOUN
dpc-4838	168	5	.	.	PROPN
dpc-4838	168	6	published	publish	VERB
dpc-4838	168	7	online	online	ADV
dpc-4838	168	8	november	november	PROPN
dpc-4838	168	9	5	5	NUM
dpc-4838	168	10	,	,	PUNCT
dpc-4838	168	11	2023	2023	NUM
dpc-4838	168	12	17	17	NUM
dpc-4838	168	13	.	.	PUNCT
dpc-4838	169	1	torres	torres	PROPN
dpc-4838	169	2	t	t	PROPN
dpc-4838	169	3	,	,	PUNCT
dpc-4838	169	4	puig	puig	PROPN
dpc-4838	169	5	l	l	NOUN
dpc-4838	169	6	,	,	PUNCT
dpc-4838	169	7	vender	vender	NOUN
dpc-4838	169	8	r	r	NOUN
dpc-4838	169	9	,	,	PUNCT
dpc-4838	169	10	et	et	PROPN
dpc-4838	169	11	al	al	PROPN
dpc-4838	169	12	.	.	PROPN
dpc-4838	169	13	drug	drug	PROPN
dpc-4838	169	14	survival	survival	NOUN
dpc-4838	169	15	of	of	ADP
dpc-4838	169	16	interleukin	interleukin	NOUN
dpc-4838	169	17	(	(	PUNCT
dpc-4838	169	18	il)-17	il)-17	PROPN
dpc-4838	169	19	and	and	CCONJ
dpc-4838	169	20	il-23	il-23	VERB
dpc-4838	169	21	inhibitors	inhibitor	NOUN
dpc-4838	169	22	for	for	ADP
dpc-4838	169	23	the	the	DET
dpc-4838	169	24	treatment	treatment	NOUN
dpc-4838	169	25	of	of	ADP
dpc-4838	169	26	psoriasis	psoriasis	NOUN
dpc-4838	169	27	:	:	PUNCT
dpc-4838	169	28	a	a	DET
dpc-4838	169	29	retrospective	retrospective	ADJ
dpc-4838	169	30	multi	multi	ADJ
dpc-4838	169	31	-	-	NOUN
dpc-4838	169	32	country	country	NOUN
dpc-4838	169	33	,	,	PUNCT
dpc-4838	169	34	multicentric	multicentric	ADJ
dpc-4838	169	35	cohort	cohort	NOUN
dpc-4838	169	36	study	study	NOUN
dpc-4838	169	37	.	.	PUNCT
dpc-4838	170	1	am	be	AUX
dpc-4838	170	2	j	j	PROPN
dpc-4838	170	3	clin	clin	PROPN
dpc-4838	170	4	dermatol	dermatol	NOUN
dpc-4838	170	5	.	.	PUNCT
dpc-4838	171	1	2022;23(6):891	2022;23(6):891	PROPN
dpc-4838	171	2	-	-	PUNCT
dpc-4838	171	3	904	904	NUM
dpc-4838	171	4	18	18	NUM
dpc-4838	171	5	.	.	PUNCT
dpc-4838	172	1	gisondi	gisondi	PROPN
dpc-4838	172	2	p	p	NOUN
dpc-4838	172	3	,	,	PUNCT
dpc-4838	172	4	loconsole	loconsole	NOUN
dpc-4838	172	5	f	f	NOUN
dpc-4838	172	6	,	,	PUNCT
dpc-4838	172	7	raimondo	raimondo	PROPN
dpc-4838	172	8	p	p	X
dpc-4838	172	9	,	,	PUNCT
dpc-4838	172	10	ravasio	ravasio	PROPN
dpc-4838	172	11	r.	r.	PROPN
dpc-4838	172	12	costo	costo	PROPN
dpc-4838	172	13	per	per	ADP
dpc-4838	172	14	responder	responder	PROPN
dpc-4838	172	15	di	di	PROPN
dpc-4838	172	16	risankizumab	risankizumab	PROPN
dpc-4838	172	17	e	e	PROPN
dpc-4838	172	18	secukinumab	secukinumab	PROPN
dpc-4838	172	19	nel	nel	PROPN
dpc-4838	172	20	trattamento	trattamento	PROPN
dpc-4838	172	21	della	della	PROPN
dpc-4838	172	22	psoriasi	psoriasi	PROPN
dpc-4838	172	23	a	a	DET
dpc-4838	172	24	placche	placche	NOUN
dpc-4838	172	25	da	da	PROPN
dpc-4838	172	26	moderata	moderata	DET
dpc-4838	172	27	a	a	DET
dpc-4838	172	28	grave	grave	NOUN
dpc-4838	172	29	in	in	ADP
dpc-4838	172	30	italia	italia	PROPN
dpc-4838	172	31	.	.	PUNCT
dpc-4838	173	1	glob	glob	PROPN
dpc-4838	173	2	reg	reg	PROPN
dpc-4838	173	3	health	health	NOUN
dpc-4838	173	4	technol	technol	NOUN
dpc-4838	173	5	assess	assess	NOUN
dpc-4838	173	6	.	.	PUNCT
dpc-4838	174	1	2021;8:120	2021;8:120	NUM
dpc-4838	174	2	-	-	PUNCT
dpc-4838	174	3	130	130	NUM
dpc-4838	174	4	costs	cost	NOUN
dpc-4838	174	5	than	than	ADP
dpc-4838	174	6	anti	anti	ADJ
dpc-4838	174	7	-	-	ADJ
dpc-4838	174	8	interleukins	interleukin	NOUN
dpc-4838	174	9	)	)	PUNCT
dpc-4838	174	10	.	.	PUNCT
dpc-4838	175	1	in	in	ADP
dpc-4838	175	2	any	any	DET
dpc-4838	175	3	case	case	NOUN
dpc-4838	175	4	,	,	PUNCT
dpc-4838	175	5	it	it	PRON
dpc-4838	175	6	should	should	AUX
dpc-4838	175	7	be	be	AUX
dpc-4838	175	8	taken	take	VERB
dpc-4838	175	9	into	into	ADP
dpc-4838	175	10	account	account	NOUN
dpc-4838	175	11	that	that	SCONJ
dpc-4838	175	12	the	the	DET
dpc-4838	175	13	choice	choice	NOUN
dpc-4838	175	14	of	of	ADP
dpc-4838	175	15	an	an	DET
dpc-4838	175	16	anti	anti	ADJ
dpc-4838	175	17	-	-	ADJ
dpc-4838	175	18	tnf	tnf	ADJ
dpc-4838	175	19	drug	drug	NOUN
dpc-4838	175	20	can	can	AUX
dpc-4838	175	21	not	not	PART
dpc-4838	175	22	be	be	AUX
dpc-4838	175	23	applied	apply	VERB
dpc-4838	175	24	indiscriminately	indiscriminately	ADV
dpc-4838	175	25	to	to	ADP
dpc-4838	175	26	each	each	DET
dpc-4838	175	27	and	and	CCONJ
dpc-4838	175	28	every	every	PRON
dpc-4838	175	29	patient	patient	NOUN
dpc-4838	175	30	.	.	PUNCT
dpc-4838	176	1	several	several	ADJ
dpc-4838	176	2	real	real	ADJ
dpc-4838	176	3	-	-	PUNCT
dpc-4838	176	4	life	life	NOUN
dpc-4838	176	5	studies	study	NOUN
dpc-4838	176	6	have	have	AUX
dpc-4838	176	7	shown	show	VERB
dpc-4838	176	8	that	that	SCONJ
dpc-4838	176	9	certain	certain	ADJ
dpc-4838	176	10	categories	category	NOUN
dpc-4838	176	11	of	of	ADP
dpc-4838	176	12	patients	patient	NOUN
dpc-4838	176	13	are	be	AUX
dpc-4838	176	14	unlikely	unlikely	ADJ
dpc-4838	176	15	to	to	PART
dpc-4838	176	16	benefit	benefit	VERB
dpc-4838	176	17	from	from	ADP
dpc-4838	176	18	the	the	DET
dpc-4838	176	19	use	use	NOUN
dpc-4838	176	20	of	of	ADP
dpc-4838	176	21	such	such	ADJ
dpc-4838	176	22	molecules	molecule	NOUN
dpc-4838	177	1	[	[	X
dpc-4838	177	2	34,35	34,35	X
dpc-4838	177	3	]	]	X
dpc-4838	177	4	making	make	VERB
dpc-4838	177	5	therapy	therapy	NOUN
dpc-4838	177	6	with	with	ADP
dpc-4838	177	7	an	an	DET
dpc-4838	177	8	anti	anti	ADJ
dpc-4838	177	9	-	-	ADJ
dpc-4838	177	10	interleukin	interleukin	ADJ
dpc-4838	177	11	drug	drug	NOUN
dpc-4838	177	12	more	more	ADV
dpc-4838	177	13	appropriate	appropriate	ADJ
dpc-4838	177	14	.	.	PUNCT
dpc-4838	178	1	in	in	ADP
dpc-4838	178	2	this	this	DET
dpc-4838	178	3	context	context	NOUN
dpc-4838	178	4	,	,	PUNCT
dpc-4838	178	5	the	the	DET
dpc-4838	178	6	availability	availability	NOUN
dpc-4838	178	7	of	of	ADP
dpc-4838	178	8	data	datum	NOUN
dpc-4838	178	9	from	from	ADP
dpc-4838	178	10	cost	cost	NOUN
dpc-4838	178	11	-	-	PUNCT
dpc-4838	178	12	effectiveness	effectiveness	NOUN
dpc-4838	178	13	analyses	analysis	NOUN
dpc-4838	178	14	,	,	PUNCT
dpc-4838	178	15	as	as	SCONJ
dpc-4838	178	16	the	the	DET
dpc-4838	178	17	one	one	NOUN
dpc-4838	178	18	performed	perform	VERB
dpc-4838	178	19	in	in	ADP
dpc-4838	178	20	our	our	PRON
dpc-4838	178	21	study	study	NOUN
dpc-4838	178	22	,	,	PUNCT
dpc-4838	178	23	can	can	AUX
dpc-4838	178	24	be	be	AUX
dpc-4838	178	25	an	an	DET
dpc-4838	178	26	important	important	ADJ
dpc-4838	178	27	decision	decision	NOUN
dpc-4838	178	28	-	-	PUNCT
dpc-4838	178	29	making	make	VERB
dpc-4838	178	30	tool	tool	NOUN
dpc-4838	178	31	to	to	PART
dpc-4838	178	32	guide	guide	VERB
dpc-4838	178	33	clinician	clinician	ADJ
dpc-4838	178	34	therapeutic	therapeutic	ADJ
dpc-4838	178	35	choices	choice	NOUN
dpc-4838	178	36	.	.	PUNCT
dpc-4838	179	1	however	however	ADV
dpc-4838	179	2	,	,	PUNCT
dpc-4838	179	3	it	it	PRON
dpc-4838	179	4	can	can	AUX
dpc-4838	179	5	also	also	ADV
dpc-4838	179	6	be	be	AUX
dpc-4838	179	7	valuable	valuable	ADJ
dpc-4838	179	8	for	for	ADP
dpc-4838	179	9	decision	decision	NOUN
dpc-4838	179	10	-	-	PUNCT
dpc-4838	179	11	makers	maker	NOUN
dpc-4838	179	12	in	in	ADP
dpc-4838	179	13	pharmaco	pharmaco	NOUN
dpc-4838	179	14	-	-	PUNCT
dpc-4838	179	15	economic	economic	ADJ
dpc-4838	179	16	policy	policy	NOUN
dpc-4838	179	17	to	to	PART
dpc-4838	179	18	comprehend	comprehend	VERB
dpc-4838	179	19	how	how	SCONJ
dpc-4838	179	20	to	to	PART
dpc-4838	179	21	optimize	optimize	VERB
dpc-4838	179	22	patient	patient	ADJ
dpc-4838	179	23	treatment	treatment	NOUN
dpc-4838	179	24	while	while	SCONJ
dpc-4838	179	25	minimizing	minimize	VERB
dpc-4838	179	26	unnecessary	unnecessary	ADJ
dpc-4838	179	27	expenses	expense	NOUN
dpc-4838	179	28	.	.	PUNCT
dpc-4838	180	1	limitations	limitation	NOUN
dpc-4838	180	2	the	the	DET
dpc-4838	180	3	limitations	limitation	NOUN
dpc-4838	180	4	of	of	ADP
dpc-4838	180	5	this	this	DET
dpc-4838	180	6	study	study	NOUN
dpc-4838	180	7	are	be	AUX
dpc-4838	180	8	mostly	mostly	ADV
dpc-4838	180	9	represented	represent	VERB
dpc-4838	180	10	by	by	ADP
dpc-4838	180	11	the	the	DET
dpc-4838	180	12	retrospective	retrospective	ADJ
dpc-4838	180	13	method	method	NOUN
dpc-4838	180	14	of	of	ADP
dpc-4838	180	15	data	data	NOUN
dpc-4838	180	16	collection	collection	NOUN
dpc-4838	180	17	(	(	PUNCT
dpc-4838	180	18	i.e.	i.e.	X
dpc-4838	180	19	potential	potential	ADJ
dpc-4838	180	20	reporting	reporting	NOUN
dpc-4838	180	21	bias	bias	NOUN
dpc-4838	180	22	)	)	PUNCT
dpc-4838	180	23	and	and	CCONJ
dpc-4838	180	24	the	the	DET
dpc-4838	180	25	relatively	relatively	ADV
dpc-4838	180	26	small	small	ADJ
dpc-4838	180	27	sample	sample	NOUN
dpc-4838	180	28	size	size	NOUN
dpc-4838	180	29	,	,	PUNCT
dpc-4838	180	30	suggesting	suggest	VERB
dpc-4838	180	31	the	the	DET
dpc-4838	180	32	need	need	NOUN
dpc-4838	180	33	for	for	ADP
dpc-4838	180	34	a	a	DET
dpc-4838	180	35	future	future	ADJ
dpc-4838	180	36	analysis	analysis	NOUN
dpc-4838	180	37	on	on	ADP
dpc-4838	180	38	a	a	DET
dpc-4838	180	39	larger	large	ADJ
dpc-4838	180	40	population	population	NOUN
dpc-4838	180	41	,	,	PUNCT
dpc-4838	180	42	possibly	possibly	ADV
dpc-4838	180	43	with	with	ADP
dpc-4838	180	44	a	a	DET
dpc-4838	180	45	prospective	prospective	ADJ
dpc-4838	180	46	method	method	NOUN
dpc-4838	180	47	,	,	PUNCT
dpc-4838	180	48	in	in	ADP
dpc-4838	180	49	order	order	NOUN
dpc-4838	180	50	to	to	PART
dpc-4838	180	51	be	be	AUX
dpc-4838	180	52	fully	fully	ADV
dpc-4838	180	53	representative	representative	ADJ
dpc-4838	180	54	of	of	ADP
dpc-4838	180	55	daily	daily	ADJ
dpc-4838	180	56	clinical	clinical	ADJ
dpc-4838	180	57	practice	practice	NOUN
dpc-4838	180	58	.	.	PUNCT
dpc-4838	181	1	such	such	DET
dpc-4838	181	2	an	an	DET
dpc-4838	181	3	approach	approach	NOUN
dpc-4838	181	4	might	might	AUX
dpc-4838	181	5	also	also	ADV
dpc-4838	181	6	encompass	encompass	VERB
dpc-4838	181	7	a	a	DET
dpc-4838	181	8	sub	sub	NOUN
dpc-4838	181	9	-	-	NOUN
dpc-4838	181	10	analysis	analysis	NOUN
dpc-4838	181	11	of	of	ADP
dpc-4838	181	12	indirect	indirect	ADJ
dpc-4838	181	13	costs	cost	NOUN
dpc-4838	181	14	associated	associate	VERB
dpc-4838	181	15	with	with	ADP
dpc-4838	181	16	the	the	DET
dpc-4838	181	17	treatment	treatment	NOUN
dpc-4838	181	18	and	and	CCONJ
dpc-4838	181	19	the	the	DET
dpc-4838	181	20	disease	disease	NOUN
dpc-4838	181	21	itself	itself	PRON
dpc-4838	181	22	.	.	PUNCT
dpc-4838	182	1	it	it	PRON
dpc-4838	182	2	should	should	AUX
dpc-4838	182	3	be	be	AUX
dpc-4838	182	4	noted	note	VERB
dpc-4838	182	5	that	that	SCONJ
dpc-4838	182	6	the	the	DET
dpc-4838	182	7	cost	cost	NOUN
dpc-4838	182	8	per	per	ADP
dpc-4838	182	9	responder	responder	NOUN
dpc-4838	182	10	analysis	analysis	NOUN
dpc-4838	182	11	was	be	AUX
dpc-4838	182	12	limited	limit	VERB
dpc-4838	182	13	to	to	ADP
dpc-4838	182	14	52	52	NUM
dpc-4838	182	15	weeks	week	NOUN
dpc-4838	182	16	,	,	PUNCT
dpc-4838	182	17	and	and	CCONJ
dpc-4838	182	18	therefore	therefore	ADV
dpc-4838	182	19	only	only	ADV
dpc-4838	182	20	covered	cover	VERB
dpc-4838	182	21	the	the	DET
dpc-4838	182	22	first	first	ADJ
dpc-4838	182	23	year	year	NOUN
dpc-4838	182	24	of	of	ADP
dpc-4838	182	25	treatment	treatment	NOUN
dpc-4838	182	26	including	include	VERB
dpc-4838	182	27	the	the	DET
dpc-4838	182	28	induction	induction	NOUN
dpc-4838	182	29	period	period	NOUN
dpc-4838	182	30	of	of	ADP
dpc-4838	182	31	the	the	DET
dpc-4838	182	32	two	two	NUM
dpc-4838	182	33	drugs	drug	NOUN
dpc-4838	182	34	,	,	PUNCT
dpc-4838	182	35	as	as	SCONJ
dpc-4838	182	36	not	not	PART
dpc-4838	182	37	all	all	DET
dpc-4838	182	38	patients	patient	NOUN
dpc-4838	182	39	in	in	ADP
dpc-4838	182	40	the	the	DET
dpc-4838	182	41	study	study	NOUN
dpc-4838	182	42	reached	reach	VERB
dpc-4838	182	43	week	week	NOUN
dpc-4838	182	44	78	78	NUM
dpc-4838	182	45	of	of	ADP
dpc-4838	182	46	treatment	treatment	NOUN
dpc-4838	182	47	.	.	PUNCT
dpc-4838	183	1	considering	consider	VERB
dpc-4838	183	2	the	the	DET
dpc-4838	183	3	optimal	optimal	ADJ
dpc-4838	183	4	drug	drug	NOUN
dpc-4838	183	5	survival	survival	NOUN
dpc-4838	183	6	data	datum	NOUN
dpc-4838	183	7	available	available	ADJ
dpc-4838	183	8	in	in	ADP
dpc-4838	183	9	literature	literature	NOUN
dpc-4838	183	10	for	for	ADP
dpc-4838	183	11	both	both	CCONJ
dpc-4838	183	12	the	the	DET
dpc-4838	183	13	drugs	drug	NOUN
dpc-4838	183	14	analyzed	analyze	VERB
dpc-4838	183	15	,	,	PUNCT
dpc-4838	183	16	we	we	PRON
dpc-4838	183	17	aim	aim	VERB
dpc-4838	183	18	in	in	ADP
dpc-4838	183	19	the	the	DET
dpc-4838	183	20	near	near	ADJ
dpc-4838	183	21	future	future	NOUN
dpc-4838	183	22	to	to	PART
dpc-4838	183	23	expand	expand	VERB
dpc-4838	183	24	this	this	DET
dpc-4838	183	25	analysis	analysis	NOUN
dpc-4838	183	26	over	over	ADP
dpc-4838	183	27	a	a	DET
dpc-4838	183	28	longer	long	ADJ
dpc-4838	183	29	period	period	NOUN
dpc-4838	183	30	of	of	ADP
dpc-4838	183	31	observation	observation	NOUN
dpc-4838	183	32	in	in	ADP
dpc-4838	183	33	order	order	NOUN
dpc-4838	183	34	to	to	PART
dpc-4838	183	35	fully	fully	ADV
dpc-4838	183	36	capture	capture	VERB
dpc-4838	183	37	the	the	DET
dpc-4838	183	38	long	long	ADJ
dpc-4838	183	39	-	-	PUNCT
dpc-4838	183	40	term	term	NOUN
dpc-4838	183	41	cost	cost	NOUN
dpc-4838	183	42	-	-	PUNCT
dpc-4838	183	43	effectiveness	effectiveness	NOUN
dpc-4838	183	44	of	of	ADP
dpc-4838	183	45	the	the	DET
dpc-4838	183	46	treatments	treatment	NOUN
dpc-4838	183	47	.	.	PUNCT
dpc-4838	184	1	moreover	moreover	ADV
dpc-4838	184	2	,	,	PUNCT
dpc-4838	184	3	differences	difference	NOUN
dpc-4838	184	4	in	in	ADP
dpc-4838	184	5	drug	drug	NOUN
dpc-4838	184	6	prices	price	NOUN
dpc-4838	184	7	between	between	ADP
dpc-4838	184	8	different	different	ADJ
dpc-4838	184	9	countries	country	NOUN
dpc-4838	184	10	(	(	PUNCT
dpc-4838	184	11	both	both	CCONJ
dpc-4838	184	12	european	european	ADJ
dpc-4838	184	13	and	and	CCONJ
dpc-4838	184	14	extra	extra	ADJ
dpc-4838	184	15	-	-	ADJ
dpc-4838	184	16	european	european	ADJ
dpc-4838	184	17	)	)	PUNCT
dpc-4838	184	18	should	should	AUX
dpc-4838	184	19	be	be	AUX
dpc-4838	184	20	considered	consider	VERB
dpc-4838	184	21	.	.	PUNCT
dpc-4838	185	1	in	in	ADP
dpc-4838	185	2	this	this	DET
dpc-4838	185	3	study	study	NOUN
dpc-4838	185	4	,	,	PUNCT
dpc-4838	185	5	the	the	DET
dpc-4838	185	6	analysis	analysis	NOUN
dpc-4838	185	7	was	be	AUX
dpc-4838	185	8	geographically	geographically	ADV
dpc-4838	185	9	limited	limited	ADJ
dpc-4838	185	10	to	to	ADP
dpc-4838	185	11	one	one	NUM
dpc-4838	185	12	single	single	ADJ
dpc-4838	185	13	region	region	NOUN
dpc-4838	185	14	in	in	ADP
dpc-4838	185	15	italy	italy	PROPN
dpc-4838	185	16	and	and	CCONJ
dpc-4838	185	17	therefore	therefore	ADV
dpc-4838	185	18	the	the	DET
dpc-4838	185	19	results	result	NOUN
dpc-4838	185	20	can	can	AUX
dpc-4838	185	21	not	not	PART
dpc-4838	185	22	be	be	AUX
dpc-4838	185	23	applied	apply	VERB
dpc-4838	185	24	to	to	ADP
dpc-4838	185	25	every	every	DET
dpc-4838	185	26	pharmaco	pharmaco	NOUN
dpc-4838	185	27	-	-	PUNCT
dpc-4838	185	28	economic	economic	ADJ
dpc-4838	185	29	scenario	scenario	NOUN
dpc-4838	185	30	.	.	PUNCT
dpc-4838	186	1	further	further	ADJ
dpc-4838	186	2	national	national	ADJ
dpc-4838	186	3	and	and	CCONJ
dpc-4838	186	4	international	international	ADJ
dpc-4838	186	5	multi	multi	ADJ
dpc-4838	186	6	-	-	ADJ
dpc-4838	186	7	center	center	ADJ
dpc-4838	186	8	studies	study	NOUN
dpc-4838	186	9	should	should	AUX
dpc-4838	186	10	investigate	investigate	VERB
dpc-4838	186	11	these	these	DET
dpc-4838	186	12	aspects	aspect	NOUN
dpc-4838	186	13	.	.	PUNCT
dpc-4838	187	1	in	in	ADP
dpc-4838	187	2	conclusion	conclusion	NOUN
dpc-4838	187	3	,	,	PUNCT
dpc-4838	187	4	risankizumab	risankizumab	NOUN
dpc-4838	187	5	proved	prove	VERB
dpc-4838	187	6	superior	superior	ADJ
dpc-4838	187	7	clinical	clinical	ADJ
dpc-4838	187	8	efficacy	efficacy	NOUN
dpc-4838	187	9	than	than	ADP
dpc-4838	187	10	secukinumab	secukinumab	NOUN
dpc-4838	187	11	in	in	ADP
dpc-4838	187	12	a	a	DET
dpc-4838	187	13	real	real	ADJ
dpc-4838	187	14	-	-	PUNCT
dpc-4838	187	15	life	life	NOUN
dpc-4838	187	16	setting	setting	NOUN
dpc-4838	187	17	and	and	CCONJ
dpc-4838	187	18	showed	show	VERB
dpc-4838	187	19	a	a	DET
dpc-4838	187	20	lower	low	ADJ
dpc-4838	187	21	cost	cost	NOUN
dpc-4838	187	22	per	per	ADP
dpc-4838	187	23	pasi90	pasi90	NOUN
dpc-4838	187	24	and	and	CCONJ
dpc-4838	187	25	pasi100	pasi100	PROPN
dpc-4838	187	26	responder	responder	NOUN
dpc-4838	187	27	in	in	ADP
dpc-4838	187	28	each	each	DET
dpc-4838	187	29	time	time	NOUN
dpc-4838	187	30	point	point	NOUN
dpc-4838	187	31	considered	consider	VERB
dpc-4838	187	32	,	,	PUNCT
dpc-4838	187	33	suggesting	suggest	VERB
dpc-4838	187	34	that	that	SCONJ
dpc-4838	187	35	it	it	PRON
dpc-4838	187	36	is	be	AUX
dpc-4838	187	37	a	a	DET
dpc-4838	187	38	cost	cost	NOUN
dpc-4838	187	39	-	-	PUNCT
dpc-4838	187	40	effective	effective	ADJ
dpc-4838	187	41	treatment	treatment	NOUN
dpc-4838	187	42	option	option	NOUN
dpc-4838	187	43	for	for	ADP
dpc-4838	187	44	moderate	moderate	ADJ
dpc-4838	187	45	to	to	ADP
dpc-4838	187	46	severe	severe	ADJ
dpc-4838	187	47	psoriasis	psoriasis	NOUN
dpc-4838	187	48	in	in	ADP
dpc-4838	187	49	italy	italy	PROPN
dpc-4838	187	50	.	.	PUNCT
dpc-4838	188	1	this	this	PRON
dpc-4838	188	2	could	could	AUX
dpc-4838	188	3	aid	aid	VERB
dpc-4838	188	4	in	in	ADP
dpc-4838	188	5	personalizing	personalize	VERB
dpc-4838	188	6	biologic	biologic	NOUN
dpc-4838	188	7	therapy	therapy	NOUN
dpc-4838	188	8	,	,	PUNCT
dpc-4838	188	9	leading	lead	VERB
dpc-4838	188	10	to	to	ADP
dpc-4838	188	11	better	well	ADJ
dpc-4838	188	12	outcomes	outcome	NOUN
dpc-4838	188	13	and	and	CCONJ
dpc-4838	188	14	increased	increase	VERB
dpc-4838	188	15	patient	patient	ADJ
dpc-4838	188	16	satisfaction	satisfaction	NOUN
dpc-4838	188	17	while	while	SCONJ
dpc-4838	188	18	also	also	ADV
dpc-4838	188	19	optimizing	optimize	VERB
dpc-4838	188	20	costs	cost	NOUN
dpc-4838	188	21	.	.	PUNCT
dpc-4838	189	1	references	reference	NOUN
dpc-4838	189	2	1	1	NUM
dpc-4838	189	3	.	.	PUNCT
dpc-4838	190	1	prignano	prignano	PROPN
dpc-4838	190	2	f	f	PROPN
dpc-4838	190	3	,	,	PUNCT
dpc-4838	190	4	rogai	rogai	ADJ
dpc-4838	190	5	v	v	NOUN
dpc-4838	190	6	,	,	PUNCT
dpc-4838	190	7	cavallucci	cavallucci	NOUN
dpc-4838	190	8	e	e	PROPN
dpc-4838	190	9	,	,	PUNCT
dpc-4838	190	10	bitossi	bitossi	PROPN
dpc-4838	190	11	a	a	PRON
dpc-4838	190	12	,	,	PUNCT
dpc-4838	190	13	hammen	hammen	NOUN
dpc-4838	190	14	v	v	NOUN
dpc-4838	190	15	,	,	PUNCT
dpc-4838	190	16	cantini	cantini	PROPN
dpc-4838	190	17	f.	f.	PROPN
dpc-4838	190	18	epidemiology	epidemiology	NOUN
dpc-4838	190	19	of	of	ADP
dpc-4838	190	20	psoriasis	psoriasis	NOUN
dpc-4838	190	21	and	and	CCONJ
dpc-4838	190	22	psoriatic	psoriatic	ADJ
dpc-4838	190	23	arthritis	arthritis	NOUN
dpc-4838	190	24	in	in	ADP
dpc-4838	190	25	italy	italy	PROPN
dpc-4838	190	26	-	-	PUNCT
dpc-4838	190	27	a	a	DET
dpc-4838	190	28	systematic	systematic	ADJ
dpc-4838	190	29	review	review	NOUN
dpc-4838	190	30	.	.	PUNCT
dpc-4838	191	1	curr	curr	PROPN
dpc-4838	191	2	rheumatol	rheumatol	PROPN
dpc-4838	191	3	rep	rep	PROPN
dpc-4838	191	4	.	.	PROPN
dpc-4838	192	1	2018;20(7):43	2018;20(7):43	PROPN
dpc-4838	192	2	.	.	PUNCT
dpc-4838	193	1	doi	doi	NOUN
dpc-4838	193	2	:	:	PUNCT
dpc-4838	193	3	10.1007	10.1007	NUM
dpc-4838	193	4	/	/	SYM
dpc-4838	193	5	s11926	s11926	NOUN
dpc-4838	193	6	-	-	PUNCT
dpc-4838	193	7	018	018	NUM
dpc-4838	193	8	-	-	PUNCT
dpc-4838	193	9	0753	0753	NUM
dpc-4838	193	10	-	-	SYM
dpc-4838	193	11	1	1	NUM
dpc-4838	193	12	.	.	PUNCT
dpc-4838	194	1	pmid	pmid	NOUN
dpc-4838	194	2	:	:	PUNCT
dpc-4838	194	3	29846817	29846817	NUM
dpc-4838	194	4	.	.	X
dpc-4838	195	1	8	8	NUM
dpc-4838	195	2	original	original	ADJ
dpc-4838	195	3	article	article	NOUN
dpc-4838	195	4	|	|	ADV
dpc-4838	195	5	dermatol	dermatol	ADJ
dpc-4838	195	6	pract	pract	NOUN
dpc-4838	195	7	concept	concept	NOUN
dpc-4838	195	8	.	.	PUNCT
dpc-4838	196	1	2025;15(1):4838	2025;15(1):4838	NUM
dpc-4838	196	2	psoriasis	psoriasis	NOUN
dpc-4838	196	3	:	:	PUNCT
dpc-4838	196	4	subgroup	subgroup	NOUN
dpc-4838	196	5	analysis	analysis	NOUN
dpc-4838	196	6	from	from	ADP
dpc-4838	196	7	the	the	DET
dpc-4838	196	8	immerge	immerge	ADJ
dpc-4838	196	9	study	study	NOUN
dpc-4838	196	10	.	.	PUNCT
dpc-4838	197	1	dermatol	dermatol	NOUN
dpc-4838	197	2	ther	ther	ADV
dpc-4838	197	3	(	(	PUNCT
dpc-4838	197	4	heidelb	heidelb	NOUN
dpc-4838	197	5	)	)	PUNCT
dpc-4838	197	6	.	.	PUNCT
dpc-4838	198	1	2022;12(2):561	2022;12(2):561	NUM
dpc-4838	198	2	-	-	SYM
dpc-4838	198	3	575	575	NUM
dpc-4838	198	4	29	29	NUM
dpc-4838	198	5	.	.	PUNCT
dpc-4838	199	1	papp	papp	PROPN
dpc-4838	199	2	ka	ka	PROPN
dpc-4838	199	3	,	,	PUNCT
dpc-4838	199	4	gordon	gordon	PROPN
dpc-4838	199	5	kb	kb	PROPN
dpc-4838	199	6	,	,	PUNCT
dpc-4838	199	7	langley	langley	PROPN
dpc-4838	199	8	rg	rg	PROPN
dpc-4838	199	9	,	,	PUNCT
dpc-4838	199	10	et	et	PROPN
dpc-4838	199	11	al	al	PROPN
dpc-4838	199	12	.	.	PROPN
dpc-4838	199	13	impact	impact	NOUN
dpc-4838	199	14	of	of	ADP
dpc-4838	199	15	previous	previous	ADJ
dpc-4838	199	16	biologic	biologic	NOUN
dpc-4838	199	17	use	use	NOUN
dpc-4838	199	18	on	on	ADP
dpc-4838	199	19	the	the	DET
dpc-4838	199	20	efficacy	efficacy	NOUN
dpc-4838	199	21	and	and	CCONJ
dpc-4838	199	22	safety	safety	NOUN
dpc-4838	199	23	of	of	ADP
dpc-4838	199	24	brodalumab	brodalumab	NOUN
dpc-4838	199	25	and	and	CCONJ
dpc-4838	199	26	ustekinumab	ustekinumab	NOUN
dpc-4838	199	27	in	in	ADP
dpc-4838	199	28	patients	patient	NOUN
dpc-4838	199	29	with	with	ADP
dpc-4838	199	30	moderate	moderate	ADJ
dpc-4838	199	31	-	-	PUNCT
dpc-4838	199	32	to	to	ADP
dpc-4838	199	33	-	-	PUNCT
dpc-4838	199	34	severe	severe	ADJ
dpc-4838	199	35	plaque	plaque	NOUN
dpc-4838	199	36	psoriasis	psoriasis	NOUN
dpc-4838	199	37	:	:	PUNCT
dpc-4838	199	38	integrated	integrate	VERB
dpc-4838	199	39	analysis	analysis	NOUN
dpc-4838	199	40	of	of	ADP
dpc-4838	199	41	the	the	DET
dpc-4838	199	42	randomized	randomized	ADJ
dpc-4838	199	43	controlled	control	VERB
dpc-4838	199	44	trials	trial	NOUN
dpc-4838	199	45	amagine-2	amagine-2	NUM
dpc-4838	199	46	and	and	CCONJ
dpc-4838	199	47	amagine-3	amagine-3	NUM
dpc-4838	199	48	.	.	PUNCT
dpc-4838	199	49	br	br	PROPN
dpc-4838	199	50	j	j	PROPN
dpc-4838	199	51	dermatol	dermatol	NOUN
dpc-4838	199	52	.	.	PUNCT
dpc-4838	200	1	2018;179(2	2018;179(2	NOUN
dpc-4838	200	2	):	):	PUNCT
dpc-4838	200	3	320	320	NUM
dpc-4838	200	4	-	-	SYM
dpc-4838	200	5	328	328	NUM
dpc-4838	200	6	30	30	NUM
dpc-4838	200	7	.	.	PUNCT
dpc-4838	201	1	garcía	garcía	ADJ
dpc-4838	201	2	-	-	PUNCT
dpc-4838	201	3	doval	doval	NOUN
dpc-4838	201	4	i	i	PROPN
dpc-4838	201	5	,	,	PUNCT
dpc-4838	201	6	pérez	pérez	NOUN
dpc-4838	201	7	-	-	PUNCT
dpc-4838	201	8	zafrilla	zafrilla	PROPN
dpc-4838	201	9	b	b	NOUN
dpc-4838	201	10	,	,	PUNCT
dpc-4838	201	11	ferrandiz	ferrandiz	NOUN
dpc-4838	201	12	c	c	NOUN
dpc-4838	201	13	,	,	PUNCT
dpc-4838	201	14	et	et	PROPN
dpc-4838	201	15	al	al	PROPN
dpc-4838	201	16	.	.	PUNCT
dpc-4838	201	17	development	development	NOUN
dpc-4838	201	18	of	of	ADP
dpc-4838	201	19	clinical	clinical	ADJ
dpc-4838	201	20	prediction	prediction	NOUN
dpc-4838	201	21	models	model	NOUN
dpc-4838	201	22	for	for	ADP
dpc-4838	201	23	good	good	ADJ
dpc-4838	201	24	or	or	CCONJ
dpc-4838	201	25	bad	bad	ADJ
dpc-4838	201	26	response	response	NOUN
dpc-4838	201	27	to	to	ADP
dpc-4838	201	28	classic	classic	ADJ
dpc-4838	201	29	systemic	systemic	ADJ
dpc-4838	201	30	drugs	drug	NOUN
dpc-4838	201	31	,	,	PUNCT
dpc-4838	201	32	anti	anti	ADJ
dpc-4838	201	33	-	-	ADJ
dpc-4838	201	34	tnfs	tnfs	ADJ
dpc-4838	201	35	,	,	PUNCT
dpc-4838	201	36	and	and	CCONJ
dpc-4838	201	37	ustekinumab	ustekinumab	NOUN
dpc-4838	201	38	in	in	ADP
dpc-4838	201	39	psoriasis	psoriasis	NOUN
dpc-4838	201	40	,	,	PUNCT
dpc-4838	201	41	based	base	VERB
dpc-4838	201	42	on	on	ADP
dpc-4838	201	43	the	the	DET
dpc-4838	201	44	biobadaderm	biobadaderm	NOUN
dpc-4838	201	45	cohort	cohort	NOUN
dpc-4838	201	46	.	.	PUNCT
dpc-4838	202	1	j	j	PROPN
dpc-4838	202	2	dermatolog	dermatolog	PROPN
dpc-4838	202	3	treat	treat	NOUN
dpc-4838	202	4	.	.	PUNCT
dpc-4838	203	1	2016;27(3):203	2016;27(3):203	NUM
dpc-4838	203	2	-	-	SYM
dpc-4838	203	3	209	209	NUM
dpc-4838	203	4	31	31	NUM
dpc-4838	203	5	.	.	PUNCT
dpc-4838	204	1	gkalpakiotis	gkalpakiotis	PROPN
dpc-4838	204	2	s	s	PROPN
dpc-4838	204	3	,	,	PUNCT
dpc-4838	204	4	cetkovska	cetkovska	ADJ
dpc-4838	204	5	p	p	NOUN
dpc-4838	204	6	,	,	PUNCT
dpc-4838	204	7	arenberger	arenberger	ADV
dpc-4838	204	8	p	p	NOUN
dpc-4838	204	9	,	,	PUNCT
dpc-4838	204	10	dolezal	dolezal	PROPN
dpc-4838	204	11	t	t	PROPN
dpc-4838	204	12	,	,	PUNCT
dpc-4838	204	13	arenbergerova	arenbergerova	VERB
dpc-4838	204	14	m	m	PROPN
dpc-4838	204	15	,	,	PUNCT
dpc-4838	204	16	velackova	velackova	PROPN
dpc-4838	204	17	b	b	AUX
dpc-4838	204	18	,	,	PUNCT
dpc-4838	204	19	fialova	fialova	PROPN
dpc-4838	204	20	j	j	PROPN
dpc-4838	204	21	,	,	PUNCT
dpc-4838	204	22	kojanova	kojanova	PROPN
dpc-4838	204	23	m	m	PROPN
dpc-4838	204	24	;	;	PUNCT
dpc-4838	204	25	biorep	biorep	PROPN
dpc-4838	204	26	study	study	PROPN
dpc-4838	204	27	group	group	NOUN
dpc-4838	204	28	.	.	PUNCT
dpc-4838	205	1	risankizumab	risankizumab	PROPN
dpc-4838	205	2	for	for	ADP
dpc-4838	205	3	the	the	DET
dpc-4838	205	4	treatment	treatment	NOUN
dpc-4838	205	5	of	of	ADP
dpc-4838	205	6	moderatetosevere	moderatetosevere	ADP
dpc-4838	205	7	psoriasis	psoriasis	NOUN
dpc-4838	205	8	:	:	PUNCT
dpc-4838	205	9	real	real	ADJ
dpc-4838	205	10	-	-	PUNCT
dpc-4838	205	11	life	life	NOUN
dpc-4838	205	12	multicenter	multicenter	NOUN
dpc-4838	205	13	experience	experience	NOUN
dpc-4838	205	14	from	from	ADP
dpc-4838	205	15	the	the	DET
dpc-4838	205	16	czech	czech	PROPN
dpc-4838	205	17	republic	republic	NOUN
dpc-4838	205	18	.	.	PUNCT
dpc-4838	206	1	dermatol	dermatol	NOUN
dpc-4838	206	2	ther	ther	ADV
dpc-4838	206	3	(	(	PUNCT
dpc-4838	206	4	heidelb	heidelb	NOUN
dpc-4838	206	5	)	)	PUNCT
dpc-4838	206	6	.	.	PUNCT
dpc-4838	207	1	2021	2021	NUM
dpc-4838	207	2	jun	jun	PROPN
dpc-4838	207	3	5:1–11	5:1–11	NUM
dpc-4838	207	4	32	32	NUM
dpc-4838	207	5	.	.	PUNCT
dpc-4838	208	1	saeki	saeki	PROPN
dpc-4838	208	2	h	h	PROPN
dpc-4838	208	3	,	,	PUNCT
dpc-4838	208	4	ishii	ishii	PROPN
dpc-4838	208	5	k	k	PROPN
dpc-4838	208	6	,	,	PUNCT
dpc-4838	208	7	joshi	joshi	PROPN
dpc-4838	208	8	a	a	PROPN
dpc-4838	208	9	,	,	PUNCT
dpc-4838	208	10	bensimon	bensimon	PROPN
dpc-4838	208	11	ag	ag	PROPN
dpc-4838	208	12	,	,	PUNCT
dpc-4838	208	13	yang	yang	PROPN
dpc-4838	208	14	h	h	PROPN
dpc-4838	208	15	,	,	PUNCT
dpc-4838	208	16	kawaguchi	kawaguchi	PROPN
dpc-4838	208	17	i.	i.	PROPN
dpc-4838	208	18	an	an	DET
dpc-4838	208	19	economic	economic	ADJ
dpc-4838	208	20	evaluation	evaluation	NOUN
dpc-4838	208	21	of	of	ADP
dpc-4838	208	22	risankizumab	risankizumab	NOUN
dpc-4838	208	23	versus	versus	ADP
dpc-4838	208	24	other	other	ADJ
dpc-4838	208	25	biologic	biologic	NOUN
dpc-4838	208	26	treatments	treatment	NOUN
dpc-4838	208	27	of	of	ADP
dpc-4838	208	28	moderate	moderate	ADJ
dpc-4838	208	29	to	to	ADP
dpc-4838	208	30	severe	severe	ADJ
dpc-4838	208	31	plaque	plaque	NOUN
dpc-4838	208	32	psoriasis	psoriasis	NOUN
dpc-4838	208	33	in	in	ADP
dpc-4838	208	34	japan	japan	PROPN
dpc-4838	208	35	.	.	PUNCT
dpc-4838	209	1	j	j	PROPN
dpc-4838	209	2	dermatolog	dermatolog	PROPN
dpc-4838	209	3	treat	treat	NOUN
dpc-4838	209	4	.	.	PUNCT
dpc-4838	210	1	2022;33(1):229	2022;33(1):229	NUM
dpc-4838	210	2	-	-	SYM
dpc-4838	210	3	239	239	NUM
dpc-4838	210	4	33	33	NUM
dpc-4838	210	5	.	.	PUNCT
dpc-4838	211	1	norden	norden	PROPN
dpc-4838	211	2	a	a	PROPN
dpc-4838	211	3	,	,	PUNCT
dpc-4838	211	4	moon	moon	PROPN
dpc-4838	211	5	jy	jy	PROPN
dpc-4838	211	6	,	,	PUNCT
dpc-4838	211	7	javadi	javadi	PROPN
dpc-4838	211	8	ss	ss	PROPN
dpc-4838	211	9	,	,	PUNCT
dpc-4838	211	10	munawar	munawar	PROPN
dpc-4838	211	11	l	l	PROPN
dpc-4838	211	12	,	,	PUNCT
dpc-4838	211	13	maul	maul	PROPN
dpc-4838	211	14	jt	jt	PROPN
dpc-4838	211	15	,	,	PUNCT
dpc-4838	211	16	wu	wu	PROPN
dpc-4838	211	17	jj	jj	PROPN
dpc-4838	211	18	.	.	PROPN
dpc-4838	211	19	anti	anti	ADJ
dpc-4838	211	20	-	-	ADJ
dpc-4838	211	21	drug	drug	ADJ
dpc-4838	211	22	antibodies	antibody	NOUN
dpc-4838	211	23	of	of	ADP
dpc-4838	211	24	il-23	il-23	NOUN
dpc-4838	211	25	inhibitors	inhibitor	NOUN
dpc-4838	211	26	for	for	ADP
dpc-4838	211	27	psoriasis	psoriasis	NOUN
dpc-4838	211	28	:	:	PUNCT
dpc-4838	211	29	a	a	DET
dpc-4838	211	30	systematic	systematic	ADJ
dpc-4838	211	31	review	review	NOUN
dpc-4838	211	32	.	.	PUNCT
dpc-4838	212	1	j	j	PROPN
dpc-4838	212	2	eur	eur	PROPN
dpc-4838	212	3	acad	acad	PROPN
dpc-4838	212	4	dermatol	dermatol	NOUN
dpc-4838	212	5	venereol	venereol	NOUN
dpc-4838	212	6	.	.	PUNCT
dpc-4838	213	1	2022;36(8):1171	2022;36(8):1171	NUM
dpc-4838	213	2	-	-	SYM
dpc-4838	213	3	1177	1177	NUM
dpc-4838	213	4	34	34	NUM
dpc-4838	213	5	.	.	PUNCT
dpc-4838	214	1	de	de	PROPN
dpc-4838	214	2	simone	simone	PROPN
dpc-4838	214	3	c	c	PROPN
dpc-4838	214	4	,	,	PUNCT
dpc-4838	214	5	caldarola	caldarola	PROPN
dpc-4838	214	6	g	g	PROPN
dpc-4838	214	7	,	,	PUNCT
dpc-4838	214	8	maiorino	maiorino	VERB
dpc-4838	214	9	a	a	PRON
dpc-4838	214	10	,	,	PUNCT
dpc-4838	214	11	et	et	PROPN
dpc-4838	214	12	al	al	PROPN
dpc-4838	214	13	.	.	PUNCT
dpc-4838	215	1	clinical	clinical	ADJ
dpc-4838	215	2	predictors	predictor	NOUN
dpc-4838	215	3	of	of	ADP
dpc-4838	215	4	nonresponse	nonresponse	NOUN
dpc-4838	215	5	to	to	ADP
dpc-4838	215	6	anti	anti	ADJ
dpc-4838	215	7	-	-	ADJ
dpc-4838	215	8	tnf	tnf	ADJ
dpc-4838	215	9	-	-	PUNCT
dpc-4838	215	10	α	α	NOUN
dpc-4838	215	11	agents	agent	NOUN
dpc-4838	215	12	in	in	ADP
dpc-4838	215	13	psoriatic	psoriatic	ADJ
dpc-4838	215	14	patients	patient	NOUN
dpc-4838	215	15	:	:	PUNCT
dpc-4838	215	16	a	a	DET
dpc-4838	215	17	retrospective	retrospective	ADJ
dpc-4838	215	18	study	study	NOUN
dpc-4838	215	19	.	.	PUNCT
dpc-4838	216	1	dermatol	dermatol	NOUN
dpc-4838	216	2	ther	ther	ADV
dpc-4838	216	3	.	.	PUNCT
dpc-4838	217	1	2016;29(5):372	2016;29(5):372	NUM
dpc-4838	217	2	-	-	PUNCT
dpc-4838	217	3	376	376	NUM
dpc-4838	217	4	35	35	NUM
dpc-4838	217	5	.	.	PUNCT
dpc-4838	218	1	mourad	mourad	PROPN
dpc-4838	218	2	a	a	PROPN
dpc-4838	218	3	,	,	PUNCT
dpc-4838	218	4	straube	straube	VERB
dpc-4838	218	5	s	s	PROPN
dpc-4838	218	6	,	,	PUNCT
dpc-4838	218	7	armijo	armijo	PROPN
dpc-4838	218	8	-	-	PUNCT
dpc-4838	218	9	olivo	olivo	PROPN
dpc-4838	218	10	s	s	PROPN
dpc-4838	218	11	,	,	PUNCT
dpc-4838	218	12	gniadecki	gniadecki	PROPN
dpc-4838	218	13	r.	r.	PROPN
dpc-4838	218	14	factors	factor	NOUN
dpc-4838	218	15	predicting	predict	VERB
dpc-4838	218	16	persistence	persistence	NOUN
dpc-4838	218	17	of	of	ADP
dpc-4838	218	18	biologic	biologic	ADJ
dpc-4838	218	19	drugs	drug	NOUN
dpc-4838	218	20	in	in	ADP
dpc-4838	218	21	psoriasis	psoriasis	NOUN
dpc-4838	218	22	:	:	PUNCT
dpc-4838	218	23	a	a	DET
dpc-4838	218	24	systematic	systematic	ADJ
dpc-4838	218	25	review	review	NOUN
dpc-4838	218	26	and	and	CCONJ
dpc-4838	218	27	meta	meta	ADJ
dpc-4838	218	28	-	-	PUNCT
dpc-4838	218	29	analysis	analysis	NOUN
dpc-4838	218	30	.	.	PUNCT
dpc-4838	219	1	br	br	PROPN
dpc-4838	219	2	j	j	PROPN
dpc-4838	219	3	dermatol	dermatol	NOUN
dpc-4838	219	4	.	.	PUNCT
dpc-4838	220	1	2019;181(3	2019;181(3	NUM
dpc-4838	220	2	):	):	PUNCT
dpc-4838	220	3	450	450	NUM
dpc-4838	220	4	-	-	SYM
dpc-4838	220	5	458	458	NUM
dpc-4838	220	6	.	.	PUNCT
dpc-4838	221	1	19	19	NUM
dpc-4838	221	2	.	.	PUNCT
dpc-4838	222	1	wu	wu	PROPN
dpc-4838	222	2	jj	jj	PROPN
dpc-4838	222	3	,	,	PUNCT
dpc-4838	222	4	jia	jia	PROPN
dpc-4838	222	5	x	x	PROPN
dpc-4838	222	6	,	,	PUNCT
dpc-4838	222	7	zhao	zhao	PROPN
dpc-4838	222	8	y	y	PROPN
dpc-4838	222	9	,	,	PUNCT
dpc-4838	222	10	et	et	PROPN
dpc-4838	222	11	al	al	PROPN
dpc-4838	222	12	.	.	PROPN
dpc-4838	222	13	comparative	comparative	ADJ
dpc-4838	222	14	cost	cost	NOUN
dpc-4838	222	15	-	-	PUNCT
dpc-4838	222	16	effectiveness	effectiveness	NOUN
dpc-4838	222	17	of	of	ADP
dpc-4838	222	18	tildrakizumab	tildrakizumab	NOUN
dpc-4838	222	19	and	and	CCONJ
dpc-4838	222	20	other	other	ADJ
dpc-4838	222	21	commonly	commonly	ADV
dpc-4838	222	22	used	use	VERB
dpc-4838	222	23	treatments	treatment	NOUN
dpc-4838	222	24	for	for	ADP
dpc-4838	222	25	moderate	moderate	ADJ
dpc-4838	222	26	-	-	PUNCT
dpc-4838	222	27	to	to	ADP
dpc-4838	222	28	severe	severe	ADJ
dpc-4838	222	29	psoriasis	psoriasis	NOUN
dpc-4838	222	30	.	.	PUNCT
dpc-4838	223	1	j	j	PROPN
dpc-4838	223	2	dermatolog	dermatolog	PROPN
dpc-4838	223	3	treat	treat	NOUN
dpc-4838	223	4	.	.	PUNCT
dpc-4838	224	1	2021;32(7):693	2021;32(7):693	NUM
dpc-4838	224	2	-	-	SYM
dpc-4838	224	3	700	700	NUM
dpc-4838	224	4	20	20	NUM
dpc-4838	224	5	.	.	PUNCT
dpc-4838	225	1	nyholm	nyholm	PROPN
dpc-4838	225	2	n	n	CCONJ
dpc-4838	225	3	,	,	PUNCT
dpc-4838	225	4	schnack	schnack	PROPN
dpc-4838	225	5	h	h	NOUN
dpc-4838	225	6	,	,	PUNCT
dpc-4838	225	7	danø	danø	VERB
dpc-4838	225	8	a	a	DET
dpc-4838	225	9	,	,	PUNCT
dpc-4838	225	10	skowron	skowron	PROPN
dpc-4838	225	11	f.	f.	PROPN
dpc-4838	225	12	cost	cost	PROPN
dpc-4838	225	13	per	per	ADP
dpc-4838	225	14	responder	responder	NOUN
dpc-4838	225	15	of	of	ADP
dpc-4838	225	16	biologic	biologic	NOUN
dpc-4838	225	17	drugs	drug	NOUN
dpc-4838	225	18	used	use	VERB
dpc-4838	225	19	in	in	ADP
dpc-4838	225	20	the	the	DET
dpc-4838	225	21	treatment	treatment	NOUN
dpc-4838	225	22	of	of	ADP
dpc-4838	225	23	moderate	moderate	ADJ
dpc-4838	225	24	-	-	PUNCT
dpc-4838	225	25	to	to	ADP
dpc-4838	225	26	-	-	PUNCT
dpc-4838	225	27	severe	severe	ADJ
dpc-4838	225	28	plaque	plaque	NOUN
dpc-4838	225	29	psoriasis	psoriasis	NOUN
dpc-4838	225	30	in	in	ADP
dpc-4838	225	31	france	france	PROPN
dpc-4838	225	32	and	and	CCONJ
dpc-4838	225	33	germany	germany	PROPN
dpc-4838	225	34	.	.	PUNCT
dpc-4838	226	1	curr	curr	PROPN
dpc-4838	226	2	med	med	PROPN
dpc-4838	226	3	res	re	NOUN
dpc-4838	226	4	opin	opin	NOUN
dpc-4838	226	5	.	.	PUNCT
dpc-4838	227	1	2023;39(6):833	2023;39(6):833	NUM
dpc-4838	227	2	-	-	SYM
dpc-4838	227	3	842	842	NUM
dpc-4838	227	4	21	21	NUM
dpc-4838	227	5	.	.	PUNCT
dpc-4838	228	1	fredriksson	fredriksson	PROPN
dpc-4838	228	2	t	t	PROPN
dpc-4838	228	3	,	,	PUNCT
dpc-4838	228	4	pettersson	pettersson	PROPN
dpc-4838	228	5	u.	u.	PROPN
dpc-4838	228	6	severe	severe	ADJ
dpc-4838	228	7	psoriasis	psoriasis	NOUN
dpc-4838	228	8	--	--	PUNCT
dpc-4838	228	9	oral	oral	ADJ
dpc-4838	228	10	therapy	therapy	NOUN
dpc-4838	228	11	with	with	ADP
dpc-4838	228	12	a	a	DET
dpc-4838	228	13	new	new	ADJ
dpc-4838	228	14	retinoid	retinoid	NOUN
dpc-4838	228	15	.	.	PUNCT
dpc-4838	229	1	dermatologica	dermatologica	PROPN
dpc-4838	229	2	.	.	PUNCT
dpc-4838	230	1	1978;157(4):238	1978;157(4):238	NUM
dpc-4838	230	2	-	-	SYM
dpc-4838	230	3	44	44	NUM
dpc-4838	230	4	22	22	NUM
dpc-4838	230	5	.	.	PUNCT
dpc-4838	231	1	caldarola	caldarola	PROPN
dpc-4838	231	2	g	g	PROPN
dpc-4838	231	3	,	,	PUNCT
dpc-4838	231	4	zangrilli	zangrilli	PROPN
dpc-4838	231	5	a	a	X
dpc-4838	231	6	,	,	PUNCT
dpc-4838	231	7	bernardini	bernardini	PROPN
dpc-4838	231	8	n	n	CCONJ
dpc-4838	231	9	,	,	PUNCT
dpc-4838	231	10	et	et	PROPN
dpc-4838	231	11	al	al	PROPN
dpc-4838	231	12	.	.	PROPN
dpc-4838	231	13	risankizumab	risankizumab	PROPN
dpc-4838	231	14	for	for	ADP
dpc-4838	231	15	the	the	DET
dpc-4838	231	16	treatment	treatment	NOUN
dpc-4838	231	17	of	of	ADP
dpc-4838	231	18	moderate	moderate	ADJ
dpc-4838	231	19	-	-	PUNCT
dpc-4838	231	20	to	to	ADP
dpc-4838	231	21	-	-	PUNCT
dpc-4838	231	22	severe	severe	ADJ
dpc-4838	231	23	psoriasis	psoriasis	NOUN
dpc-4838	231	24	:	:	PUNCT
dpc-4838	231	25	a	a	DET
dpc-4838	231	26	multicenter	multicenter	NOUN
dpc-4838	231	27	,	,	PUNCT
dpc-4838	231	28	retrospective	retrospective	ADJ
dpc-4838	231	29	,	,	PUNCT
dpc-4838	231	30	1	1	NUM
dpc-4838	231	31	year	year	NOUN
dpc-4838	231	32	real	real	ADJ
dpc-4838	231	33	-	-	PUNCT
dpc-4838	231	34	life	life	NOUN
dpc-4838	231	35	study	study	NOUN
dpc-4838	231	36	.	.	PUNCT
dpc-4838	232	1	dermatol	dermatol	NOUN
dpc-4838	232	2	ther	ther	ADV
dpc-4838	232	3	.	.	PUNCT
dpc-4838	233	1	2022	2022	NUM
dpc-4838	233	2	;	;	PUNCT
dpc-4838	233	3	35(6):e15489	35(6):e15489	NUM
dpc-4838	233	4	23	23	NUM
dpc-4838	233	5	.	.	PUNCT
dpc-4838	234	1	brunasso	brunasso	PROPN
dpc-4838	234	2	amg	amg	PROPN
dpc-4838	234	3	,	,	PUNCT
dpc-4838	234	4	burlando	burlando	PROPN
dpc-4838	234	5	m	m	PROPN
dpc-4838	234	6	,	,	PUNCT
dpc-4838	234	7	amoruso	amoruso	PROPN
dpc-4838	234	8	f	f	PROPN
dpc-4838	234	9	,	,	PUNCT
dpc-4838	234	10	et	et	PROPN
dpc-4838	234	11	al	al	PROPN
dpc-4838	234	12	.	.	PROPN
dpc-4838	234	13	risankizumab	risankizumab	PROPN
dpc-4838	234	14	:	:	PUNCT
dpc-4838	234	15	daily	daily	ADJ
dpc-4838	234	16	practice	practice	NOUN
dpc-4838	234	17	experience	experience	NOUN
dpc-4838	234	18	of	of	ADP
dpc-4838	234	19	high	high	ADJ
dpc-4838	234	20	need	need	NOUN
dpc-4838	234	21	patients	patient	NOUN
dpc-4838	234	22	.	.	PUNCT
dpc-4838	235	1	biomedicines	biomedicine	NOUN
dpc-4838	235	2	.	.	PUNCT
dpc-4838	236	1	2023;11(6):1769	2023;11(6):1769	PROPN
dpc-4838	236	2	24	24	NUM
dpc-4838	236	3	.	.	PUNCT
dpc-4838	237	1	dastoli	dastoli	PROPN
dpc-4838	237	2	s	s	PROPN
dpc-4838	237	3	,	,	PUNCT
dpc-4838	237	4	passante	passante	PROPN
dpc-4838	237	5	m	m	PROPN
dpc-4838	237	6	,	,	PUNCT
dpc-4838	237	7	loconsole	loconsole	NOUN
dpc-4838	238	1	f	f	X
dpc-4838	238	2	,	,	PUNCT
dpc-4838	238	3	et	et	PROPN
dpc-4838	238	4	al	al	PROPN
dpc-4838	238	5	.	.	PUNCT
dpc-4838	238	6	long	long	ADJ
dpc-4838	238	7	-	-	PUNCT
dpc-4838	238	8	term	term	NOUN
dpc-4838	238	9	efficacy	efficacy	NOUN
dpc-4838	238	10	and	and	CCONJ
dpc-4838	238	11	safety	safety	NOUN
dpc-4838	238	12	of	of	ADP
dpc-4838	238	13	secukinumab	secukinumab	NOUN
dpc-4838	238	14	in	in	ADP
dpc-4838	238	15	real	real	ADJ
dpc-4838	238	16	life	life	NOUN
dpc-4838	238	17	:	:	PUNCT
dpc-4838	238	18	a	a	DET
dpc-4838	238	19	240	240	NUM
dpc-4838	238	20	weeks	week	NOUN
dpc-4838	238	21	multicenter	multicenter	NOUN
dpc-4838	238	22	study	study	NOUN
dpc-4838	238	23	from	from	ADP
dpc-4838	238	24	southern	southern	PROPN
dpc-4838	238	25	italy	italy	PROPN
dpc-4838	238	26	.	.	PUNCT
dpc-4838	239	1	j	j	PROPN
dpc-4838	239	2	dermatolog	dermatolog	PROPN
dpc-4838	239	3	treat	treat	NOUN
dpc-4838	239	4	.	.	PUNCT
dpc-4838	240	1	2023;34(1):2200868	2023;34(1):2200868	NUM
dpc-4838	240	2	25	25	NUM
dpc-4838	240	3	.	.	PUNCT
dpc-4838	241	1	thaçi	thaçi	PROPN
dpc-4838	241	2	d	d	PROPN
dpc-4838	241	3	,	,	PUNCT
dpc-4838	241	4	körber	körber	PROPN
dpc-4838	241	5	a	a	PROPN
dpc-4838	241	6	,	,	PUNCT
dpc-4838	241	7	von	von	PROPN
dpc-4838	241	8	kiedrowski	kiedrowski	PROPN
dpc-4838	241	9	r	r	PROPN
dpc-4838	241	10	,	,	PUNCT
dpc-4838	241	11	et	et	PROPN
dpc-4838	241	12	al	al	PROPN
dpc-4838	241	13	.	.	PROPN
dpc-4838	241	14	secukinumab	secukinumab	NOUN
dpc-4838	241	15	is	be	AUX
dpc-4838	241	16	effective	effective	ADJ
dpc-4838	241	17	in	in	ADP
dpc-4838	241	18	treatment	treatment	NOUN
dpc-4838	241	19	of	of	ADP
dpc-4838	241	20	moderate	moderate	ADJ
dpc-4838	241	21	-	-	PUNCT
dpc-4838	241	22	to	to	ADP
dpc-4838	241	23	-	-	PUNCT
dpc-4838	241	24	severe	severe	ADJ
dpc-4838	241	25	plaque	plaque	NOUN
dpc-4838	241	26	psoriasis	psoriasis	NOUN
dpc-4838	241	27	:	:	PUNCT
dpc-4838	241	28	real	real	ADJ
dpc-4838	241	29	-	-	PUNCT
dpc-4838	241	30	life	life	NOUN
dpc-4838	241	31	effectiveness	effectiveness	NOUN
dpc-4838	241	32	and	and	CCONJ
dpc-4838	241	33	safety	safety	NOUN
dpc-4838	241	34	from	from	ADP
dpc-4838	241	35	the	the	DET
dpc-4838	241	36	prospect	prospect	NOUN
dpc-4838	241	37	study	study	NOUN
dpc-4838	241	38	.	.	PUNCT
dpc-4838	242	1	j	j	PROPN
dpc-4838	242	2	eur	eur	PROPN
dpc-4838	242	3	acad	acad	PROPN
dpc-4838	242	4	dermatol	dermatol	NOUN
dpc-4838	242	5	venereol	venereol	NOUN
dpc-4838	242	6	.	.	PUNCT
dpc-4838	243	1	2020;34(2):310	2020;34(2):310	NUM
dpc-4838	243	2	-	-	SYM
dpc-4838	243	3	318	318	NUM
dpc-4838	243	4	26	26	NUM
dpc-4838	243	5	.	.	PUNCT
dpc-4838	243	6	narcisi	narcisi	PROPN
dpc-4838	243	7	a	a	PROPN
dpc-4838	243	8	,	,	PUNCT
dpc-4838	243	9	valenti	valenti	PROPN
dpc-4838	243	10	m	m	PROPN
dpc-4838	243	11	,	,	PUNCT
dpc-4838	243	12	cortese	cortese	PROPN
dpc-4838	243	13	a	a	X
dpc-4838	243	14	,	,	PUNCT
dpc-4838	243	15	et	et	PROPN
dpc-4838	243	16	al	al	PROPN
dpc-4838	243	17	.	.	PUNCT
dpc-4838	243	18	anti	anti	PROPN
dpc-4838	243	19	-	-	ADJ
dpc-4838	243	20	il17	il17	ADJ
dpc-4838	243	21	and	and	CCONJ
dpc-4838	243	22	anti	anti	ADJ
dpc-4838	243	23	-	-	ADJ
dpc-4838	243	24	il23	il23	ADJ
dpc-4838	243	25	biologic	biologic	NOUN
dpc-4838	243	26	drugs	drug	NOUN
dpc-4838	243	27	for	for	ADP
dpc-4838	243	28	scalp	scalp	NOUN
dpc-4838	243	29	psoriasis	psoriasis	NOUN
dpc-4838	243	30	:	:	PUNCT
dpc-4838	243	31	a	a	DET
dpc-4838	243	32	single	single	ADJ
dpc-4838	243	33	-	-	PUNCT
dpc-4838	243	34	center	center	NOUN
dpc-4838	243	35	retrospective	retrospective	ADJ
dpc-4838	243	36	comparative	comparative	ADJ
dpc-4838	243	37	study	study	NOUN
dpc-4838	243	38	.	.	PUNCT
dpc-4838	244	1	dermatol	dermatol	NOUN
dpc-4838	244	2	ther	ther	ADV
dpc-4838	244	3	.	.	PUNCT
dpc-4838	245	1	2022;35(2):e15228	2022;35(2):e15228	NUM
dpc-4838	245	2	27	27	NUM
dpc-4838	245	3	.	.	PUNCT
dpc-4838	246	1	cortese	cortese	PROPN
dpc-4838	246	2	a	a	PRON
dpc-4838	246	3	,	,	PUNCT
dpc-4838	246	4	gargiulo	gargiulo	ADJ
dpc-4838	246	5	l	l	NOUN
dpc-4838	246	6	,	,	PUNCT
dpc-4838	246	7	ibba	ibba	ADJ
dpc-4838	246	8	l	l	NOUN
dpc-4838	246	9	,	,	PUNCT
dpc-4838	246	10	et	et	PROPN
dpc-4838	246	11	al	al	PROPN
dpc-4838	246	12	.	.	PUNCT
dpc-4838	247	1	anti	anti	PROPN
dpc-4838	247	2	-	-	ADJ
dpc-4838	247	3	interleukin-17	interleukin-17	ADJ
dpc-4838	247	4	and	and	CCONJ
dpc-4838	247	5	anti	anti	ADJ
dpc-4838	247	6	-	-	ADJ
dpc-4838	247	7	interleukin-23	interleukin-23	ADJ
dpc-4838	247	8	biologic	biologic	NOUN
dpc-4838	247	9	drugs	drug	NOUN
dpc-4838	247	10	for	for	ADP
dpc-4838	247	11	genital	genital	ADJ
dpc-4838	247	12	psoriasis	psoriasis	NOUN
dpc-4838	247	13	:	:	PUNCT
dpc-4838	247	14	a	a	DET
dpc-4838	247	15	single	single	ADJ
dpc-4838	247	16	-	-	PUNCT
dpc-4838	247	17	center	center	NOUN
dpc-4838	247	18	retrospective	retrospective	ADJ
dpc-4838	247	19	comparative	comparative	ADJ
dpc-4838	247	20	study	study	NOUN
dpc-4838	247	21	.	.	PUNCT
dpc-4838	248	1	dermatol	dermatol	NOUN
dpc-4838	248	2	reports	report	NOUN
dpc-4838	248	3	.	.	PUNCT
dpc-4838	249	1	2023	2023	NUM
dpc-4838	249	2	;	;	PUNCT
dpc-4838	249	3	15(3):9692	15(3):9692	NUM
dpc-4838	249	4	28	28	NUM
dpc-4838	249	5	.	.	PUNCT
dpc-4838	250	1	crowley	crowley	PROPN
dpc-4838	250	2	jj	jj	PROPN
dpc-4838	250	3	,	,	PUNCT
dpc-4838	250	4	langley	langley	PROPN
dpc-4838	250	5	rg	rg	PROPN
dpc-4838	250	6	,	,	PUNCT
dpc-4838	250	7	gordon	gordon	PROPN
dpc-4838	250	8	kb	kb	PROPN
dpc-4838	250	9	,	,	PUNCT
dpc-4838	250	10	et	et	PROPN
dpc-4838	250	11	al	al	PROPN
dpc-4838	250	12	.	.	PROPN
dpc-4838	250	13	efficacy	efficacy	PROPN
dpc-4838	250	14	of	of	ADP
dpc-4838	250	15	risankizumab	risankizumab	PROPN
dpc-4838	250	16	versus	versus	ADP
dpc-4838	250	17	secukinumab	secukinumab	NOUN
dpc-4838	250	18	in	in	ADP
dpc-4838	250	19	patients	patient	NOUN
dpc-4838	250	20	with	with	ADP
dpc-4838	250	21	moderate	moderate	ADJ
dpc-4838	250	22	-	-	PUNCT
dpc-4838	250	23	to	to	ADP
dpc-4838	250	24	-	-	PUNCT
dpc-4838	250	25	severe	severe	ADJ